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The human immune system carefully balances the need to maintain
stable responses to familiar stimuli with the need for agile responses to an
ever changing array of potential dangers. Classic techniques allow for detailed
evaluation of parts of the immune system, while emerging technologies allow
for more systems-level analysis of the immune system as a whole. In this
dissertation, I use high-throughput techniques and computational analysis to
advance our understanding of the human bone marrow B cell repertoire. First,
I describe the variation in composition of human bone marrow plasma cells
from the same individual over time. I show that the frequency of gene and gene
combination usage, assayed by high-throughput sequencing, is temporally sta-
ble over 6.5 years. Next, I describe a computational model that simulates the
process of high-throughput sequencing of immune cells and identify the major
vii
sources of error in these experiments. Specifically, this simulation demon-
strates that the typical shape of the experimental distribution of antibodies
may be in large part be due to error generated in the experimental process
and not a biologically relevant observation. I go on to demonstrate the current
limits in understanding the initial distribution of the immune repertoire due to
accumulated noise in the experimental process. The work presented here rep-
resents the longest longitudinal study to date of high-throughput sequencing
techniques used to study the repertoire of human B cells. In addition, the com-
putational model frames the technical challenges of immunological repertoire
analysis. This knowledge will provide the basis of future studies to under-
stand the nature of B cells in human bone marrow. It will be relevant for
both academic and clinical researchers studying the immune system at basal
state as well as at an active defense state. Ultimately, it provides guidance to
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The immune system is unique in its potential for diversity. The need for
diversity stems from its role in preventing disease progression in all its forms
[61]. The diversity of the immune system manifests itself on many levels, in-
cluding at the level of cellular compartment, cell type, or cell receptor. At the
level of the B cell receptor, or antibody, this diversity is accomplished by ge-
nomic rearrangement, junctional diversity, and somatic hypermutation (SHM)
[25]. In humans, estimating the theoretical limit of diversity using genomic re-
arrangement alone results in 2.3×106 antibody arrangements [20]. Junctional
diversity increases the possible antibody sequences to 1011 [20]. SHM increases
the diversity even more. Despite this extraordinarily large amount of possi-
ble diversity, the actual available repertoire has been estimated to be 107 [5].
Nevertheless, the true size and degree of diversity of the antibody repertoire
remains unknown. Additional measurements of the size, diversity, and tem-
poral dynamics of the immune repertoire will provide knowledge of a person's
environmental history and innate ability to handle any future encounters with
disease causing agents.















Figure 1.1: The structure of IgG
in humans: the blood, bone marrow, lymph nodes, thymus, and spleen among
others. The most easily accessible (and heavily researched) of these compart-
ments is the blood, where B cells in the peripheral blood mononuclear cells
(PBMCs) are readily accessible. However, the major reservoir of antibody pro-
ducing cells is in the bone marrow, where antibody producing cells can survive
for long periods of time [45]. The actual lifetime of these antibody producing
cells remains an open and important question. The answer would reveal how
long our immune system can effectively maintain an active response to past
stimuli.
The structure of the antibody balances the need for effective defense
and enormous diversity. Antibodies are homodimeric tetramers (Figure 1.1).
The dimer is made of two polypeptide chains referred to as heavy and light
chains. The heavy and light chains are composed of a variable and constant
region. The variable heavy chain is composed of three genes (V, D, and J).
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The light variable chain is composed of two genes (V and J). There are five
classes (IgM, IgD, IgG, IgA, and IgE) of heavy chains and two classes of
light chains (lambda and kappa). The mature molecule is a 150 kDa protein
molecule. The separate variable light and heavy chains and the size of each
molecule make full length sequencing challenging. However, there are regions
in the variable regions that are hypervariable [68]. Particularly, the region
encompassing the end of the V gene, the entire D gene, and the beginning of
the J gene, known as the CDR-H3. This region is typically short enough to
be covered by sequencing reads; therefore, by sequencing the variable heavy
chain, a measure of antibody diversity and clonality can be calculated.
In recent years, the development of high-throughput sequencing (HTS)
has enabled researchers to interrogate the immune system at a previously
unattainable depth [46]. HTS technologies have been used to find biases in
antibody gene selection and rearrangements across patients [4, 25]. They have
been used to look at antigen induced responses, specifically against HIV-1
[65] and influenza [33, 39, 36, 63]. In addition, they have been important in
technologies that identify heavy and light chain pairing [14, 9].
There are two primary sequencing technologies used for antibody reper-
toire analysis [26]. The first, 454 GS FLX Titanium is based on a method of
sequencing by synthesis using single-nucleotide addition. While having the
benefits of relatively long reads (600-1000bps), it suffers from susceptibility
to homopolymer misidentifications, high error rate (∼1%), and high cost per
run. The second and more prevalently used method is Illumina MiSeq. This
3
technology is based on sequencing by synthesis using cyclic reversible termi-
nation. The maximum read length is shorter than 454 GS FLX Titanium at
600 bps (achieved by 2 × 300 paired end reads), but it has a lower error rate
(0.1%) and cost per run. No matter what platform is used, there are many
challenges of HTS that are prominent specifically for antibody repertoire se-
quencing. First, the antibody repertoire is highly variable across individuals
preventing the generation of a reference sequence. In addition, because an-
tibodies are the product of multiple gene recombination, junctional diversity,
and short hypervariable regions separated by long highly similar sequences,
short reads are insufficient to identify antibody sequences accurately.
The fundamental question on how best to describe antibody diversity
remains open. To better understand these intricacies, the antibody repertoire
community has looked to ecology for various methods to measure diversity [43].
The total population of immune cells is much like an ecosystem. In addition,
the difficulty of sampling an immune system is similar to that of sampling an
entire ecosystem [5]. The methods of sampling, therefore, are highly analo-
gous. Many different metrics of diversity exist, e.g. Parker-Berger, Shannon,
and Simpson. These metrics tend to focus on two characteristics: species
richness and species evenness, generally emphasizing one trait more than the
other. Recently, specific indices have been suggested for immune repertoire
diversity [35]. Diversity index choice is highly context dependent; therefore,
the assumptions and biases of those diversity indices should be defined when
used for biological interpretation. A well controlled and repeatable framework
4
for that analysis remains absent for the community.
In this dissertation, I explore the immune repertoire at the level of
the bone marrow plasma cells and further interrogate the methods of immune
repertoire analysis via simulation. In Chapter 2, I observe the longevity of
antibody producing cells. I analyzed antibody producing cells across several
timepoints from the same human donor and explored the temporal dynamics
of gene usage and rearrangement, CDR-H3 length, and isotype usage. In ad-
dition, by analyzing the B cell bone marrow repertoire, I take one step toward
furthering our understanding of the human immune response. In Chapter 3, I
build a simulation of error modes in order to understand the extent to which
the HTS empirical immune repertoire can be used to interpret the true bio-
logical immune repertoire. I demonstrate that there are multiple sources of
error, including cell sampling, nucleic acid amplification, and high-throughput
sequencing. I quantify the extent of error correction that can be achieved by
sequence clustering. Surprisingly, I find that different true biological distri-
butions, when processed through our simulation of HTS immune repertoire
workflow, result in the same empirical distribution. Based on these results, I




Temporal Stability and Molecular Persistence
of the Bone Marrow Plasma Cell Antibody
Repertoire1
2.1 Abstract
Plasma cells in human bone marrow (BM) are thought to be responsible
for sustaining lifelong immunity, but its underlying basis is controversial. Using
high-throughput sequence analysis of the same individual across 6.5 years,
we show that the BM plasma cell immunoglobulin heavy chain repertoire is
remarkably stable over time. We find a nearly static bias in individual and
combinatorial gene usage across time. Analysis of a second donor corroborates
these observations. We also report the persistence of numerous BM plasma cell
clonotypes (∼2%) identifiable at all points assayed across 6.5 years, supporting
a model of serological memory based upon intrinsic longevity of human plasma
cells. Donors were adolescents who completely recovered from neuroblastoma
prior to the start of this study. Our work will facilitate differentiation between
1Published as Wu GC, Cheung NV, Georgiou G, Marcotte EM, Ippolito GC, Temporal
Stability and Molecular Persistence of the Bone Marrow Plasma Cell Antibody Repertoire.
bioRxiv, (2016): 066878. Also accepted for publication at Nature Communications. GG and
NKC conceived the study. GCW and GCI designed and performed experiments, analyzed
data, prepared figures, and wrote the manuscript, under the supervision of EMM. All authors
reviewed the manuscript.
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healthy and diseased antibody repertoires, by serving as a point of comparison
with future deep sequencing studies involving immune intervention.
2.2 Introduction
The human bone marrow (BM) is a specialized immune compartment
that is responsible for both the initial generation of newly formed B cells
and the maintenance of terminally differentiated, antibody-secreting plasma
cells. The BM, and the plasma cells it harbors, is a central site of antibody
production and is the major source of all classes and subclasses of human
immunoglobulins (Ig) in the serum [47, 6]. Ig-secreting BM plasma cells are
generally believed to be long-lived and to persist for the lifespan of the or-
ganism [51]. Longitudinal serological studies have established that antiviral
serum antibodies can be remarkably stable, with half-lives ranging from 50
years (e.g. varicella-zoster virus) to 200 years (e.g. measles and mumps); how-
ever, by contrast, antibody responses to non-replicating antigens (e.g. tetanus
and diphtheria bacterial toxins) rapidly decay with much shorter half-lives of
only 10-20 years [2]. These differences not only suggest that antigen-specific
mechanisms have a substantial role in the establishment and/or maintenance
of serological memory, but raises the question of whether the differential stabil-
ity of antibody responses might reflect differential intrinsic longevity of plasma
cells. This mechanism has been previously proposed in the context of vaccina-
tions and infections [2, 28], and is also supported by observations of differential
stability of autoantibody titers when using B cell depleting therapies to treat
7
autoimmune diseases [11, 10].
The basis of lifelong serological memory (antibody responses) is con-
troversial [51, 3, 69]. A model for intrinsic longevity in plasma cell survival
(and hence longevity in serum antibody maintenance) has been posited for the
laboratory mouse [44, 54], but data for human plasma cells have not been gen-
erated. On the basis of mouse models, human BM plasma cells are assumed
to be similarly long-lived and the major source of serum antibodies; however,
the contribution of antigen-specific BM plasma cells in humans has only re-
cently been shown experimentally [28, 48]. Despite these notable advances,
the availability of corresponding molecular data (namely, sequence data of
BM plasma cell Ig transcripts) and of information regarding plasma cell dy-
namics in vivo is scarce. Persistent antigens as well as the memory B cell
compartment are implicated in alternative models of lifelong serological mem-
ory, implying continual clonal replacement of antigen-specific plasma cells, in
contrast to intrinsic plasma cell longevity [45, 7, 55].
Three studies have generated BM plasma cell data using next-generation
sequencing techniques, but did not examine the temporal changes that occur
in the antibody repertoire over time [28, 13, 57]. Here, building upon our prior
experiences with the comprehensive analysis of human cellular and serological
antibody repertoires [14, 31, 62, 40, 15], we present the first longitudinal study
of serially acquired human BM plasma cells assayed by next-generation deep
sequencing. To directly measure the temporal dynamics of BM plasma cells—
and to indirectly gain insight into long-lived serological memory—we sequence
8
recombined VHDJH regions (cDNA), which encode the variable domain (pro-
tein) of antibody IGH heavy chains. Most of the VHDJH genetic diversity
is in the CDR-H3 hypervariable interval (encoded by a D element, random
non-templated nucleotides, and small portions of the VH and JH elements).
CDR-H3 is a primary determinant of antibody specificity [66, 32] and has long
been considered a unique fingerprint which aids identification of a progenitor
B cell and its clonal progeny (B cell clonotype) [67]. We sequence BM plasma
cells from the same individual at seven time points over a total of 6.5 years
and from a second individual with two timepoints over 2.3 years. The tempo-
ral resolution and duration of sampling provides a method to interrogate the
in vivo temporal dynamics of BM plasma cells in a previously uncharacter-
ized way. We provide detailed temporal information on the individual genes
(IGH V, D, and J), gene combinations (V-D, V-J, D-J, V-D-J), and temporally
persistent CDR-H3 clonotypes. The second individual provides support that
our observations are not unique. Moreover, persisting CDR-H3 clonotypes are
class-switched and somatically mutated (in the IGHV gene segment) imply-
ing derivation from activated B cell progenitors that must have been selected
by antigen. Crucially, persisting CDR-H3 clonotypes reside exclusively in the
plasma cell compartment, but are absent among comparable memory B cells
(also a class-switched and somatically mutated B cell compartment) isolated
from the same BM biopsy. Overall, our results underscore the temporal stabil-
ity of the IGH V region repertoire according to multiple metrics (temporally
stable IGH molecular phenotypes), and provide unequivocal sequence-based
9
evidence for the persistence of plasma cell clonotypes spanning 6.5 years.
2.3 Results
2.3.1 High-throughput sequencing of serial bone marrow biopsies
To investigate the temporal dynamics of the IGH antibody gene reper-
toire of bone marrow (BM) plasma cells, we sampled, sorted, and performed
high-throughput sequencing (Figure 2.1a). Serial bone marrow biopsies were
obtained from two adolescents (Table 2.1) as part of routine evaluations for
non-immuno-hematological disease. BM plasma cells were isolated using FACS
(fluorescence-activated cell sorting) for CD38++ CD138+ cells within the
mononuclear light-scatter gate (Figure 2.1b). Additionally, the cells were
uniformly positive for the TNF-receptor superfamily member CD27 (Figure
2.1b, inset). Importantly, we avoided gating of the pan-B cell marker CD19
since previous characterizations of human BM plasma cells show heterogeneous
expression of CD19 [34, 21]. Therefore, our method captured all recently
described BM plasma cell subpopulations [28, 48] with an overall CD19+/-
CD27+ CD38++ CD138+ phenotype. Subsequently, transcripts were am-
plified from BM plasma cells expressing IgM, IgG, and IgA using RT-PCR
followed by high-throughput sequencing.
In total, 503,415 total sequencing reads were generated from 51,200 BM
plasma cells (see Methods and Table 2.1). These data span seven timepoints
across 6.5 years for Donor 1 (Figure 2.1c) and two timepoints across 2.3 years
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Figure 2.1: Overview of bone marrow plasma cell sampling and NGS
(a) Overview of antibody repertoire characterization method. Serial sampling
of human bone marrow (BM) plasma cells over 6.5 years (left). Analysis of
individual genes, gene combinations, and CDR-H3s (center) show temporally
stable expression of persistent entities (right). (b) Representative fluorescence-
activated cell sorting (FACS) gates of BM plasma cells (CD138+, CD38++)
isolated from bone marrow mononuclear cells (BMMCs). (c) Sample collection
timeline and summary of cell counts, quality-filtered sequencing reads, and
unique CDR-H3s for Donor 1.
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Sample ID Donor Age (years) Time (years) Cells counted Read counts Unique CDR-H3s
d1t00a 1 10.9 0 6,674 49,742 4,290
d1t00b 1 10.9 0 1,298 110,619 4,338
d1t05 1 11.2 0.5 2,877 50,468 2,773
d1t06 1 11.5 0.6 5,047 39,683 3,265
d1t15 1 12.4 1.5 5,629 45,949 3,691
d1t40 1 14.9 4 1,870 70,692 3,709
d1t58 1 16.5 5.8 14,307 20,330 3,276
d1t65 1 17.3 6.5 6,735 21,996 2,843
d2t00 2 13.5 0 3,642 17,726 2,120
d2t23a 2 15.78 2.28 2,021 39,096 2,855
d2t23b 2 15.78 2.28 1,100 37,114 4,999
Total 51,200 503,415 38,159
Table 2.1: Donor history and sequencing information Bone marrow
(BM) plasma cells were isolated from each sample by flow cytometry. BM
plasma cells are defined as CD138+ CD38++ cells from bone marrow mononu-
clear cells. See Figure 2.1 and Methods. Donor 1 was diagnosed at the age
of 9 years with adrenal neuroblastoma metastatic to the bone marrow. Donor
underwent multiagent chemotherapy consisting of high dose alkylators, then
consolidated with myeloablative therapy followed by hematopoietic stem cell
transplant. Because of progressive disease in bone marrow and bones at age
10, local radiation and systemic 131 I-MIBG was given followed by anti-GD2
antibody immunotherapy, 3F8+ GM-CSF+ beta-glucan+ 13-cis- retinoic acid
till age 14. Donor continued in remission through age 17 years. Because of
cancer therapy, donor had to be re-immunized with tetanus, Hemophilus in-
fluenza b (Hib), Hepatitis B, and Polio at age 12 (before sample d1t15) and
boosted again with Hib, Hepatitis B and Polio at age 13 (between sample
d1t15 and d1t40). MMR (mumps measles rubella) vaccine was then given at
age 14 (before sample d1t40 and d1t58 and d1t65). Donor 2 was diagnosed
at the age of 4 with mediastinal neuroblastoma metastatic to bone and bone
marrow and received high dose multiagent chemotherapy. Tumor recurred as
epidural mass in the lumbar at the age of 12 and was retreated with high dose
multiagent chemotherapy followed by myeloablative therapy plus autologous
hematopoietic stem cell rescue and focal radiation to the spine. Donor was
treated with anti-GD2 3F8 immunotherapy plus oral etoposide till age 14, and
remained in remission through age 20 years.
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the same bone marrow aspiration) was also collected from each donor and
analyzed. Replicate sampling from the same donor and time point allowed us
to confidently discern the active spectrum of heavy chain genes comprising a
donors antibody repertoire.
2.3.2 Individual gene frequencies are highly stable
For Donor 1, we identified 38 IGHV genes, 21 IGHD genes, and 6
IGHJ genes (4,788 combinations). We assessed the frequency of each IGH V,
D, and J gene across time (Figure 2.2) and found stability of individual gene
usage. The most frequently used genes (e.g. IGHV4-34) show consistently high
expression while less frequently used genes (e.g. IGHV3-72) show consistently
low expression. This observation was quantified using the Mann-Kendall Test,
which evaluates trends in time series data. We find that 89% of IGHV genes,
95% of IGHD genes and 100% IGHJ genes show no statistically significant
trends (Mann-Kendall test, p>0.05), indicating that the IGHV (Figure 2.2a),
IGHD (Figure 2.2b), and IGHJ (Figure 2.2c) genes are time stable.
Next, we analyzed population behavior of gene usage. Averaging across
all timepoints, we observe a highly skewed distribution of individual gene fre-
quencies, consistent with previous single timepoint observations. Only 6 IGHV
genes (16%) account for greater than 50% of total IGHV gene usage by fre-
quency (Figure 2.2d). IGHD2-2, IGHD3-3, and IGHD3-22 [38], previously
shown to have biased usage, together account for 33% of total IGHD usage












































































































































































































































































































































































































































































































Figure 2.2: IGH gene segment frequencies among BM plasma cells are
temporally stable For Donor 1: (a-c) IGHV (a), IGHD (b), and IGHJ (c)
gene usage frequency over time. Plots are sorted by decreasing mean frequency.
Only gene identifications that appear in all timepoints are shown. (d) Mean
frequency of IGHV gene use. Error bars are standard deviation.
14
IGHJ4, IGHJ6, and IGHJ5 account for 86% of total IGHJ usage. Furthermore,
IGH V, D, and J gene usage are not significantly different from a log-normal
distribution (Anderson-Darling, H=0, p>0.05).
2.3.3 Gene combination frequencies are stable over time
Given the temporal stability of individual genes, we hypothesized that
differential intrinsic longevity might be found in gene combinations. Surpris-
ingly, our analysis indicates that gene combinations, like their individual com-
ponent genes, are time stable as well. We find that 92% V-J (Figure 2.3), 97%
V-D (Figure 2.4), 95% D-J (Figure 2.5), and 97% V-D-J (Figure 2.6) do not
show significant trends (Mann-Kendall, H=0, p>0.05).
To better understand the nature of gene combinations, we analyzed
preferential gene pairing biases by comparing the expected versus observed
frequency of pairwise gene combinations. The observed frequency of each gene
combination is correlated to its expected frequency (Spearman r): V-D (0.74),
V-J (0.87), D-J (0.93), and V-D-J (0.65) (Figure 2.7a-d). This high level
of correlation and lack of significant outliers suggests minimal gene pairing
linkage and that gene pairing is a random process.
2.3.4 Persistent CDR-H3 clonotypes are unique to BM plasma cells
To understand how each of these individual genes and gene combina-
tions together might indicate the existence of long lived plasma cells, we ana-







































































































































Figure 2.3: Frequencies of gene combinations among BM plasma cells
are temporally stable IGH V-J usage frequencies for Donor 1 are shown.
Plots are sorted by decreasing mean frequency. Only gene identifications that
appear in all timepoints are shown. See Figure 2.4(a-c) for usage frequencies





































































































































Figure 2.4: IGH V-D combination gene use frequency of plasma cells
from Donor 1 Plots are sorted by decreasing mean frequency. Only gene





































































































































Figure 2.5: IGH D-J usage frequencies for Donor 1 Plots are sorted























































































































Figure 2.6: IGH V-D-J usage frequencies for Donor 1 Plots are sorted
by decreasing mean frequency. Only gene identifications that appear in all
timepoints are shown.
















































































Figure 2.7: Gene combinations among BM plasma cells do not pref-
erentially associate Gene combinations are randomly assorted in Donor 1.
(a-d) Spearmans rank correlation of expected versus observed IGH V-D (a),
V-J (b), D-J (c), and V-D-J (d) gene combination frequencies. Expected (by
random association) frequencies are calculated as products of the frequencies
of the individual component genes. Diagonal lines in red indicate no difference
between the expected and observed frequencies.
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identifier of an antibody producing cell. To eliminate errors and ambiguities,
we clustered CDR-H3s into clonotypes based on previously established criteria
(see Methods). On average, 16% of clonotypes are shared between adjacent
timepoints (Figure 2.8a, top). Comparison of the BM plasma cell compart-
ment with memory B cells (mBCs) co-isolated from the same biopsy specimens
provided a baseline to gauge stability across the larger framework of the B cell
compartment. In mBCs, gene stability was statistically similar to the plasma
cell compartment (Figure 2.9). However, no persistent CDR-H3 clonotypes
were found among 58,953 mBCs isolated by flow cytometry from the same
biopsies across four years in this same donor.
Interestingly, among BM plasma cells, 23 clonotypes persist across all
timepoints spanning 6.5 years (Figure 2.8b). We find that 100% of these persis-
tent clonotypes are time stable (Figure 2.8a, bottom, Mann-Kendall test, h=0,
p>0.05) and 78% (18/23) are of the IgA isotype. In addition, characteristics of
the complete CDR-H3 population, specifically CDR-H3 lengths (Figure 2.10)
and hydropathy index (Figure 2.11a), are unchanged over time. The overall
total distribution of CDR-H3 lengths are consistent with previously reported
single timepoint values. Also, higher expressing CDR-H3s tend to be neither
hydrophobic nor hydrophilic (Figure 2.11b) and we find no significant trends
















IGHV4-30-4/31 | IGHJ4 | IGHA 
CARAYQFTLFGVTSHHYFDYW 
IGHV4-b | IGHJ4 | IGHA 
CVRFTSRDMMFDQW 






IGHV3-74 | IGHJ4 | IGHA 
CARTSTASQGGYFDSW 
IGHV1-69 | IGHJ5 | IGHA 
CAREASVKGPYFDPW 






IGHV3-53/66 | IGHJ4 | IGHA 
CAIGTSWSLYYFDYW 
IGHV1-69 | IGHJ3 | IGHA 
CARVLSGGTYYEWDAFDIW 






IGHV3-64 | IGHJ4 | IGHA 
CVKGQRRDSGDYDDFDCW 
IGHV4-34 | IGHJ5 | IGHA 
CARGAGIVVIPGEVEDSWFDPW 






IGHV3-30/33rn | IGHJ6 | IGHA 
CARGGLILDYYYGMGVW 
IGHV1-69 | IGHJ6 | IGHA 
CARSPAQGFGDSDFYMNVW 






IGHV1-24 | IGHJ4 | IGHA 
CATLAYDNWGSGFDYW 
IGHV1-2 | IGHJ4 | IGHA 
CAKGEDSALVLYFDSW 






IGHV1-18 | IGHJ6 | IGHA 
CAREQLAPLYGMDVW 
























































Figure 2.8: Frequencies of persistent antibody clonotypes among BM
plasma cells are temporally stable (a) Circos plot of shared CDR-H3 an-
tibody clonotypes between adjacent timepoints across 6.5 years for Donor 1
(top). Circos plot of the persistent clonotypes across all timepoints (bottom).
Each band in the outermost perimeter represents the clonotypes found in a
given timepoint, sorted by decreasing frequency. The inner curved lines in-
dicate the same clonotype shared by two timepoints. Green indicates high
frequency; purple, low frequency; with lighter colors indicating intermediate
frequency. (b) Gene usage frequency over time of the 23 persistent clonotypes
(see Methods) found in all timepoints. Plots are sorted by decreasing mean
frequency. Gene names (for IGHV and IGHJ), representative amino acid se-











































































































































































































































Figure 2.9: IGHV frequencies across four years in Donor 1 in imma-
ture B and memory B cell subsets isolated from bone marrow Plots




























































Figure 2.10: CDR-H3 length distribution for each timepoint from
Donor 1
23
Figure 2.11: CDR-H3 frequency and hydropathy distribution For
Donor 1 (a) CDR-H3 hydropathy distribution for each timepoint. (b) CDR-
H3 frequency versus hydropathy scatter plot.
24
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Figure 2.12: Gene and gene combination use frequencies correlate be-
tween Donor 1 and Donor 2 (a) Spearmans rank correlation of individual
gene frequencies between the two donors: IGHV (top), IGHD (center), and
IGHJ (bottom). (b-e) Spearmans rank correlation of combination gene fre-
quencies between the two donors: V-D (b), V-J (c), D-J (d), and V-D-J (e).
(a-e) Red lines indicate least squares regression.
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2.3.5 Second donor corroborates observations from first donor
To verify our longitudinal observations of stability and random gene
choices from Donor 1, we analyzed a second donor across two years (Figure
2.12). We identified 38 IGHV genes, 22 IGHD genes, and 6 IGHJ genes (5,016
combinations, 6,763 cells, 93,936 reads) (Table 2.1 and Figure 2.13). Donor
1 and Donor 2 show highly correlated IGHV gene usage (r=0.82). Thus, the
trends observed in Donor 1 are also observed in Donor 2. Specifically, individ-
ual IGHV, IGHD, and IGHJ gene usages are time stable (Figure 2.13), as are
the gene combinations (Figure 2.14). Consistent with Donor 1, Donor 2 shows
no preferential pairing in gene combinations (Figure 2.15). These results are
highly consistent with the trends observed in Donor 1, and together, they in-
dicate that BM plasma cell antibody gene and gene combination usage show
surprisingly minimal variation between individuals and across time. Interest-
ingly, minimal variation and a high degree of correlation is maintained when
the BM plasma cell repertoires of Donor 1 or Donor 2 are compared with the
BM plasma cell repertoire that was obtained from a single donor (age 64) in
a separate study [28] (Figures 2.16 and 2.17).
Like Donor 1, no persistent CDR-H3 clonotypes are found among 24,287
mBCs sorted from the same biopsies across 2.3 years in Donor 2. In contrast,
persistent CDR-H3 clonotypes (165) are readily detected in the BM plasma cell
compartment (Figure 2.18). Importantly, these 165 clonotypes are exclusive to
the plasma cell compartment (i.e., absent among mBCs). Lastly, as a measure
































































































































































































Figure 2.13: Gene usage frequency over time for Donor 2 For Donor
2: (a-c) IGHV (a), IGHD (b), and IGHJ (c) gene usage frequency over time.
Plots are sorted by decreasing mean frequency. Only gene identifications that
appear in all timepoints are shown. (d) Mean frequency of IGHV gene use.




























































































































Figure 2.14: IGH V-J usage frequencies for Donor 2 Plots are sorted
by decreasing mean frequency. Only gene identifications that appear in all
timepoints are shown.
28














































































Figure 2.15: Gene combinations among BM plasma cells are randomly
assorted in Donor 2 Gene combinations among BM plasma cells are ran-
domly assorted in Donor 2. (a-d) Spearmans rank correlation of expected ver-
sus observed IGH V-D (a), V-J (b), D-J (c), and V-D-J (d) gene combination
frequencies. Expected (by random association) frequencies are calculated as
products of the frequencies of the individual component genes. Diagonal lines
in red indicate no difference between the expected and observed frequencies.
29
−3.0 −2.0 −1.0 0.0



















y Spearman r: 0.76
−3.0 −2.0 −1.0 0.0



















y Spearman r: 0.84
−3.0 −2.0 −1.0 0.0


















y Spearman r: 1.00
−5 −4 −3 −2 −1 0



















−5 −4 −3 −2 −1 0


















−5 −4 −3 −2 −1 0


















−5 −4 −3 −2 −1 0





















Figure 2.16: Gene and gene combination use frequencies correlate
between Donor 1 and donor from Halliley, 2015 (a) Spearmans rank
correlation of individual gene frequencies between the two donors: IGHV (top),
IGHD (center), and IGHJ (bottom). (b-e) Spearmans rank correlation of
combination gene frequencies between the two donors: V-D (b), V-J (c), D-J
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Figure 2.17: Gene and gene combination use frequencies correlate
between Donor 2 and donor from Halliley, 2015 (a) Spearmans rank
correlation of individual gene frequencies between the two donors: IGHV (top),
IGHD (center), and IGHJ (bottom). (b-e) Spearmans rank correlation of
combination gene frequencies between the two donors: V-D (b), V-J (c), D-J
(d), and V-D-J (e). (a-e) Red lines indicate least squares regression.
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two donors, we observe no inter-donor sequences shared between their mBC
compartments, as expected, and only one of the total 188 persistent plasma


































































































































Figure 2.18: Gene usage frequency over time of the 165 persistent
clonotypes found in both timepoints in Donor 2 Plots are sorted by
decreasing mean frequency. The gene names (for IGHV and IGHJ), represen-




Position VH gene JH Gene Isotype Representative CDR-H3
A1 IGHV1-69 IGHJ1 IGHG CARHPSNSWFRIHFQHW
B1 IGHV1-69 IGHJ1 IGHA CARGGEQGNYYRTWEYYPYW
C1 IGHV4-34 IGHJ4 IGHM CARWIRYCSGGDCYPSMYYFDYW
D1 IGHV1-18 IGHJ6 IGHG CARDRCSGGSCYPGRPQYFYGMDVW
E1 IGHV1-24 IGHJ3 IGHG CATVAITVDYDSTAYDGLDVW
F1 IGHV1-69 IGHJ4 IGHG CAKASQNYDSSGYFDCW
G1 IGHV1-3 IGHJ6 IGHA CARVTATSILGDSGRHHYYAMDVW
H1 IGHV1-46 IGHJ3 IGHA CARGLRGNLRVLAILPAGAFDMW
I1 IGHV1-46 IGHJ6 IGHA CARPLSQRGHFYYGMDVW
J1 IGHV4-34 IGHJ4 IGHG CARGRIVVAPAAMFRRRGSDYFDYW
K1 IGHV1-69 IGHJ6 IGHG CASDNKIYDYGDGDFQYHNLAVW
A2 IGHV3-15 IGHJ5 IGHG CVTQATAATAGLAAIITNFDLW
B2 IGHV1-46 IGHJ3 IGHA CARVIKPGKNDVFEIW
C2 IGHV1-3 IGHJ5 IGHG CARVVDTPFCRSSNCHNWLDPW
D2 IGHV1-69 IGHJ5 IGHA CATWGGHCTWYNWCSRVTAFSLDIW
E2 IGHV3-23 IGHJ4 IGHA CAKAPLDVVTELDYW
F2 IGHV4-34 IGHJ4 IGHG CARVVNGVAPAAIFHRRGLDYFDYW
G2 IGHV1-69 IGHJ3 IGHA CARDLRDMSASGGVTFDAFNIW
H2 IGHV1-69 IGHJ4 IGHA CARWDGHCSFFNWCSGRTVFPLDFW
I2 IGHV1-8 IGHJ4 IGHG CARGGGSNWRRIHPVDYW
J2 IGHV1-69 IGHJ5 IGHG CARDMNDYYDPSGYSGALDHW
K2 IGHV4-34 IGHJ4 IGHG CARARVRNPTGLFRRGYPVFDSW
A3 IGHV4-30-4/31 IGHJ4 IGHA CAVMYNWNYGFDYW
B3 mIGHV6-3/6 IGHJ4 IGHG CARYVWYSSYPHSYSGLDYW
C3 IGHV4-30-4/31 IGHJ3 IGHG CARVGYDGRDYVGKYGFDIW
D3 IGHV4-34 IGHJ4 IGHG CAGKRRLYSYGLGSYYYFESW
E3 IGHV3-7 IGHJ5 IGHM CARRGPTFWSGYYESYYDAW
F3 IGHV1-3 IGHJ6 IGHG CATTNRQIRAARDFYGMDVW
G3 IGHV3-53/66 IGHJ4 IGHG CARTGQDWYDIHLEHW
H3 IGHV3-30/33rn IGHJ4 IGHG CARELYAGSSGYVGYFDSW
I3 IGHV1-69 IGHJ4 IGHA CATWGGQCAWYNWCNRNTAFSLDFW
J3 IGHV1-69 IGHJ5 IGHG CALGVKGFMVHGGAKNWFESW
K3 IGHV1-18 IGHJ3 IGHG CARGTDYGDYIGAFDFW
A4 IGHV1-3 IGHJ6 IGHG CARVTATSELRDTGRHHYYIMDVW
B4 IGHV3-15 IGHJ6 IGHG CATGSHPGRKFYYGSVFW
C4 IGHV3-30/33rn IGHJ6 IGHG CARDSVHMINSYDYYFGMDVW
D4 IGHV3-30/33rn IGHJ4 IGHG CARDCSGYFCFDHW
E4 IGHV4-34 IGHJ3 IGHG CAACGGSSSCGRAFDIW
F4 IGHV5-51 IGHJ4 IGHG CARHRGDPFYHGLESRMRFFDYW
G4 IGHV4-34 IGHJ6 IGHG CARGHDFLSPPGYYYGLDVW
H4 IGHV1-69 IGHJ3 IGHG CARTRALADGGAFEIW
I4 IGHV3-30/33rn IGHJ6 IGHG CAKEESNHVNYYYYYAMDVW
J4 IGHV3-30/33rn IGHJ5 IGHG CARYYYDTSGPVLDLW
K4 IGHV4-34 IGHJ4 IGHG CARLVSVVVPSALFHRRGLEYFDSW
A15 IGHV4-34 IGHJ3 IGHG CARRVATIARGAFDIW
B5 IGHV3-30/33rn IGHJ4 IGHG CARIHISAPGNNFDYW
C5 IGHV1-24 IGHJ6 IGHA CATGEGDAYNYGLDVW
D5 IGHV3-30/33rn IGHJ1 IGHG CARIHIAAHGNNFESW
E5 IGHV4-34 IGHJ4 IGHG CASFAGFRDKWSHLAYW
F5 IGHV1-18 IGHJ4 IGHG CARDLKGVSVSATFWGLSDDW
G5 IGHV3-11 IGHJ4 IGHG CARVHSYGDRGPFDYW
H5 IGHV4-34 IGHJ6 IGHG CVRGHPYKGLGKLYYHYYYGMDVW
I5 IGHV1-69 IGHJ5 IGHA CATWGGHCTWYNWCSRVTAFSLDIW
J5 IGHV1-46 IGHJ6 IGHG CARGDTMVGGIDCMDVW
K5 IGHV1-69 IGHJ6 IGHG CSRSLRGRWLQSDRDYYYAMDVW
A6 IGHV4-30-4/31 IGHJ4 IGHG CARVVETATDYW
B6 IGHV3-30/33rn IGHJ4 IGHA CARVFESYNLDHW
C6 IGHV4-59/61 IGHJ2 IGHG CARGRSGDYILYWYLDLW
D6 IGHV1-24 IGHJ5 IGHG CASIMGHDYGDYVETPNWFDPW
E6 IGHV1-46 IGHJ6 IGHA CARDPVGATRGGGGMDVW
F6 IGHV1-2 IGHJ3 IGHG CARGSDRGYAVLGELSAGGAFDIW
G6 IGHV1-2 IGHJ5 IGHM RATTYCNGVCPDDNWFDPW
H6 IGHV1-2 IGHJ5 IGHG CARDGRPLQFLKNWFDPW
I6 IGHV4-34 IGHJ6 IGHG CARMVVKQQLLPRFQVGYYGMDVW
J6 IGHV1-18 IGHJ1 IGHA CTRDNSNYPEYFQHW
K6 IGHV1-8 IGHJ3 IGHM CARGSYYDSSGHYHRIAFDIW
A7 IGHV3-30/33rn IGHJ6 IGHG CARWAYEGTDVYYYYGMDVW
B7 IGHV1-18 IGHJ5 IGHA CAKDLWTVTPSFNWFDSW
C7 IGHV1-46 IGHJ4 IGHA CAREFLGPDYYGSGTKYEYW
D7 IGHV1-69 IGHJ6 IGHA CARVPYFGSGSYYENYYDMDVW
E7 IGHV1-69 IGHJ6 IGHA CARLPFFGSGSYYENYYDMDVW
F7 IGHV1-69 IGHJ6 IGHG CAREGGYCTSPRCYVLEWPRNAGPDYYYNYHMNVW
G7 IGHV1-3 IGHJ5 IGHG CARSDQWLVGLDPW
H7 IGHV4-34 IGHJ6 IGHG CARGRFKVVVFGVALEYGLDVW
Continued on next page
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Table 2.2 – continued from previous page
Position VH Gene JH Gene Isotype Representative CDR-H3
I7 IGHV1-69 IGHJ4 IGHA CATTEDGRVPGYFDYW
J7 IGHV3-30/33rn IGHJ6 IGHG CAKDEQMTATYYYYFYGMDVW
K7 IGHV1-69 IGHJ4 IGHA CVRESRKDGYGRDW
A8 IGHV4-34 IGHJ6 IGHG CARRYDASGSHYYFYYYHMDVW
B8 IGHV3-30/33rn IGHJ4 IGHG CAKDGGIGFTDFDSW
C8 IGHV1-46 IGHJ4 IGHA CAREGTSRFFQYW
D8 IGHV3-30/33rn IGHJ1 IGHG CARIHIRAGGNNFDSW
E8 IGHV4-30-4/31 IGHJ4 IGHG CARVGPFDTTGYYFDYW
F8 IGHV1-2 IGHJ4 IGHG CAREAPNLRYYFDFW
G8 IGHV3-30/33rn IGHJ2 IGHA CAKDRGISGSYLDWYFDLW
H8 IGHV4-34 IGHJ4 IGHG CARGVYSGSGSYDYW
I8 IGHV1-69 IGHJ6 IGHA CAREETEYTTSSLRTTTPYNYGLDIW
J8 IGHV1-46 IGHJ3 IGHA CARVTKPGKNDVFEIW
K8 IGHV1-18 IGHJ5 IGHA CARGHIWKELDSW
A9 IGHV1-3 IGHJ6 IGHG CARDGRGSYGSDFYHSMDAW
B9 IGHV1-69 IGHJ4 IGHA CARVPTTNILDSGYDYYFDYW
C9 IGHV1-46 IGHJ4 IGHG CARDISSWHEPRYYFDDW
D9 IGHV1-8 IGHJ5 IGHG CARVYGVWGVERGLQNQHFDQW
E9 IGHV1-18 IGHJ5 IGHG CARDTPNYQLLEDFW
F9 IGHV1-18 IGHJ4 IGHA CTRDTPNYQLLEDYW
G9 IGHV4-39 IGHJ4 IGHG CTRDSGFYLRMGYW
H9 IGHV3-21 IGHJ4 IGHA CARGAGGNPVGPTKEPKGGFDYW
I9 IGHV3-30/33rn IGHJ4 IGHG CARIHIRAAGNNFDNW
J9 IGHV1-3 IGHJ4 IGHA CAREGVDMPTVWPIRPSRNYFDSW
K9 IGHV1-69 IGHJ4 IGHA CARWNGHCSFFNWCSGRTVFPLDFW
A10 IGHV4-34 IGHJ5 IGHG CARLGVVLPAAMFSRKGGNQFDPW
B10 IGHV4-b IGHJ4 IGHA CARGPRTMYNSNYYDYFFDYW
C10 IGHV1-3 IGHJ6 IGHA CARVTATSIVTDAGRLWYYAMDVW
D10 IGHV1-8 IGHJ4 - CARGRGAAVVRPETYW
E10 IGHV1-2 IGHJ4 IGHA CARAWNDVPGGYW
F10 IGHV4-59/61 IGHJ5 IGHG CARSTLSYCGDSCYPLDSW
G10 IGHV1-18 IGHJ6 IGHG CVRDIFSTEWTLGYHGMDVW
H10 IGHV4-34 IGHJ5 IGHG CARLTSVVPAAMFSRMGGDHFDPW
I10 IGHV3-30/33rn IGHJ3 IGHG CAREGSGWLAAFDIW
J10 IGHV3-23 IGHJ4 IGHG CAKKRLVGFLHHFFDSW
K10 IGHV1-69 IGHJ4 IGHM CARVMEYCSGGSCYEDFDYW
A11 IGHV1-46 IGHJ3 IGHG CARGVTLYYGESDAGDAFDIW
B11 IGHV1-18 IGHJ5 IGHA CARDRCITTSCYPWFDPW
C11 IGHV3-53/66 IGHJ6 IGHA CARAPGLQGGYYYYYGMEVW
D11 IGHV1-18 IGHJ5 IGHA CARVDFYDLLPGYCKYW
E11 IGHV3-74 IGHJ4 IGHA CVRSHTGRYDNW
F11 IGHV1-18 IGHJ5 IGHA CARDLWTVTPSFNWFESW
G11 IGHV1-69 IGHJ5 IGHG CATWGGHCTWYSWCSRVTAFSLDIW
H11 IGHV4-34 IGHJ6 IGHG CVRGPREEPAGPSHPRYYFYYSAIDVW
I11 IGHV1-2 IGHJ4 IGHA CATSLELRVPDDSW
J11 IGHV4-39 IGHJ3 IGHA CAREDSYKTRNTFDIW
K11 IGHV1-2 IGHJ4 IGHG CARTLEDYEDYW
A12 IGHV1-69 IGHJ5 IGHG CARGRDDYKGEVFDHW
B12 IGHV4-34 IGHJ6 IGHG CARMVIKQQPLPRFQVAYYGMDVW
C12 IGHV4-34 IGHJ4 IGHA CARGPPGYALDYW
D12 IGHV1-46 IGHJ6 IGHA CARDFRAILLVRGVLRDYALDVW
E12 IGHV3-23 IGHJ4 IGHG CAKEDCSSANCYRLDYW
F12 IGHV4-59/61 IGHJ6 IGHA CARVVTLRVAGSSQYYMDTW
G12 IGHV1-3 IGHJ6 IGHG CARVTATSRVTDAGRLWFYAMDVW
H12 IGHV4-59/61 IGHJ4 - CAVNYDSSGYTRGFDSW
I12 IGHV1-69 IGHJ3 IGHG CARDGGYCSGRACHAYAFDMW
J12 IGHV1-69 IGHJ6 IGHG CARDIAVSETDYYYFALDVW
K12 IGHV3-30/33rn IGHJ4 IGHA CASELTRVAAAGKGNDYW
A13 IGHV4-59/61 IGHJ3 IGHG CARPIWEPRDAFDIW
B13 IGHV1-3 IGHJ1 IGHA CARRPYCSGGSCYTGEYFQHW
C13 IGHV1-8 IGHJ5 IGHA CARGNKPDHTASSLSKNWFDPW
D13 IGHV1-18 IGHJ6 IGHA CARDDRYSSAWYLGSYYGMDVW
E13 IGHV4-39 IGHJ5 IGHG CARHYDFVWGTYRDQARNWFDPW
F13 IGHV5-51 IGHJ3 IGHA CARPEAISGFYAFDVW
G13 IGHV1-69 IGHJ5 IGHA CARWDGHCSFFNWCSGRTVFPLDFW
H13 IGHV1-69 IGHJ4 IGHA CASAGGDDIFAVVTYYW
I13 IGHV3-11 IGHJ4 IGHM CARGLRGYSYGLSDYW
J13 IGHV4-4 IGHJ4 IGHM RASRRVGATFYW
K13 IGHV1-18 IGHJ4 IGHA CARVQSNSIFGVFIPYHLDSW
A14 IGHV4-34 IGHJ5 IGHA CARWIRYCSGGDCYPSMYYFDSW
B14 IGHV1-2 IGHJ6 IGHA CFRETQRGYGMDVW
C14 IGHV3-15 IGHJ6 - CATGSHPGRKVLHGSVVW
D14 IGHV1-69 IGHJ4 IGHA CARESGDGYNPKRAHVFDYW
E14 IGHV1-69 IGHJ3 IGHA CASHQPKNYYDSSSYRAFDIW
Continued on next page
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Position VH Gene JH Gene Isotype Representative CDR-H3
F14 IGHV1-3 IGHJ5 IGHG CAREPVPHQLLYWFDPW
G14 IGHV4-34 IGHJ4 IGHG CARGRIVVASAALFRRRGSDYFDYW
H14 IGHV4-34 IGHJ4 IGHA CARLVSVVQPAALFHRRGLDYIDFW
I14 IGHV1-18 IGHJ1 IGHG CARGHIWKELDSW
J14 IGHV3-48 IGHJ5 IGHM CALSRDGYSHKW
K14 IGHV4-59/61 IGHJ6 IGHM CARRSGGSHYYMDVW
A15 IGHV4-34 IGHJ6 IGHA CVRGHPYKGFGEKYYLYYYGMDVW
B15 IGHV4-34 IGHJ4 IGHG CARGQTALKPVVFGVVITRPTNNYFDYW
C15 IGHV3-21 IGHJ4 IGHA CARDDGDSVAEEYW
D15 IGHV4-34 IGHJ5 IGHG CARLGVVVPVAMFSRKEGNHFDPW
E15 IGHV1-2 IGHJ6 IGHA CARDFLPPGQVATIPLWHGMDVW
F15 IGHV4-34 IGHJ6 IGHM CARGHEDYSNYYYYGMDVW
G15 IGHV1-8 IGHJ6 - CARVGGPYSIHYMDVW
H15 IGHV1-69 IGHJ6 IGHG CARDGRGQRPTRHIIIINTDWYLW
I15 IGHV1-69 IGHJ4 IGHG CARSPVAGAYFFDYW
J15 IGHV1-69 IGHJ1 IGHG CARGGNRGVIIGPGNTYPYW
K15 IGHV4-30-4/31 IGHJ4 IGHG CARGAYFYGSGLDYW
Table 2.2: Gene names, representative amino acid sequences, and
isotypes for persistent CDR-H3s in Donor 2 The IGHV and IGHJ gene




High-throughput sequencing has enabled unprecedented ability to ex-
plore the details of the human B cell repertoire [23, 41]. Whereas previous
studies have been able to describe some aspects of the B cell repertoire at a sin-
gle point in time, our study harnesses the power of high-throughput sequenc-
ing and longitudinal biopsies of bone marrow (BM) to elucidate the temporal
dynamics of BM plasma cells over 6.5 years. Importantly, our data provide
molecular resolution of antibody identity in the form of CDR-H3 clonotypes,
which is not possible with classic techniques like enzyme-linked immunosor-
bent assay (ELISA).
In this study, we show that the human plasma cell compartment is nat-
urally polarized in both IGH gene choice and gene combination and that the
polarization is maintained over time. Although our donors were originally di-
agnosed with and treated for neuroblastoma, they had been asymptomatic and
disease-free for several years, and it was during this span when their BM biop-
sies were acquired; moreover, it is noteworthy that their IGH polarization is
statistically similar to a distinct high-throughput sequencing dataset obtained
independently by another research group [28] using a single donor at a single
point in time. We also found that the bias is not primarily a result of gene
linkage, suggesting there are additional genomic or extrinsic factors that con-
tribute to polarization. Specifically, high-throughput sequencing of identical
twin pairs [24, 53] has revealed clear trends for genetic, or heritable, determi-
nants of IGH gene segment use. Nonetheless, the CDR-H3 region maintains
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hypervariability and fingerprints inter-individual variation that distinguishes
twin pairs. In addition, the long arms race between the human immune sys-
tem and the antigens it has confronted throughout evolutionary history may
have established a preferential gene choice long ago, and thus there may ex-
ist common antibody-mediated solutions to protective immunity. Higher ex-
pressing genes are likely broad-spectrum antibodies that have been useful in
fighting particular classes of disease and continue to do so today. For example,
IGHV1-69 is repeatedly implicated in deep sequencing studies of anti-viral an-
tibody repertoires (e.g., influenza and HIV-1), and the inherently autoreactive
IGHV4-34 element is associated with a range of autoimmune disorders (e.g.,
cold agglutinin disease and systemic lupus erythematosus). Indeed, conver-
gent, or public, responses using these IGHV gene segments coupled within
homologous CDR-H3 clonotypes continue to be discovered [29, 56, 33].
Immunological memory is a well-established concept, and memory B
cells (mBCs) and BM plasma cells are thought to be key contributors, in
part, through their putative cellular longevity and hypothesized capacity for
self-renewal. How intrinsic longevity might be established and maintained re-
mains an outstanding question. It has been proposed that mBCs generate
plasma cells for the lifetime of the human host. It is further hypothesized that
mBCs are endowed with a stem cell-like capacity for self-renewal and could be
the basis for the continual production of plasma cells [19]. Evidence in sup-
port of this hypothesis includes the demonstration that polyclonal activation
of mBCs results in their differentiation into plasma cells in vitro [7]. Since
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class-switched mBCs coexist with plasma cells in human bone marrow [50],
we sequenced both compartments to test the hypothesis that BM mBCs may
be a renewable source of plasma cells and, indirectly, the source of long-term
antibody production in humans. Steady usage of IGH gene and gene com-
binations observed in both donors throughout our experiment suggests that
there are large resident pools of plasma cells of the same identity, from which
we can sample continuously with no loss of relative expression levels. Most
importantly, we observe years-long temporal persistence of 188 unique, highly
diverse CDR-H3 clonotypes exclusively within the plasma cell compartment,
whereas CDR-H3 temporal persistence was devoid in the mBC compartment.
This provides a crucial point of comparison between these two B-cell subsets
pivotal to immunological memory. The data imply that the molecular se-
quence stability in the plasma cell compartment is due to persistence of the
cellular clonotype. It is not simply a reflection of the näıve B cell repertoire
nor mBC repertoire in general (i.e., heritable influences of IGH gene use, nor
replenishment from the mBC compartment).
Whereas ample data have established the persistence of antigen-specific
serum immunoglobulin titers, which have half-lives of decades or longer [2],
there is to date no insight as to whether the molecular composition of these
antibody titers is a homogenous pool of immunoglobulin maintained by a hand-
ful of long-lived plasma cell cellular clonotypes or is rather a continual flux and
turnover of transitory plasma cell clonotypes. Although our results are unable
to verify the lifespan of any one particular plasma cell, we can conclude that
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clonal members of the CDR-H3 clonotype, which defines identity and binding
specificity at the molecular level, do persist for at least 6.5 years. Our results
suggest that clonotype persistence contributes to the mechanism underlying
long-term immunological memory.
In conclusion, we use high-throughput, next-generation sequencing to
definitively identify long-term persistent BM plasma cell clonotypes, which
has implications in clinical intervention studies, vaccines, and immunotherapy.
Future next-generation sequencing studies can provide an even more detailed
picture of the B cell immune repertoire including advances in VH:VL native-
pair sequencing (paired BCR-Seq [15, 16]), analysis of correlations between BM
plasma cell repertoires and serum immunoglobulin species (Ig-Seq [62, 40, 41]),
and examination of the connectivity of B cells at various developmental stages
(e.g., clonal relationships between circulating memory B cells and sessile BM
plasma cells). Our study provides a foundation upon which these further
studies can be built.
2.5 Methods
2.5.1 Bone marrow specimens
Serially acquired human bone marrow specimens were collected from
two donors by aspiration from the ileac crest, and mononuclear cells were en-
riched by Ficoll hypaque centrifugation. The two adolescent-teenage donors
(10-17 years of age) were originally diagnosed with neuroblastoma but had
been asymptomatic and disease-free for many years according to routine bone
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marrow histology before the first timepoints in our study. A complete descrip-
tion of the donors past medical history and ages at the time of the multiple
time point collections is included in Table 2.1. Aspirates were withdrawn from
four sites and combined (total of 810 mL from 4 sites, 22.5 mL per site) drawn
from the following: anterior right iliac crest, anterior left iliac crest, posterior
right iliac crest, and posterior left iliac crest. The same attending physicians
performed these procedures and usually biopsied through the same surgical
site each time. De-identified specimens were shipped overnight on dry ice to
the University of Texas at Austin.
2.5.2 Flow cytometry and isolation of plasma cells
BM samples were quick-thawed in a 37◦C H2O bath and slowly di-
luted into RPMI-1640 complete medium containing DNaseI (Sigma D 4513;
20 U/mL), pelleted, washed and re-suspended in 2 mL FACS buffer (Dulbec-
cos PBS + 0.5% BSA Fraction V). Cell viability was determined using Trypan
Blue exclusion and on average was approximately 90% per specimen. After
a one-hour recovery at room temperature, BM cells were stained for 30 min-
utes at room temperature using empirically-determined optimal titrations of
monoclonal antibodies: CD38-FITC (HIT2), CD138-PE (B-B4), CD27-APC
(M-T271), and CD19-v450 (HIB19). CD19+/-CD38++CD138+ cells in hu-
man BM were collected as plasma cells. Plasma cells were observed to be
heterogeneous for expression of the CD19 B-lineage marker; therefore, CD19-
gating was avoided. CD38++CD138+ plasma cells were additionally gated by
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light scatter properties (FSC v. SSC) to exclude debris, apoptotic cells, and
remnant granulocytes. In a subset of bone marrow specimens, memory B cells
(mBC) were also collected as CD19+CD27+CD38-CD138-. Donor 1 included
mBCs at 0, 0.5, 0.6, 1.5, and 4.0 years; Donor 2 included mBCs at 0 and 2.3
years. All cell sorts were performed on a FACSAria (BD Biosciences). Cells
were sorted directly into TRI Reagent for RNA preservation.
2.5.3 RT-PCR and high-throughput sequencing of IGH genes
Total RNA was isolated using the RNeasy Micro Kit (QIAGEN). Ap-
proximately 100 nanograms of total RNA was then used to prepare oligo-
dT primed cDNA using the SuperScript III First-Strand Synthesis System
(Thermo-Fisher Scientific) according to the manufacturers protocol. Approxi-
mately 25%-50% (5-10 µl) of cDNA was then used as template for polymerase
chain reaction (PCR) amplification of variable genes (recombined VHDJH
region, which encodes the V region) of IGH isotypes IgM, IgG, and IgA.
PCR primers have been published [31]. FastStart High Fidelity PCR Sys-
tem (Roche) was used for amplification combined the following thermocycler
conditions: 92◦C denaturation for 3 min; 92◦C 1 min, 50◦C 1 min, 72◦C 1
min for 4 cycles; 92◦C 1 min, 55◦C 1 min, 72◦C 1 min for 4 cycles; 92◦C 1
min, 63◦C 1 min, 72◦C 1 min for 20 cycles; and a final extension of 72◦C for
7 minutes. Samples were then submitted to the University of Texas Genome
Sequencing and Analysis Facility for library construction using the NEBNext
Quick DNA Library Kit for 454 (New England Biolabs) and next-generation
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sequencing (NGS) was accomplished using the Roche 454 GS FLX technol-
ogy using titanium long-read chemistry. Read counts per sample are listed in
Table 2.1.
2.5.4 Data processing and visualization
IGHV, IGHD, IGHJ, and CDR-H3 regions for each read was qual-
ity filtered, processed and annotated using the VDJFasta utility [25]. Refer-
ence IGHV, IGHD, and IGHJ genes from the international ImMunoGeneT-
ics (IMGT) database [1] were used. Mann-Kendall Tests were performed in
Matlab, against the null hypothesis of no trend (α = 0.05). Spearman r
non-parametric correlation analysis was performed in Python using the scipy
library. CDR-H3 sequences were clustered to form antibody clonotypes, as
established previously [67, 12], using full-length VHDJH gene nucleotide se-
quences. VHDJH genes were grouped into clonotypes based on single-linkage
hierarchical clustering, and cluster membership required 85% identity across
the CDR-H3 amino sequence (as measured by Levenshtein edit distance).
Circular visualization plots were created with Circos software v0.67-7
[37] where genes were sorted by expression within each timepoint and con-
nected to adjacent timepoints via colored lines showing their expression levels.
All other data visualization was performed using Python and matplotlib.
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2.5.5 Data availability
All sequence data have been deposited to NCBI SRA under BioProject
number PRJNA310043.
2.5.6 Ethics approval
All procedures were performed with parental consent at the Memorial
Sloan-Kettering Cancer Center under a protocol approved by the MSKCC
Institutional Review Board. The protocol is registered at ClinicalTrials.gov
(NCT00588068).
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Computational Simulation of Error in Immune
Repertoire Sequencing
3.1 Abstract
While the advent of high-throughput sequencing makes accessible pre-
viously intractable questions regarding the immune repertoire, the nature and
consequences of errors in the multistep experimental and computational ma-
nipulations are not well understood. It remains an open question whether
the true biological antibody repertoire of the tissue sampled is accurately cap-
tured in the empirically observed repertoire. There lacks a tractable experi-
mental approach for understanding the extent of error generated by the high-
throughput sequencing pipeline. Here, we present a computational simulation
that is capable of addressing these problems. We demonstrate that there are
multiple sources of error, including cell sampling, nucleic acid amplification,
and high-throughput sequencing. Under reasonable assumptions, we find that
10-18% of cell sampling is required to capture a majority of the antibody di-
versity. PCR and sequencing contribute most to the overall error. We quantify
the extent of error correction that can be achieved by sequence clustering and
demonstrate that clustering is critical for a more accurate reconstruction of the
true underlying repertoire. Surprisingly, different true biological distributions,
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when processed through our simulation of HTS immune repertoire workflow,
result in the same empirical distribution due to the cumulative workflow er-
rors. Based on these results, we provide concrete recommendations to others
in the field wanting to perform immune repertoire studies.
3.2 Introduction
Antibody diversity allows the immune system to protect the host from
an enormous number of antigens, many of which are pathogenic. This diversity
is only possible because of the immune systems ability to rearrange on the ge-
netic level at the post germ-stage of development, a process known as somatic
recombination. This process is highly active in B cells that rearrange three
genes (V, D and J) in order to produce antibodies. Understanding antibody
diversity may enable us to better understand how our immune system responds
to external stimuli and the full extent to which it can maintain our health.
However, antibody diversity may theoretically be as high as 1011 [20], mak-
ing the full scope and nature of the antibody repertoire difficult to observe.
The emergence of high-throughput sequencing (HTS) has led to significant
advances in our understanding of the immune repertoire and its diversity. In
zebrafish, it was shown that up to 86% of all possible VDJ combinations were
used [60]. In humans, complete repertoires have not been studied, but numer-
ous studies have still made significant advances toward that end. For example,
preferential V and J gene usage in response to an influenza vaccine has been
observed [33]. In addition, VH and D gene use in antibodies have been shown
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to be strongly biased by genetics and resistant to chronic lymphocyte deple-
tion [24]. In another study, long lived plasma cells in the bone marrow were
shown to have different VH gene usage and RNA transcriptomes in contrast to
their non-long lived counterparts [28]. Recently, gene and gene combination
usage in bone marrow plasma cells were shown to maintain their bias over
time [64]. HTS experiments ultimately result in frequency distributions of
immune sequence identities. These distributions are highly polarized, where a
small number of sequences account for a disproportionate amount of the total
repertoire. The shape of this distribution has been described as a power law
[60, 17], more specifically, Zipf's law [49, 27] or in some cases as a Poisson
distribution [5, 52]. In order to describe and compare these frequency distri-
butions, two key metrics of diversity are used: species richness and species
evenness. Species richness is the total number of unique species in the sys-
tem. Species evenness measures the degree of polarization in a distribution.
Researchers tend to emphasize one of these metrics over the other resulting
in metrics that attempt to blend these two properties together into a single
number. Specifically, the Shannon Index, Simpson Index, and Berger-Parker
Index are common metrics of diversity. A recent proposal attempts to unify
many of these most commonly used diversity indices along a single spectrum
with species richness on one extreme and species evenness on the other [27].








Where f is the clonal frequency distribution with fi being the frequency
of each clone and n the total number of clones.
In this equation, when α = 0, αD(f) is species richness, when α = 1,
αD(f) is Shannon entropy index, when α = 2, αD(f) is the Simpson entropy
index, and when α→∞, αD(f) is Berger-Parker.
Observations about the HTS-generated empirical distributions and di-
versity measures have been used to infer properties of the underlying biological
repertoires. However, it is still unclear whether these empirical distributions
are representative of true biological distributions. This is because antibody
repertoire sequencing poses unique problems to HTS. In contrast to genomic
sequencing experiments, HTS antibody experiments cannot rely on a reference
sequence, and high fold sequence coverage is difficult to obtain. In addition,
short reads are insufficient to accurately identify antibodies because they are
the product of multiple gene recombination, junctional diversity, and short
hypervariable regions separated by long highly similar sequences. These traits
necessitate long accurate reads that push the boundaries of HTS abilities.
Furthermore, because of their complex biology, antibodies exacerbate
existing challenges of HTS experiments. First, the immense size and diversity
of the immune repertoire result in dramatic undersampling of the cellular
compartment. Next, polymerase error from both reverse transcriptase and
DNA polymerase generate sequence mutations. Finally, error in the high-
throughput sequencer is much higher than by traditional Sanger sequencing.
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Here, we present a computational simulation that aims to understand
how each of these dependent processes contributes to the overall error of the an-
tibody repertoire HTS experiment. In addition, we asked: given an empirical
distribution, could we computationally deduce the true biological distribution
from which it originated? To that end, we explore the changes in a theoretical
input distribution when subjected to simulations of previously reported anti-
body repertoire HTS experimental procedures. We offer recommendations on
how best to mitigate the errors inherent in the process and suggest the current



























Figure 3.1: Experimental and model methodology overview (a) Ex-
perimental workflow begins with BM plasma cell sampling followed by FACS
sorting, PCR amplification, 454 sequencing and subsequent analysis. (b) Com-
putational modules that simulate experimental steps. (c) Empirical distribu-
tion of clonotype counts obtained from workflow depicted in (a)
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3.3 Results
3.3.1 Computational simulation of experimental workflow
Our computational simulation aims to provide a theoretical framework
for a typical experimental workflow for an antibody repertoire HTS experi-
ment, as depicted in Figure 3.1a. In a typical profiling experiment, samples
are first collected from either peripheral blood or bone marrow. Subsequently,
B cells are isolated by fluorescently activated cell sorting (FACS). Next, RNA is
purified and made into cDNA using reverse transcriptase followed by amplifica-
tion by polymerase chain reaction (PCR). Then, high-throughput sequencing
is performed using pyrosequencing or Illumina sequencing technology. Finally,
the data from the sequencer is analyzed and visualized computationally.
In order to understand the errors generated at each of these experi-
mental steps, we computationally simulated each step in Figure 3.1b, using
separable computational modules that modeled the errors arising from each
of the major experimental manipulations. Because the true biological distri-
bution of the immune repertoire is as yet still unknown, we assumed different
theoretical initial distributions of the immune cell identities, i.e. the frequency
of unique antibody sequences. We then simulated the cell sampling, amplifica-
tion, high-throughput sequencing, and data analysis pipeline under different
parameters in order to observe how different points of intervention changed
the distribution.
49
3.3.1.1 Theoretical biological distributions
First, we considered possible forms that the true underlying repertoire
might take. We analyzed three theoretical distributions that are widely preva-
lent in nature, testing each in turn as the starting biological distributions in
our simulation: exponential, normal, and uniform. In all three distribution
types, we used 10,000 total cells and 3,000 unique sequences. The three dis-
tributions varied in their levels of polarization and parameterization. For the
most polarized distribution, the exponential distribution, the values 0.1, 0.3,
and 0.5 were used for the rate parameter, λ. For the normal distribution, vary-
ing of the mean parameter did not affect the degree of polarization and the
simulation results; a mean value of 10 was chosen for all normal distributions.
Also, variance values of 0.2, 0.5, 1, and 5 were used to vary the polarization
of the normal distribution. Finally, the uniform distribution relies solely on
the number of total cells and unique sequences. The distribution is inherently
unpolarized and no additional parameters were used.
3.3.1.2 Mixed Diversity Index
In order to compare across different distributions, we used a mixed
diversity index (MDI), which avoids emphasis of any single diversity metric.
The MDI is calculated as the average of αD(f) [27] for α values from 0-10,
since αD(f) does not change dramatically for α values larger than 10 [27].
Species Richness (SR), the number of unique individuals, was used in cases
where αD(f) was divergent for small values of alpha.
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Figure 3.2: Simulated errors resulting from cell sampling with differ-
ent initial distributions (a) Exponential and normal initial distributions
used as inputs into the model (left). Total error, defined as the difference be-
tween post and pre-sampling MDI (Mixed Diversity Index), resulting from a
range of sampling percentages (0-100%). (b) Total error resulting from a range
of sampling percentages of various initial distributions. Uniform: dark blue,
Normal: green, Exponential: red (c) Percent of diversity captured, measured
using percent of unique clonotype IDs represented, over a range of sampling
percentages (0-100%). Percent sampling needed for half maximal of species
richness are represented by dotted lines.
51
3.3.2 Cell sampling bias distorts the initial distribution
In order to test the effect of cell sampling on the final distribution, we
sampled from the true theoretical biological distributions described above. We
found, unsurprisingly, that with increasing percentage of the 10,000 total cells
sampled, the difference between the distribution pre- and post- cell sampling
decreases (Figure 3.2a). This difference, measured by changes in the MDI
(Total Error), varied by type of distribution (Figure 3.2b). For example, the
diversity of the uniform distribution was more difficult to fully sample than
the exponential. This effect is also seen in the sampling needed to achieve
half maximal species richness (as a percent of unique cells captured) (Figure
3.2c). While the uniform distribution requires ∼18% sampling to capture 50%
of the diversity, the exponential and normal only require ∼10% to capture
the same 50% of the diversity. Interestingly, we find that the extreme values
of the distribution parameters were overall less significant than changing the
distribution type. Overall, we find that the more polarized the distribution
independent of its parameter values, the less sampling needed to minimize the
error.
3.3.3 PCR of a monoclonal antibody generates a distribution of
sequences
Next, we isolated the effect of PCR amplification on the various initial
distributions. In order to examine the effects of PCR on the repertoire, we
first considered the case of PCR on a population of antibodies with only one
52
unique identity, i.e. a monoclonal antibody repertoire. Any change to the
repertoire introduced by the PCR would then be obvious as an expansion of
the repertoire away from the single progenitor sequence.
We find that PCR of a single molecule of a single antibody identity
can result in a large number of errors (Figure 3.3a, left). That is, only 95%
of the final sequences are the original monoclonal sequence. Singleton errors
comprise of only ∼0.02% of the overall counts, and can likely be attributed to
errors arising in later cycles of PCR. In addition, since errors are generated
at any cycle in the PCR process and subsequently amplified, large sections of
the resulting tail are not just single errors, but rather amplified errors.
Moreover, we found that the number of starting molecules of a partic-
ular monoclonal antibody affects the PCR result. When a small number of
starting molecules are used (N=1 and 10), the most abundant error (i.e. the
second highest ranked sequence identity) is approximately two orders of mag-
nitude less frequent than the correct sequence (the highest ranked sequence
identity) (Figure 3.3a). In contrast, when a large number of starting molecules
are used (N=1000), the correct sequence identity outnumbers the most abun-
dant sequence error by four orders of magnitude.
Error due to the reverse transcriptase (RT) was hypothesized to con-
tribute more to the error than DNA polymerase error, since RT enzymes typ-
ically exhibit an overall higher rate of error than DNA polymerase. Also, the
RT treatment occurs in the first cycle, so errors are expected to be amplified
more than errors occurring in later cycles. The resultant distribution when the
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Figure 3.3: Simulated distributions of PCR amplified monoclonal an-
tibody (a) Amplified sequence counts after 1 cycle of simulated reverse tran-
scription with error rate of 0 (no error) and 19 cycles of simulated PCR with
error rate of 4.4×10−7, shown on log-log scale. (b) Amplified sequence counts
after 1 cycle of simulated reverse transcription with error rate of 3.4 × 10−5
(Superscript III) and 19 cycles of simulated PCR with error rate of 4.4× 10−7
(phusion), shown on log-log scale. N represents the number of molecules of
the same identity that were amplified.
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RT error is removed shows that the difference between counts of the original
monoclonal sequence and the error is ∼102.5. This is in contrast to Figure
3.3b, where the error rate of the RT is included in the first round of PCR, and
there is a broadening of the left side shoulder, where that same difference is
∼102.
Overall, removal of the RT step improves the discrimination between
the first and second rank identities by half an order of magnitude. RT, while
crucial to the HTS experimental workflow, makes it more difficult to use fre-
quency as a measure of discrimination between the correct sequence and the
subsequent tail of incorrect sequences.
When we ran multiple simulation trials (N=15) and visualized the vari-
ation in the resulting distributions, we found that the higher the number of
starting molecules, the less scatter we observed (Figure 3.3, in grey). This is
consistent with the hypothesis that early cycle mutations occurring in a small
starting population of molecules will result in a large percentage of the incor-
rect sequences in the final distribution. In contrast, an early cycle mutation in
a large starting population will be less likely to dominate the final distribution.
3.3.4 Sequencing increases the apparent number of unique sequences
In order to model the effects of different high-throughput sequencing
platforms on the immune repertoire reconstruction, we took advantage of soft-
ware for simulating the collection of high-throughput sequencing reads with
realistic errors, as implemented in the ART simulation tools from the Na-
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tional Institute of Environmental Health Sciences [30]. We hypothesized that
sequencing more (i.e., higher number of reads) beyond a certain threshold of
reads would result in a less accurate representation of the original initial anti-
body repertoire, due to additional sequencing error introduced by additional
reads and lack of a reference sequence with which to correct those errors.
Indeed, we find this to be the case (Figure 3.4), and in a simulation of the
sequencing of a monoclonal repertoire, the apparent repertoire is considerably
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Figure 3.4: Simulated high-throughput sequencing of a monoclonal
antibody introduces additional error, broadening the apparent
repertoire (a) Sequence counts after generation of the indicated number of
reads using the ART 454 read simulator. (b) Sequence counts after generation
of the indicated number of reads using the ART MiSeq read simulator. Num-
ber of reads denoted in upper right corner of each plot and model assumes no
error in prior PCR amplification (a-b).
We considered two alternate high-throughput sequencing platforms, the
Roche 454 (the instrument used for many early repertoire sequencing projects
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due to its ability to generate longer sequencing reads) and the newer Illu-
mina MiSeq platform. We found that in both 454 simulations (Figure 43.4a)
and MiSeq simulations (Figure 3.4b), increasing the number of read counts
above 10,000 reads strictly increased the number of errors. When generating
10,000 reads, ∼1×104 unique sequence identities resulted and when generating
100,000 reads, ∼1× 105 unique sequence identities resulted.
Furthermore, we found that the amount and shape of error generated
varied by sequencing technology used. The MiSeq simulation shows a very
tight distribution, but little discriminatory power between the correct mon-
oclonal sequence and the remaining tail. Almost every sequence (>99%) is
error. On the other hand, the 454 simulation shows a bipartite distribution.
The left side is composed of mostly high frequency errors, where only the far
left point is the correct sequence. The right side shows a fast decay of fre-
quency of incorrect sequences. In both types of sequencing, generating more
sequencing reads results in more incorrect sequences. Overall, sequencing adds
a large amount of error to the process.
3.3.5 Clustering compensates for the PCR and sequencing inflation
of unique sequence identifications
We have observed that each of the physical manipulations of the mRNA
and DNA during repertoire sequencing serves to introduce errors: the copying
of the immunoglobulin cDNA from expressed mRNAs, the amplification of
the cDNAs by PCR, and the high-throughput sequencing of these molecules
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into observed sequencing reads. The result is to generate clouds of sequences
around the true sequences, related by minor (<5%) sequencing changes. Thus,
clustering of the sequences potentially offers substantial error-correction and
should in principle improve the reconstruction of the underlying repertoire.
We therefore quantified the contribution of clustering to error correction of the
simulated PCR and HTS data from earlier modules. Note that in contrast to
these earlier modules, which computationally simulated experimental methods,
this part of the simulation replicates the actual informatic methods used to
analyze data from immune repertoire HTS experiments.
We find that clustering at a threshold of at least 98% amino acid iden-
tity largely removes the effect of the PCR error (Figure 3.5a), whereas cluster-
ing at a threshold of at least 90% identity is needed to remove high-throughput
sequencing error (Figure 3.5b), indicating that sequencing is a larger source
of error compared to PCR. Interestingly, clustering thresholds necessary to re-
capitulate the original distribution are similar whether or not RT is included,
indicating that while RT introduces abundant high rank errors, they are cor-
rectable via clustering (Figure 3.5a). In addition, while 454 sequencing re-
sults in a smaller number of total errors than MiSeq sequencing, a clustering
threshold of 90% is equally effective at reducing the error in both types of
high throughput sequencing (Figure 3.5b). Our conclusion is that clustering is
critical for a more faithful reconstruction of the antibody repertoire. However,
it is important to note that clustering only compensates for errors introduced
via physical copying and sequencing of the mRNA/DNA, and not due to cell
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Figure 3.5: Sequence clustering largely corrects the PCR and
sequencing-induced errors in a monoclonal antibody repertoire (a-b)
Species richness, defined as the number of unique sequences represented, cal-
culated from distributions obtained after clustering (40%-100% thresholding).
Clustering was applied to the results of monoclonal PCR (shown in Figure 3.3)
either with (green diamonds) or without (blue vertical bars) RT error in (a).
Clustering was applied to the results of sequencing (Figure 3.4) with either the
454 simulator (blue vertical bars) or the MiSeq simulator (green diamonds).
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sampling.
3.3.6 The full model recapitulates the empirical distribution
We simulated the entire pipeline shown in Figure 3.1b and found that
in order to recover the original species richness (N=3,000), a ∼75% clustering
threshold is needed (Figure 3.6a). In addition, we find that the final empirical
distributions, which result from simulations using three distinct theoretical
biological distributions, are indistinguishable from each other (Figure 3.6b).
Specifically, each empirical distribution is Zipfian and the species richness is
higher than the species richness of the theoretical biological distribution. Also,
the counts are continuous and there is no threshold count value that intuitively
separates the high count from the low count identifications.
3.4 Discussion
In this study, we simulated the HTS immunoglobulin repertoire work-
flow from sample collection through data analysis. We isolated individual
modules of error including cell sampling, PCR, and HTS. The amount of cell
sampling required to sample half of the diversity is relatively small (∼14%),
but would still be prohibitive to perform in humans. Within these modules,
we find that PCR and sequencing contribute the most to the overall error
in the process. We also find that aggressive clustering to be a simple error
correction method for restoring the empirical distribution to the species rich-
ness of the original theoretical distribution. Strikingly, we found that even
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Figure 3.6: Antibody repertoire distributions resulting from the com-
plete simulation pipeline resemble empirical distributions (a) Species
richness resulting from simulation of cell sampling, PCR amplification, 454
sequencing, and clustering from 40%-100% thresholding levels. Initial distri-
butions were either exponential (blue vertical bars), normal (green diamonds)
or uniform (red horizontal dashes). (b) Clonal cluster count distributions
from complete simulation (using 86% clustering threshold). Initial distribu-
tion types are indicated in the top right corner. Clonal cluster IDs are sorted
in descending order and plotted on a log-log scale. (c) Sequence count distri-
bution from experimental data [64].
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a single molecule, when processed through our pipeline, can generate a full
spectrum of error that is comparable to empirical distributions from experi-
mental data. It has been proposed that the true biological distribution could
be deduced from the empirical distribution [49], and our model attempted to
provide a computational algorithm for doing so. However, this remains an
unsolved challenge, since using different theoretical biological distributions as
input resulted in the same empirical distributions that were indistinguishable
from one another. Specifically, the true biological distribution may be normal,
exponential, or even uniform and not necessarily Zipfian, as the empirical dis-
tributions might suggest. This has implications for our understanding of the
diversity of the immune system; the true diversity and shape of the distribu-
tion may deviate significantly from what the experimental data indicates. In
this way, the HTS immunoglobulin repertoire workflow may be a many-to-one
function, where the empirical distribution may not have an inverse function
that can be used to determine the true biological distribution.
It is important to note that we did not attempt to fit the parameters
of the simulations to optimize the match between the simulated and empir-
ical distributions. Rather, we used established error rates and estimates of
the sampling regime that best matched our experimental setup. The result-
ing agreement between the simulated and empirical repertoire distributions
emerges without further optimization, and suggests that the simulation is cor-
rectly recapitulating the major sources of error in the real pipeline.
Based on our simulation results, we offer several recommendations for
62
HTS immune repertoire data generation and interpretation. First, due to the
observation that every theoretical biological distribution resulted in highly
similar final empirical distributions, we recommend that no claims on the
true biological distribution be made based on the empirical distribution alone.
Second, our results indicate that PCR and HTS are two major sources of
error. Specifically, given the significant amount of error generated by the first
cycle in PCR, we recommend using a reverse transcriptase with lower error
rates such as RTX [18]. In addition, because PCR is an exponential process,
minimizing the number of PCR cycles will greatly reduce error generation.
Finally, our simulation suggests that aggressive clustering, as we showed using
a 75% identity threshold, may be important for reducing amplification and
sequencing errors to restore the original species richness.
Future experiments might involve deliberately modifying the exper-
imental protocol to test these assumptions (for example, by using a error
correcting reverse transcriptase [18]). Alternatively, sweeping the parameter
choices of the simulation to find a better fit to the experimental distribution
could be used as a means of better estimating the true error rates.
Our model can be tailored to different experimental parameters as
needed, by swapping in different PCR emulators, sequence generators, and
clustering algorithms. In addition, our model is versatile enough to allow for
simulation of HTS of systems other than the immune repertoire of humans,
such as immune systems of zebrafish or metagenomics in ecological niches.
Common methods of error correction, such as sequence barcoding, could also
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be included as additional modules to increase the utility of the simulation.
3.5 Materials and methods
A sequence database was generated from previously published data [64].
The sequences were annotated with VDJFasta, and filtered for valid V and J
gene calls. For the PCR simulation, sequences were randomly selected from
this database and mutated probabilistically, consistent with the error rate of
the theoretical polymerase at each cycle of PCR. The mutated sequence were
then used for subsequent analysis in downstream modules. Clustering was
performed across full length amino acid sequences.
We chose to focus on a small number of widely prevalent distributions
in nature that vary dramatically in their levels of polarization; namely, the
uniform, normal, and exponential. The uniform distribution is a simple and
extreme distribution in that it shows no polarization; there is no difference
in frequency to any individual identity. It can be visualized as a horizontal
line. It is defined entirely by two parameters: the total number of unique
identities and the total number of members. We also chose a highly polarized
distribution, the exponential distribution, where a small number of individual
identities represent a disproportionate fraction of the total number of mem-
bers. In addition to the parameters required in the uniform distribution, the
exponential distribution requires one additional parameter, the rate parame-
ter, represented by λ. Variation of λ can change the degree of polarization of
the exponential distribution. Finally, we chose a distribution of intermediate
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polarization, the normal distribution. This distribution is highly prevalent and
appears in fields as disparate as social science and theoretical physics. The
normal distribution is defined by two parameters in addition to the two pa-
rameters that define the uniform distribution: the mean, µ, and the variance,
σ. The mean is the value where the most highly frequent identities appear
and the variance describes how far away identities are from the mean.
We chose values of 0.1, 0.3, and 0.5 for lambda to cover a wide range
of polarization in the exponential distribution. The mean in the normal dis-
tribution does not affect the degree of polarization; therefore, we fixed it at 10
for convenience, and then chose the values of 0.2, 0.5, 1, and 5 for the variance
to cover a wide range of polarization for the normal distribution. Ultimately,
the specific parameter choices for any given distribution was less important
than the type of distribution chosen. The distributions maintained the same
relative degree of polarization between distributions (i.e., exponentials were
always more polarized than normal, which were always more polarized than
uniform). This change in polarization was less extreme within a distribution
as compared to between distributions. We also found that the ratio of unique
sequences to total cell number was more important than the absolute values.
We chose values that created sufficient diversity consistent with current ex-
perimental procedures while maintaining reasonable computational demands.
For the full simulation, we ran the full simulation assuming 10,000 total cells
and 3,000 unique cells. We sampled separately 2,000 cells from a uniform
distribution, an exponential with the rate parameter, λ=0.1, and a normal
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distribution with the variance, σ=1. We simulated 20,000 454 reads.
Our computational models were programmed using Python. Visualiza-
tions were all made using Python and matplotlib. High-throughput sequencing
simulations were performed using ART [30]. FLASH [42] was used to combine
paired-end sequences, when necessary. VDJFasta [25] was used to annotate
sequences. Reference genes were acquired from the international ImMuno-
GeneTics (IMGT) [1] database. Clustering was done using CDHit [22].
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The immune repertoire is intricate and vast. A better understanding
of immune cells at both the tissue and molecular level teaches us how we
continue to survive in an environment that can reproduce, grow, and adapt
faster than we can. The antibody repertoire is one particularly large part
of the immune repertoire. The work presented here gives insight into the
bone marrow plasma cell repertoire, a specific aspect of the human antibody
repertoire. More broadly, we also characterized a method used in the study of
the immune repertoire, high-throughput sequencing (HTS). Future work will
improve the quality of data interpretation and the depth of biological insight.
Here, I propose future simulations and experiments that could address some
of the remaining outstanding questions in the study of the immune repertoire.
My work demonstrates that high-throughput sequencing is a power-
ful, if imperfect tool for studying the antibody repertoire. I evaluated and
quantified one particular clustering method for informatic correction of am-
plification and sequencing errors. A variety of different clustering algorithms
are used commonly in error correction for HTS, with different parameters and
use cases (e.g. phylogenetic clustering). Many of these algorithms are op-
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timized for speed, but accuracy is an important and previously intractable
optimization parameter. Future simulations can build on the one presented
here in order to evaluate the accuracy of error correction methods and resolve
conflicting hypotheses on proper data analysis and interpretation. Another
technical challenge in immune repertoire analysis is optimizing diversity index
choice to provide the most comprehensive and accurate view on the true di-
versity. There are many methods of measuring diversity, including Simpson,
Shannon, and Berger-Parker. The simulation presented in Chapter 3 may pro-
vide a framework that enables the comparison of various diversity indices. By
controlling the inputs and parameters of the simulation, particularly the true
biological distribution, and observing the resulting outputs, it will be easier to
understand the benefits and limitations of each diversity metric. In addition
to the technical questions discussed above, the nascent immune repertoire field
continues to pursue unanswered biological questions.
Beyond technical methods of ensuring accurate data generation, the
antibody repertoire is a complex mix of diverse sequences and functions that
elude simple interpretation. At the level of individual sequences—even cor-
rected ones—there is too much noise for biological interpretation. There is
a need to group these sequences with the intent of biological interpretation.
One potential solution would be to look at the evolutionary relationships of
the sequences by performing ancestral sequence reconstruction by phylogenetic
analysis. This is possible because antibody sequences are known to undergo se-
quential evolutionary steps involving somatic hypermutation to increase bind-
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ing affinity without changing antigen specificity. Phylogenetic analysis, there-
fore, could provide a method of classification for antibodies, which would group
individuals with similar, but not identical, immune repertoires and identify
immune signatures. These signatures can then be used in a wide variety of
research and clinical applications, such as targeted therapy development for
personalized medicine.
In this work, I observed that the immune repertoire is remarkably stable
across time; however, within a single timepoint, the biological resolution of the
immune repertoire is still fairly limited. While immune repertoire composition
on the sequence level was observed, the cellular level information was not at-
tainable. Concretely, the heterogeneity in gene expression among a population
of single plasma cells remains poorly understood. Early studies suggested that
plasma cells only produce one type of antibody [58]. From studies of B cell
derived cell lines, the amount of antibody produced per cell was observed to
vary considerably [8]. However, it is not known how much of this variation is
due to the B cell developmental stage, how much is the consequence of active
regulation, and how much is due to cellular noise. Deep sequencing of plasma
cells in bulk like those used in this work cannot distinguish between the possi-
bility of one cell producing large amounts of immunoglobulin and many cells
producing smaller amounts of immunoglobulin, nor can deep sequencing iden-
tify sources of noise that are hidden by bulk sampling. Emerging single cell
analysis platforms will enable the study of the heterogeneity of immune cells.
The primary function of the antibody is to recognize, bind, and neu-
69
tralize potentially dangerous assaults on the host. The major force shaping the
immune repertoire is therefore the antigen repertoire, which high-throughput
sequencing, even at the single cell level, cannot capture. This is because the
possible repertoire of antigens goes beyond nucleic acids and includes other
macromolecules like carbohydrates and proteins. The most promising technol-
ogy for pursuing the antigen repertoire is mass spectrometry. This proteomic
technology has already been used as a powerful antibody discovery tool. How-
ever, even this technology would only have the ability to look at the protein
antigen repertoire. The full extent of the antigen repertoire remains to be
discovered.
Strikingly, all these questions and areas of research can be posed and
pursued in different immunological compartments, cell types, and animal mod-
els. The field of human repertoire analysis remains vibrant, accelerated by
current technologies, and holds tremendous progress as it anticipates future
breakthroughs. The immune system is an exquisite system that protects the
host from danger. It is finely tuned to recognize self from non-self, danger from
benign. As we learn more about the immune systems intricacies, we advance
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SUMMARY
Cellular processes often depend on stable physical
associations between proteins. Despite recent
progress, knowledge of the composition of human
protein complexes remains limited. To close this
gap, we applied an integrative global proteomic
profiling approach, based on chromatographic sepa-
ration of cultured human cell extracts into more than
one thousand biochemical fractions that were subse-
quently analyzed by quantitative tandemmass spec-
trometry, to systematically identify a network of
13,993 high-confidence physical interactions among
3,006 stably associated soluble human proteins.
Most of the 622 putative protein complexeswe report
are linked to core biological processes and encom-
pass both candidate disease genes and unannotated
proteins to inform onmechanism. Strikingly, whereas
larger multiprotein assemblies tend to be more
extensively annotated and evolutionarily conserved,
human protein complexes with five or fewer subunits
are far more likely to be functionally unannotated or
restricted to vertebrates, suggesting more recent
functional innovations.
INTRODUCTION
Protein complexes are stable macromolecular assemblies that
perform many of the diverse biochemical activities essential to
cell homeostasis, growth, and proliferation. Comprehensive
characterization of the composition of multiprotein complexes
in the subcellular compartments of model organisms like yeast,
fly, worm, and bacteria have provided critical mechanistic
insights into the global modular organization of conserved bio-
logical systems (Hartwell et al., 1999), accelerated functional
annotation of uncharacterized proteins via guilt by association
(Hu et al., 2009; Oliver, 2000), and facilitated understanding of
both evolutionarily conserved and disease-related pathways
(Vidal et al., 2011). How the 20,000 or so proteins encoded
by the human genome are partitioned into heteromeric ‘‘protein
machines’’ remains an important but elusive research question,
however, as less than one-fifth of all predicted human open
reading frames are currently annotated as encoding subunits
of protein complexes in public curation databases (Ruepp
et al., 2010).
Loss-of-function mutations in genes encoding the subunits of
protein complexes typically give rise to similar phenotypes or,
through genetic interaction, amplify the phenotypic effects
of other alleles in functionally linked sets of genes. Identifying
the membership of protein complexes, therefore, addresses a
crucial layer in the hierarchical functional organization of biolog-
ical systems that links the core biochemistry of a functioning
cell to the general physiology of an organism and is fundamental
to deciphering the relationship between genotype and pheno-
type.Althoughbioinformatics analyseshavebeenused topredict
evolutionarily conserved human protein-protein interactions
(PPIs) on a large scale (Ramani et al., 2008; Rhodes et al., 2005),
most of these associations remain to be verified experimentally.
Affinity purification (AP) of tagged exogenous proteins
coupled with tandem mass spectrometry (MS) is an effective
method for isolating and characterizing the composition of stably
associated human proteins in experiments ranging from dozens
to hundreds of different ‘‘baits’’ (Behrends et al., 2010; Bouw-
meester et al., 2004; Ewing et al., 2007; Hutchins et al., 2010;
Jeronimo et al., 2007; Mak et al., 2010; Sardiu et al., 2008;
Sowa et al., 2009). Likewise, immunoprecipitation can be used
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to systematically isolate endogenous human protein complexes
from human cell lines (Malovannaya et al., 2011). Nevertheless,
the limited availability of high-quality antibodies or sequence-
verified complementary DNA (cDNA) clones suitable for targeted
protein complex enrichment precludes scale-up required for the
unbiased assessment of the molecular association networks
underlying human cells. Hence, despite considerable successes
in the comprehensive identification of protein complexes in
model organisms (Butland et al., 2005; Gavin et al., 2002,
2006; Guruharsha et al., 2011; Ho et al., 2002; Hu et al., 2009;
Krogan et al., 2006; Kühner et al., 2009), clone-based protein
purification techniques remain challenging for proteome-scale
studies of physical interaction networks in mammalian cells.
Conversely, although traditionally used to isolate discrete
complexes with specific assayable biochemical properties
(e.g., enzymatic activity), classical biochemical fractionation
procedures have been used to resolve biological mixtures as
a means of ascertaining the collective composition of human
protein complexes present in certain subcellular compartments
(Ramani et al., 2008; Wessels et al., 2009).
Here, we have combined extensive, scaled-up biochemical
fractionation with in-depth, quantitative mass spectrometric
profiling and stringent computational filtering to resolve and
identify endogenous, soluble, stably associated human protein
complexes present in cytoplasmic and nuclear extracts gener-
ated from cultured cells. Although the resulting reconstructed
high-quality physical interaction network shows strong overlap
with existing curated and experimentally derived sets of anno-
tated protein complexes, it contains many predicted subunits
and previously unreported complexes with specific functional,
evolutionary, and disease-related biological attributes. To our
knowledge, this resource represents the largest experimentally
derived catalog to date of human protein complexes from cell
culture, measured using a single standardized assay, and a reli-
able first draft reference of the basic physical wiring diagram of
a human cell.
RESULTS
High-Throughput Complex Fractionation and Detection
by Tandem Mass Spectrometry
To isolate human protein complexes in a sensitive and unbiased
manner, we subjected cytoplasmic and nuclear soluble protein
extracts isolated from human HeLa S3 and HEK293 cells grown
as suspension and adherent cultures, respectively, to extensive
complementary biochemical fractionation procedures. These
two widely studied laboratory cell lines have been used as
models of human cell biology for many decades (Graham
et al., 1977; Masters, 2002), providing a rich biological context
for interpreting the resulting proteomic data. Stably interacting
proteins that cofractionated together were identified subse-
quently by nanoflow liquid chromatography-tandemmass spec-
trometry (LC-MS/MS). We optimized our entire experimental
pipeline, illustrated schematically in Figure 1A, by using a multi-
pronged strategy to minimize two major confounding issues:
limited dynamic range (i.e., preferential detection of high-abun-
dance components) and ‘‘chance’’ coelution (i.e., cofractiona-
tion of functionally unrelated proteins).
To address the former concern, we performed extremely deep
biochemical fractionations by employing multiple orthogonal
separation techniques to better resolve distinct protein com-
plexes. As a primary separation technique, we employed nonde-
naturing high-performance multibed ion exchange chromatog-
raphy (IEX-HPLC) by using four different empirically optimized
analytical column combinations (see Experimental Procedures)
and shallow salt gradients unlikely to perturb nonionic protein
associations (Havugimana et al., 2007). In parallel, we applied
complementary sucrose gradient centrifugation and isoelectric
focusing technologies to capture salt-sensitive protein assem-
blies. In total, we collected 1,163 different fractions in a total of
eight nuclear and five cytosolic extract fractionation experiments
(for details see Table S1 available online), which were each sub-
jected to label-free shotgun sequencing (duplicate LC-MS/MS
analyses) using highly sensitive ion trap-based mass spectro-
meters (see Experimental Procedures).
We identified 5,584 distinct human proteins (Figure 1C; esti-
mated theoretical false discovery rate of 1% at both the protein
and peptide levels based on a statistical model [Kislinger et al.,
2003]; see Experimental Procedures for details). Despite the
underrepresentation of membrane proteins in the starting cell
extracts, this coverage encompasses about half of the experi-
mentally verified human proteome (Figure S1B) (Nagaraj et al.,
2011). This included 989 proteins detected exclusively in nuclear
fractions (of which 376 were annotated transcription or chro-
matin-related factors) and 1,006 with links to human disease
(e.g., annotated in a public database like OMIM). Only 1,632
(29%) of the identified proteins had biochemical annotations as
subunits of previously reported protein complexes (correspond-
ing to 64% of all existing human protein entries) in the CORUM
curation database (Figure S1C; Ruepp et al., 2010). Due to the
extensive fractionation, we observed minimal bias in terms of
protein abundance beyond that reported for previously anno-
tated complexes or the experimentally defined human proteome
(Figure 1D).
Next, to minimize the possibility of chance coelution, rather
than simply identifying the proteins present in each fraction,
we quantified variation in protein abundance based on the
observed patterns of spectral counts recorded across all of the
collected fractions to determine the extent to which pairs of
proteins coeluted. As shown in Figure 1B, these experimental
profiles were highly reproducible (i.e., average Spearman rank
correlation coefficients >80% between replicate experiments;
Figure S2), even using alternate methods of mass spectrometric
quantification (i.e., extracted MS1 peak intensities were largely
consistent with spectral counting; Figure S2D). To objectively
evaluate the biochemical data, we calculated a stringent
summary statistic, termed the coapex score, for each pair of
proteins identified by LC-MS/MS by determining the number
of fractionation experiments in which the proteins showed
maximum (modal) abundance in the same exact peak fraction.
To assess the effectiveness of our cofractionation approach,
we performed an initial validation by examining the coelution
profiles and coapex scores obtained for a reference set of 20
well-known human protein complexes reported in CORUM. As
illustrated by the representative HeLa nuclear extract IEX-
HPLC profiles shown in Figure 1B, the subunits of these
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complexes typically coeluted in the same biochemical fractions.
Of the 155 components detected by mass spectrometry, most
(85%; 499/585) of the detected subunit pairs of the reference
complexes had high coapex similarity scores (i.e., coeluted
together in at least two ormore experiments), validating the over-
all efficacy of the fractionation procedures we used to isolate
native protein complexes and the general correctness of the
protein identification and quantification pipeline.
Reconstruction of a High-Confidence Cocomplex
Interaction Network
Despite the consistency in coelution of annotated complex
members, certain functionally distinct complexes occasionally
exhibited overlapping chromatographic elution profiles (e.g.,
splicing factor 3b andCoatomer complexes; Figure 2A), present-
ing a potential source of spurious interactions. Although this arti-
fact was minimized to a certain degree by performing multiple
independent fractionation experiments, we used an integrative
computational approach to further improve deconvolution (Fig-
ure 2B). Because physically interacting cocomplexed proteins
often perform related biological functions (Alberts, 1998) and
are often evolutionarily coconserved (Hartwell et al., 1999), we
devised a machine learning procedure (Figure 2B; see Experi-
mental Procedures for details) to score and select higher-confi-
dence physical interactions based on both the experimentally
measured coelution profiles and the existence of additional
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Figure 1. Integrative Cofractionation Strategy Used to Identify Human Soluble Protein Complexes
(A) Cell extracts were extensively fractionated using different biochemical techniques (IEX, ion exchange chromatography; IEF, isoelectric focusing; SGF, sucrose
density gradient centrifugation). Coeluting proteins were identified by mass spectrometry, and a coelution network was generated by calculating profile similarity
(see Extended Experimental Procedures).
(B) Cofractionation (IEX-HPLC) profiles of annotated subunits of 20 representative human protein complexes from HeLa nuclear extract. Shading indicates
normalized spectral counts (SPC). Peak apex and adjacent peaks are shown.
(C) Hierarchical clustering of 5,584 proteins identified by LC-MS/MS.
(D) Protein abundance levels corresponding to components of our identified coeluting proteins (red line), reconstructed complexes (blue), or annotated CORUM
complexes (black) estimated from the reported HeLa proteome (Nagaraj et al., 2011).
See also Figure S1 and Table S1.
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supporting functional association evidence inferred from
correlated evolutionary rates (Tillier and Charlebois, 2009)
and functional genomics data sets compiled for H. sapiens,
S. cerevisiae, D. melanogaster, and C. elegans (see Table S6
for details).
First, for each of the 13 fractionation experiments, we calcu-
lated correlation measures between all possible pairs of proteins
to capture their tendency to coelute. In addition to the coapex
summary statistic, to account for mass spectrometry sampling
error, we devised a weighted cross-correlation function to
account for slight variation in the protein profiles measured in
each experiment. To account for low spectral values, we also
generated a Poisson noise model before calculating Pearson
correlation scores, deeming the coelution profiles of protein
pairs measured with low spectral counts as less predictive of




Figure 2. Denoising the Biochemical Coelution Network and Generation of High-Confidence Physical Interactions
(A) Biochemical cofractionation network of 20 reference complexes with coelution coapex scoresR2. Nodes represent protein subunits (colors reflect complex
membership), whereas edges represent interactions (thickness proportional to the number of shared coapexes).
(B) The biochemical data were combined with weighted functional association evidence by using a Random Forest classifier and a training set of reference
complexes (CORUM) to filter out spurious connections and to infer a high-confidence interactome. The PPI and predicted clusters were evaluated with inde-
pendent functional criteria to ensure high quality. Arrows represent data flow, blue diamonds are attributes in the decision tree vector, and green diamonds (leafs)
are the final result (positive or negative).
(C) Cumulative precision-prediction rank curves for the LC-MS/MS data alone and after integration with genomic evidence. Incorporation of the functional
evidence increased both precision (reduced false positives) and recall (more true positives).
(D) Network of 20 reference complexes after filtering with functional evidence.
(E) Overall correlation (Spearman r = 0.40; n = 11,675) of our scored human PPI with corresponding interaction scores reported for orthologous fly PPI fromwhich
validated, high-confidence complexes were derived (Guruharsha et al., 2011). Heatmap shows prediction accuracy (log ratio of CORUM reference positives to
negatives), with high-scoring pairs in both studies highly enriched for positives.
(F) Precision-recall curve showing performance obtained after denoising reconstructing withheld reference CORUM complexes highlighted by red dots at the
threshold at which half of the protein pairs per complex are recovered.
See also Figure S5 and Table S2.
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with a correlation score of at least 0.5 by at least one of these
measures in one or more experiments were considered for
further analysis, reducing the total number of pairs from over
15 million initially to the roughly 800,000 pairs with reasonable
biochemical evidence.
To improve the assignment of interaction probabilities, we also
exploited the predictive power of correlated protein evolutionary
rates (Tillier and Charlebois, 2009), messenger RNA (mRNA)
coexpression, and domain co-occurrence and, via orthology,
fly protein-protein interactions (based on binary yeast two-hybrid
assay studies) and extensive physical and functional associa-
tions reported previously for yeast and worm (see Experimental
Procedures) (Lee et al., 2011). The discriminatory power of the
procedure was further improved by penalizing those interactions
that lacked independent supporting evidence—and that were
thus more likely to correspond to cases of ‘‘chance’’ coelu-
tion—by integrating evidence from these functional association
data (Figure 2B). A feature selection algorithmwas used to select
the most informative data sets (Table S2) in addition to the
biochemical correlation scores, and the resulting features were
used to estimate the probability of interaction to protein pairs
using a cross-validated random forest classifier.
For training, we used the CORUM curated set of human
protein complexes as our base reference, filtered for those
complexes annotated as having been observed by biochemical
methods. As many CORUM complexes are highly overlapping
due to redundancy in existing annotations, we combined
complexes sharing subunits (Simpson coefficient >0.5 between
complexes). We used half of the resulting 324 nonredundant
reference complexes (Table S3) as the training set for cocomplex
probability prediction, defining gold standard positive interac-
tions as pairs of proteins in the same complex and inferring
gold standard negatives between proteins in different
complexes. (The other half of the reference complexes was with-
held for subsequent use as an independent training set for
cluster optimization, as described below.)
Although the biochemical data were a prerequisite for scoring,
the performance curves shown in Figure 2C indicate that the
inclusion of the additional functional genomic information
substantially increased recall at the same level of precision
compared to classifiers based on the profiling data alone. More-
over, the integration of this additional supporting functional
evidence removed the bulk of spurious, intercomplex interac-
tions (Figure 2D). Another advantage of our bioinformatic pipe-
line is that the results of the feature selection algorithm (Table
S2) can be explored to examine the impact of each data set.
For example, we find generally that sets of smaller biochemical
fractionations using different separation techniques, although
individually yielding a higher PPI false discovery rate, collectively
providedmore information on protein complex composition than
deeper fractionations using a single separation method.
As an alternatemeasure of reliability, we compared our scored
human protein interactions to a recently reported network of
Drosophila cocomplex protein interactions (Guruharsha et al.,
2011), which had not been used for building the classifier. Strik-
ingly, despite using vastly different experimental methods and
scoring schemes, we observed a remarkably good overall corre-
lation (Spearman r = 0.40; n = 11,675 orthologs mapped using
Inparanoid). Even after removing interactions supported by
alternate Drosophila data, high-scoring fly pairs matched high-
scoring pairs in our analysis and were strongly enriched for
reference-positive cocomplex members (Figure 2E).
Finally, in order to remove any remaining false positive interac-
tions, we further denoised our cocomplex data set by pruning
loosely connected interactions using a computational diffusion
procedure calibrated by protein colocalization semantic simi-
larity scores (Pesquita et al., 2009; Yang et al., 2012) to enforce
local network topologies more consistent with annotated
complexes from the withheld portion of the reference Corum
complexes (see Experimental Procedures). Benchmark preci-
sion and recall versus the holdout set of known reference
complexes (Figure 2F) were significantly higher than those re-
ported for a smaller, recently published set of affinity-purified
human protein complexes (Hutchins et al., 2010), validating the
reliability of our scoring procedure.
Applying a PPI score threshold of 0.75, which corresponds to
an estimated false discovery rate of 21.5% (i.e., well below the
40% reported for AP/MS-based analyses of protein complexes
in model organisms [Gavin et al., 2006; Krogan et al., 2006;
Kühner et al., 2009]), we thus derived a high-confidence set of
13,993 cocomplex interactions among 3,006 unique human
proteins (Table S2), most of which (8,691 PPI) have not been
reported before (i.e., are not publicly annotated). It is worth reit-
erating that all of these physical interactions were directly sup-
ported by the experimental biochemical cofractionation data;
the addition of functional data and denoising served only to
flag candidates lacking either functional support or topological
support within the network (Table S2). The interaction probability
scores may be underestimated, however, because the reference
‘‘gold standards’’ used for learning are imperfect (Jansen and
Gerstein, 2004).
Construction and Validation of Protein Complexes
from the Probabilistic Interaction Network
In order to define complex membership, we partitioned the high-
confidence probabilistic physical interaction network by using
the cluster growth algorithm ClusterONE (Nepusz et al., 2012),
which outperformed other clustering methods on the denoised
PPI network (Table S5). In total, the clustering predicts 622
discrete putative complexes encompassing 2,634 distinct
proteins (Table S3). Complex membership size distribution
approximated an inverse power law with a median of four
subunits (Figure S4A). The majority (62%; 385/622) of the
complexes have not been annotated (i.e., only 237 are currently
curated in a public database like CORUM; Figures 3A and 3C).
Although the fraction of curated components varies, we also
recapitulated 258 previously reported complexes (Figure 3C),
including several well-known membrane-associated com-
plexes, such as the coat protein I and II (COPI/II) vesicle transport
complexes that shuttle cargo between the Golgi and endo-
plasmic reticulum. Strikingly, most (67%; 335) of the 500 smaller
putative complexes with five or fewer components, including the
bulk (74%; 83) of the 112 predicted heterodimers, have never
been curated before (Figure 3C).
Both independent experimental validation based on more tra-
ditional immunoprecipitation or coaffinity purification methods
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and orthology mapping support at least 21 of these putative
complexes (i.e., not in any reference database) (Table S3; see
Supplemental Information for details). For example, Guruharsha
et al. (2011) recently reported 299 cocomplex interactions based
on pull-down experiments of 43 affinity-tagged human proteins
present in 41 of our complexes, of which 143 interactions map
precisely to our predicted complexes, representing a 47.8% vali-
dation rate (which may be an underestimate, as Guruharsha
et al. [2011] do not report human interactions that fall outside
the fly interologs examined in their study). Likewise, the results
of Malovannaya et al. (2011), who used large-scale immunopre-
cipitation to isolate native human protein complexes, show
excellent agreement to 123 of our complexes (i.e., Benjamini-
corrected hypergeometric p % 0.05), including 42 (34%) of our
complexes that are not curated in CORUM (Figure 3B and Table
S3). Figure 3D summarizes the highly significant overlap of our
inferred complexes with these fully independent data sets, with
enrichments ranging from 4- to 477-fold more than chance,
thus broadly and systematically validating our network of derived
human protein complexes.
By design, insoluble membrane-associated (hydrophobic)
protein complexes were largely missed in this study, and the
proteins assigned to complexes had a higher average transcript
abundance (Figures S2A and S2B). Moreover, in an effort to
control the false positive rate, our conservative clustering algo-
rithm, ClusterONE, underweighted small clusters of size 2 or 3
for lack of sufficient association evidence, likely contributing to
the prominence of complexes with four subunits in Figure 3A.
But we did not observe any significant bias toward negative
(pI % 7) or positive (pI R 7) charge as compared to complexes
curated in CORUM (Figure S4B).
Figure 4 shows the broad functional diversity of the predicted
complexes (a navigable map is available online for close visual-
ization of individual clusters and their supporting cocomplex
interactions). Consistent with biological expectation (Hartwell




Figure 3. Global Validations of the Map of High-Confidence Human Protein Complexes
(A) Complex size distribution of the 622 inferred complexes.
(B) Network of predicted human protein complexes proportioned according to subunit number and displaying existing curations, validation status by AP/MS
(Malovannaya et al., 2011), and PPI connectivity (proportioned edge width).
(C) Proportions of annotated complexes in public repositories (CORUM, PINdb, REACTOME, and HPRD) or independently experimentally verified.
(D) Enrichment analysis showing overlap with large-scale APMS data sets generated for human (Hutchins et al., 2010; Malovannaya et al., 2011) and
(via orthology) fly (Guruharsha et al., 2011).
See also Table S3.
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Figure 4. Global Map of High-Confidence Human Protein Complexes
(A) Schematic of the global network of inferred human soluble protein complexes (colored by membership) with representative examples and supporting PPI
highlighted.
(B) Putative complexes with two or more components with human disorder associations annotated in UniProt (UniProt Consortium, 2011), Online Inheritance
of Man (OMIM) (Hamosh et al., 2005), or the Genetic Association Database (GAD) (Becker et al., 2004). Inset table shows highly significant interaction overlap
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the subunits of the complexes were significantly enriched for
related biological functions, transcriptional regulatory motifs,
and pathological processes (Figure 4B, inset table). Compared
to the entire set of identified proteins, the clustered proteins
also showed enrichment for posttranslation modifications
linked to cellular regulation, like acetylation (Benjamini-corrected
p % 1041) and phosphorylation (p % 105). Many of the
complexes are linked to core cellular processes, such as
mRNA splicing (p% 1015) or transcription (p% 105), that either
are essential in human (p % 10138) or that have RNA interfer-
ence (RNAi)-induced phenotype in cell culture (e.g., cell division
arrest, p % 1031) or are associated, via orthology, with similar
mouse, yeast, or worm mutant phenotypes (Figure 4B, inset
table; see Table S4 for details).
(i.e., shared annotated edges) with phenotypic data sets that reveals that protein subunits of the same predicted human complex tend to exhibit similar disease
and genetic associations in human populations (see Extended Experimental Procedures), RNAi phenotypes in cell culture (Neumann et al., 2010), mutational and
RNAi phenotypes in other species (via orthology), and shared transcriptional regulatory motifs (Xie et al., 2005).
See also Figure S4C and Table S4.
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Figure 5. Membership in Complexes
Predicts Protein Function and Disease
Associations
(A) Three of four proteins mapped to the cohesin
complex account for roughly half of cases of the
human congenital disorder Cornelia de Lange
syndrome (Pié et al., 2010), implicating the fourth
component, RAD21, as a candidate disease gene.
This association may explain similarities in clinical
presentation between CdLS and Langer-Giedion
syndrome, as the latter patients routinely harbor
RAD21 deletions, e.g., McBrien et al. (2008) and
Wuyts et al. (2002).
(B) Confirmation of ribosome biogenesis
candidate (orange) associations with annotated
components (blue) by AP/MS analysis of tagged
proteins (top). Colored squares indicate validation
(see Extended Experimental Procedures).
(C) Polysome profiling after siRNA targeting in
tissue culture supports functional roles in ribo-
some biogenesis for three candidate proteins.
Knockdown of MKI67IP, FTSJ3, and, to a lesser
extent, GNL3, results in 60S ribosomal subunit
biogenesis defects manifested by a reduced
ratio of free 60S to 40S ribosomal subunits during
gradient sedimentation as compared to control.
Percentages indicate siRNA knockdown effi-
ciency as measured by qRT-PCR.
Clinical and Biological Implications
of the Reconstructed Human
Protein Complexes
Consistent with this strong tendency for
proteins in the same complex to be affili-
ated with similar mutational and RNAi
phenotypes, subunits of the predicted
human protein complexes were much
more likely than chance (p % 1046) to
have links to a documented clinical
pathology (Figure 4B; see Table S4 for
details), with disease-associated proteins distributed broadly
among the complexes (Figures 4B and S4C). Closer examination
of the interaction subnetworks—comprising known human
disease genes with genes that currently lack annotation or that
have not previously been associated with any human disorders
(Figure 4B)—highlights the utility of the map.
One such example is shown in Figure 5A, illustrating the case
of the human developmental disorder Cornelia de Lange
syndrome (CdLS). Mutations in three subunits of the cohesin
complex (SMC1A, SMC3, and NIPBL) have been linked to
CdLS (Pié et al., 2010), implicating an additional component
(RAD21) as a candidate CdLS locus, and are consistent with at
least one unmapped CdLS locus residing on chromosome 8
(DeScipio et al., 2005). The link to RAD21 provides a likely
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explanation for the occasional overlap of Langer-Giedion
syndrome (LGS) clinical presentation with CdLS, as all LGS
patients are at least partially defective for RAD21 (see e.g.,
McBrien et al., 2008; Wuyts et al., 2002). Similarly, RAD18,
a homolog of SMC3 and SMC1A, may play a role in CdLS that
is consistent with unmapped CdLS deletions within chromo-
some 3p25 (DeScipio et al., 2005). Reports coinciding with the
preparation of this manuscript confirm that RAD21 mutations
do indeed lead to a CdLS-like syndrome (Deardorff et al.,
2012), supporting the use of the complex map to prioritize prom-
ising candidate genes for human diseases.
Similarly, participation in the same complex suggests shared
functions; the map can thus be used to predict new biochemical
functions for proteins and other types of functions. We experi-
mentally validated one such case for a ribosome-associated
subcomplex containing BOP1, RRS1, GNL3, EBP2, FTSJ3,
and MK1671P, and we first confirmed the interactions by affinity
tagging/purification and mass spectrometry (Figure 5B). BOP1,
EBP2, and the yeast ortholog of RRS1 are known to participate
in maturation of the large 60S ribosomal subunit, suggesting
that the other factors likewise engage in ribosome assembly,
which is consistent with the nucleolar localizations of GNL3,
FTSJ3, and MKI67IP. Supporting a role in ribosome biogenesis,
short interfering RNA knockdowns of FTSJ3, MKI67IP, and, to
a lesser extent, GNL3, perturbed 60S formation in cell culture,
decreasing the ratio of free 60S to 40S subunits (Figure 5C).
Taken together, these data support roles in ribosome biogenesis
for these proteins and confirm the utility of themap for identifying
biological functions.
Conservation of Human Protein Complexes
Estimates based on sequence similarity across orthologs indi-
cate that the components of the complexes we detect are gener-
ally more ancient and have higher conservation on average
than most human proteins (Figure 6A; see Table S3 for details).
Using orthology relationships derived from well-established
sources and calculating evolutionary rates and ages for all
human proteins as a base distribution for gauging the emer-
gence of complexes (see Extended Experimental Procedures),
we found that many complexes appear to be quite ancient and
slowly evolving (Figure 6B). Strikingly, however, most (60%;
376/622) human complexes likely arose with vertebrates, i.e.,
orthologs not present in invertebrates or fungi (Table S3). Hence,
our analyses suggest a major shift/expansion in the ancestral
protein interaction network coincident with the emergence of
vertebrates.
Given the availability of experimentally derived networks of fly
and yeast protein complexes, we could directly examine the
evolutionary conservation of protein complexes across animals
by comparing our network of human complexes with the
extensive maps of 556 fly protein complexes recently reported
for D. melanogaster (Guruharsha et al., 2011) and 720 yeast
protein complexes documented for S. cerevisiae (Babu et al.,
2012). Roughly one quarter (24%; 149/622) of the predicted
human protein complexes showed statistically significant
overlaps with complexes reported for these models (Figure 6B,
inset; see Table S3 for details), with half of the subunits having
clear orthologs (Figure 6C); the remaining components presum-
ably represent genuine differences or incomplete orthology
annotations.
The functional significance of unannotated ancestral human
complexes supported by conservation in yeast or fly (Table S3
and Figure 6) warrants further investigations. At least one such
complex, a multisubunit transfer RNA (tRNA)-splicing ligase
(Popow et al., 2011), was characterized recently. The interaction
between DDX1 and C14orf166 was detected at high confidence
both in our data set (probability score 0.899) and in the Guruhar-
sha et al. (2011) fly cocomplex data, and the other respective
associated complex subunits likewise show significant overlap
(Benjamini-corrected p value 1.1 3 107). Additional examples
of complex conservation are similarly supported by independent
experimental evidence, e.g., such as the matching tissue spec-
ificities of the putatively interacting proteins endoplasmin and
glucosidase 2b (Figure 6D), which form an uncharacterized
complex conserved in both the fly and human maps.
Functional enrichment analysis of ancient complexes in com-
parison to vertebrate-specific ones also reveals intriguing bio-
logical trends. For example, we expected ancient, core cellular
functions to be depleted among vertebrate-specific complexes.
Consistent with this expectation, we find proteins associated
with the ribosome (p% 1067, 113 proteins) andRNApolymerase
II (p% 1027, 45 proteins) to be highly enriched only among con-
served complexes. However, we also observe several notable
variations from this hypothesis. For example, compared to the
genomic background,mitochondrial proteins aremore highly en-
riched among proteins assigned to vertebrate complexes than
among those assigned to conserved complexes; 159 vertebrate
proteins have amitochondrial Gene Ontology Biological Process
(GOBP) annotation (p% 1031) versus only 81 proteins assigned
to conserved complexes (p % 105). Similarly, proteins anno-
tated as being part of the splicing apparatus are enriched in
both conserved (p % 1033; 63 proteins) and vertebrate
complexes (p % 1011, 43 proteins), which is consistent with
an ancient function gaining additional complexity in vertebrates
(e.g., increased alternative splicing). Our study therefore offers
a unique perspective into the functional conservation and diver-
sification of protein complexes across animals.
Protein Abundance, Ubiquity, and Complex Subunit
Stoichiometries
Consistent with the documented origins of the HeLa and
HEK293 cells analyzed in this study, the complexes we identified
were significantly enriched for epithelial markers (p % 10183;
UniProt tissue annotations). Explicit comparison of results
across the two cell lines used in this study provided little
evidence for tissue-specific or cell-type-specific complexes
(see Supplemental Information). Most proteins were detected
in both cell line fractionations, which is consistent with the similar
protein and mRNA expression patterns observed in these cell
lines (Figure S1), whereas the few proteins detected uniquely in
one cell line or the other did not preferentially assort into
tissue-specific complexes (Figure S2). The vast majority of
complex components are universally expressed in 11 cancer
cell lines (Geiger et al., 2012) (Figure S3A) and show high and
largely invariant expression in an mRNA sequencing (mRNA-
seq) study of 16 normal human tissues (EBI accession number
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E-MTAB-513) (Figure S3B). Indeed, complex subunits are
considered near ubiquitous (p % 1011; protein information
resource [PIR] tissue specificity annotations) and are expressed
in the top quartiles of 1,045 of 7,067 neoplastic and normal
tissue CGAP EST libraries (1% false discovery rate [FDR]),
including normal kidney (p % 1039), muscle (p % 1020), liver
(p % 1012), brain (p % 1020), vascular (p % 1030), bone
(p % 1015), and embryonic tissue (p % 1031). Consistent
with this, genes encoding complex subunits also tend to share
common upstream transcriptional regulatory motifs (p % 108)
(Figure 4B, inset table). Proteins mapped to complexes showed
no major bias in abundance over the complete set of human
proteins identified by mass spectrometry (Figure 1D).
The pervasiveness of ubiquitously expressed protein com-
plexes argues strongly for broad relevance to basic human cell
biology. Although often coexpressed, the subunit stoichiome-
tries of human protein complexes in vivo are largely unknown
and have never been systematically measured globally. Because
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Figure 6. Evolutionary Conservation of Protein Complexes
(A) Components of predicted human complexes—calculated as the average of evolutionary rate ratios—evolved more slowly, as compared to the entire set of
expressed proteins (see Extended Experimental Procedures).
(B) Pronounced spike in number of complexes originated with the emergence of vertebrates. x axis shows increasingly inclusive orthologous groups in the
phylogeny of eukaryotes.
(C) Human complexes conserved in fly (Guruharsha et al., 2011) and yeast (Babu et al., 2012) (see Table S3 and Extended Experimental Procedures). Nodes
represent complexes (human, blue; fly, green; yeast, orange), with size proportional to subunit number. Reciprocal best matches shown as dark gray edges, and
nonreciprocal is shown as lighter gray directed edges, with edge thickness proportional to Sorensen-Dice overlap of complex members. Human complexes
absent from public databases (putative complexes) are drawn as rectangles, and the remaining are drawn as circles.
(D) Similar tissue-specific expression patterns support a functional association between interacting proteins ENPL andGLU2B, whose orthologs were reported to
interact in fly (Guruharsha et al., 2011). Panels show representative antibody staining in normal tissue biopsies collected and reported by the Human Protein Atlas
(Uhlen et al., 2010) (www.proteinatlas.org).
See also Figure S3 and Table S3.
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all reconstructed complexes are supported by the same set of
extensive experimental mass spectrometry data, we could esti-
mate subunit stoichiometries based on the ratios of recorded
spectral counts after correcting appropriately for protein size
and composition (see Extended Experimental Procedures).
Although only approximate ratios were inferred and peaked at
1:1 (Figure 7A), such as between known ribosomal subunits
(Figures 7B and 7C), the results highlight intriguing deviations
in subunit abundance (Table S2). An example drawn from the




Figure 7. Protein Complex Stoichiometries
(A) Overall distribution of derived intracomplex
component stoichiometries.
(B and C) Estimated subunit stoichiometries
within and between proteins of the large and
small ribosome subunits agree on average with
the expected 1:1 ratio. Boxes summarize first
quartile, median, and third quartiles, whiskers
represent ±1.5 IQR, and circles represent outliers.
(D and E) Estimated protein subunit stoichiome-
tries within and between proteasomal pro-
teins. Intrasubunit stoichiometries within the
core, ATPase, or nonATPase regulatory subunits
agree well with the expected 1:1 ratio, but
stoichiometries observed between these com-
plexes deviate significantly from 1:1 (ATPase:non-
ATPase, Mann-Whitney p % 103; core:ATPase,
p % 1012; core:non-ATPase, p % 1016).
See also Table S2.
core a and b enzymatic subunits is close
to the expected 1:1 ratio, the median of
stoichiometries of core to non-ATPase
regulatory subunits deviated significantly
at 4:1 (Mann-Whitney p % 1016; Fig-
ures 7D and 7E). Hence, these data
suggest a rich source of information
about the physical organization of human
proteins.
DISCUSSION
The biochemically based interaction data
obtained in this integrative proteomic
study have enabled the identification of
both 364 previously unannotated protein
complexes (i.e., predicted complexes
with no statistically significant match to
complexes in public databases) encom-
passing 1,278 human proteins, many of
which are linked to human disease, and
unexpected components and interac-
tions for well-studied, widely conserved
nuclear and cytoplasmic protein machin-
eries, such as ribosome biogenesis,
with clear biological implications. Most
of the high-confidence protein interac-
tions provided in this resource have not
been previously reported in public interaction databases and
hence motivate mechanistic investigations of specific biological
systems.
Prior to this work, experimental knowledge regarding soluble
protein complex membership in human cells has generally
been ad hoc or focused on specific subcellular systems. Our
relatively unbiased integrative approach, wherein biochemical
evidence (cofractionation) of soluble native macromolecules
was combined with genomic inferences (imputed functional
associations), provides an inclusive snapshot of human protein
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complexes present under a standardized cellular context, thus
serving as a reference against which future process- or cell-
type-specific or dynamic interaction data sets can be compared.
Information gleaned from orthology proved to be an important
resource in separating true pairwise interactions from putative
false positives and, in turn, could reasonably be expected to
bias our results toward conserved complexes. In fact, although
we do find conserved complexes as expected, we also find
a majority that are not conserved (in fly and yeast) and that
seemingly have arisen with vertebrates (i.e., Figure 6B). The
slower rate of evolution of the subunits we report for our protein
complexes is also a feature of other human PPI networks, such
as in CORUM, and thus, our predictions of broad complex
conservation, albeit incomplete, are not just artifacts of our
methodology.
The fact that we detected little evidence of tissue specificity for
most of the derived human protein complexes and few cell-type-
specific components likely reflects undersampling by our mass
spectrometry procedures, which is a common limitation of LC-
MS/MS. At the level of predicted PPI (which are derived from
multiple biochemical fractions), differences in the proteomic
profiles generated for the two cell lines lie within the variance
observed between biological replicates of the same cell line
(Figures S1 and S2). Yet it is clear that differential interactomes
and the contextual rewiring of PPI networks are major determi-
nants of cell behavior and phenotypes. The complexes we report
undoubtedly undergo differential rewiring in response to environ-
mental, physiological, developmental, or disease states. With
further refinements to our experimental procedures, our interac-
tion mapping strategy has the potential to interrogate changes in
interaction space in a systematic manner in the future.
To enable exploitation of these data by the scientific
community, we have generated a dedicated web database of
human protein complexes (http://human.med.utoronto.ca) that
contains all the data generated in this study in an easily navi-
gated format. These include all of the supporting information
for each of the pairwise protein interactions obtained through
integration of our cofractionation data with public genomic
evidence, a list of the 5,584 proteins detected in each of the
1,163 biochemical fractions collected, and the subunit composi-
tion of the 622 putative protein complexes obtained through
clustering of our generated high-confidence interaction network.
This ‘‘first pass’’ draft of the soluble, stably associated human
protein ‘‘complexome’’ provides a glimpse into the global phys-
ical molecular organization of human cells, which is likely to be
perturbed in pathological states.
EXPERIMENTAL PROCEDURES
Cell Culture and Extract Preparation
HeLa S3 (ATCC#: CCL-2.2) and HEK293 (ATCC#: CRL-1573) soluble nuclear
and cytoplasmic protein extracts were prepared by conventional methods
(see Extended Experimental Procedures). Prior to fractionation, lysates were
treated with 100 units/ml Benzonase (Novagen Inc.) to remove nucleic acids
and clarified by centrifugation to remove debris.
Biochemical Fractionation and Proteomic Analysis
We performed weak anion-exchange and mixed-bed ion exchange, both with
and without a heparin precolumn to enrich for nucleic-acid-binding proteins.
In total, 1,095 chromatography fractions were collected (see Extended Exper-
imental Procedures). Isoelectric focusing was carried out on a MicroRotofor
Liquid-Phase IEF cell (Bio-Rad) according to the manufacturer’s protocol,
with 40 fractions collected across a pH range. Sucrose density gradient centri-
fugation was performed as previously described (Ramani et al., 2008), with 28
fractions collected.
Proteins were acid precipitated and trypsin digested, and the peptide
mixtures were fractionated and sequenced by using nanoflow liquid chroma-
tography-electrospray tandemmass spectrometry. Spectra were collected on
an LTQ linear ion trap (ThermoFisher Scientific) (majority) or LTQ Orbitrap
Velos hybrid mass spectrometer and searched against a UniProt human
target-decoy sequence database by using SEQUEST (Eng et al., 2008) (see
Extended Experimental Procedures). The LC-MS/MS identifications were
filtered to a 1.0% protein and peptide theoretical FDR.
Bioinformatics Analyses
Protein cofractionation networks were scored by correlation analysis (Pearson
correlation, weighted cross-correlation, coapex) based on the protein spectral
counts recorded across each set of fractions (see Extended Experimental
Procedures). Weighted networks were likewise constructed based on func-
tional evidence reported in HumanNet (Lee et al., 2011), omitting human
protein interaction data to minimize circularity that might bias our association
predictions. A coevolution network (Tillier and Charlebois, 2009) based on
correlated evolutionary rates was built to account for additional associations
not covered in HumanNet.
For the machine-learning classifier, we used the fast random forest imple-
mentation in Weka (see Extended Experimental Procedures) to integrate all
generated networks. Cross-validated decision trees were learned and bench-
marked by using independent training and test sets of CORUM reference
complexes (Ruepp et al., 2010). We denoised the network by using a diffusion
procedure to delete interactions lacking network topology support and by
calibrating the diffused interaction scores with Gene Ontology (Cellular
Component) normalized semantic similarity scores (see Extended Experi-
mental Procedures).
Clusters were defined by using the ClusterONE algorithm with parameter
settings chosen to yield the highest maximum matching ratio (Nepusz et al.,
2012) between the predicted complexes and set of cluster-training complexes
(see Extended Experimental Procedures).
Stoichiometries calculation is shown in Extended Experimental Procedures.
ACCESSION NUMBERS
The interaction data have been deposited into BioGRID and are also publicly
accessible via a dedicated web portal (http://human.med.utoronto.ca/).
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Biochemical Fractionation Using Native Chromatography
HPLC Columns, Buffers, and Instrumentation
IEX chromatography columns (weak anion-exchange PolyWAX LP; weak cation-exchange PolyCAT A; mixed-bed PolyCATWAX50/
50 columns) were purchased from PolyLC Inc (MD, USA). TSKgel Heparin-5PW affinity column was obtained from Tosoh Bioscience
LLC (PA, USA). Our buffer systems (fresh prepared with HPLC grade H2O) comprised low salt buffer A [10mM Tris-HCl, pH7.6, 3 mM
NaN3, 0.5 mM DTT, 5%-Glycerol] and high salt Buffer B [Buffer A + 1.5 M NaCl]. We performed all HPLC fractionations using an
Agilent 1100 HPLC binary pump system (Agilent Technologies, ON, Canada), essentially described elsewhere (Havugimana et al.,
2007). Protein elution was monitored by absorption at 280 nm.
Single-Phase Heparin Fractionation of Nuclear Extract
HeLa nuclear extract (6.0 mg total proteins) prepared using traditional methods (Dignam et al., 1983) was fractionated on a TSKgel
Heparin-5PW affinity column (753 7.5 mm id, 10 mm, 1000-A) previously equilibrated with buffer A at a flow rate of 0.5 ml/min. After
loading, the bound proteinswere eluted from the columnwith a 50min gradient from 0 to 50%buffer B (buffer A + 1.5MNaCl). A 5min
gradient with 50%–100% buffer B was applied to elute tightly bound proteins, with 100% buffer B maintained for an additional
3 min before returning back to 0% B for 7 min to re-equilibrate the column. In total, 48 3 0.75-ml fractions were collected from
0 to 72 min (1.5 min/fraction). Protein was precipitated with 10% TCA overnight at 4C. The pellet was washed twice with 20C
acetone for 30 min. After air drying, the pellet was dissolved in 50 ml digest solution (50 mM NH4HCO3- 50 mM Tris, 1 mM CaCl2).
The sample reduction (room temperature, 1 hr) and alkylation (room temperature, 30 min) were respectively performed using
5 mM and 15 mM of Dithiothreitol and Iodoacetamide. Each protein fraction was digested with 1 mg of sequencing grade trypsin
(Roche, Mississauga, Canada). After incubation for 18 hr at 30C with gentle shaking (VWR incubating micro-plate shaker;
300 rpm) samples were dry speed-vac. 20 ml of LC-MS grade buffer (5% Formic Acid in HPLC grade water) were used to solubilise
the peptide- digests. 8 ml tryptic peptides aliquot were directly analyzed by LC-MS.
Single-Phase Weak Anion-Exchange Fractionation of HeLa Cytosolic Extract
A total of 2.0-3.0 mg soluble protein in HeLa S3 cytosolic extract were applied to a PolyWAX LP column (200 3 4.6 mm id, 5 mm,
1000-A) equilibrated with buffer A. Elution of bound proteins was achieved through application of a 30 min gradient from 0 to
50%buffer B, with a final 2min gradient of 50%–100%buffer B applied to elute tightly bound proteins. 100%buffer Bwasmaintained
for an additional 2 min before returning back to 0% buffer B in 2 min for re-equilibration of the column for 3 min. A total of 453 1.2-ml
fractions were collected using a flow rate of 1.2 ml/min. The first and last fractions lacking protein (as judged by UV-absorption at
280 nm) were discarded. The rest of collected fractions were processed as described above.
Dual-Phase Heparin-Mixed-Bed Ion Exchange Fractionation of Nuclear Extracts
To enhance detection of low abundance nuclear proteins by MS, we used an optimized high resolution tandem affinity column
coupled online with a mixed-bed ion exchange column to enrich and resolve multi-proteins complexes in nuclear extracts. Typically,
8-10mg proteins fromHeLa or HEK293 nuclear extracts were loaded on a dual TSKgel Heparin-5PW affinity column (753 7.5mm id,
10 mm, 1000-A) coupled in series with PolyCATWAX mixed-bed ion exchange column (2003 4.6 mm id, 12 mm, 1500-A) mounted to
our integrated Agilent 1100 HPLC system (Agilent Technologies, ON, Canada). A 4 hr salt gradient (0.15 - 1.5 M NaCl) in Binding
Buffer A was used at 0.25 ml/min to resolve and fractionate proteins into 120 3 0.5-ml time-based fractions for downstream MS
protein identification. HeLa nuclear extract was fractionated in duplicates to confirm the reproducibility.
Triple-Phase Ion-Exchange Fractionation of HeLa Nuclear Extracts
As we have shown in our previous work (Havugimana et al., 2006, 2007), tandem weak anion-exchange (WAX) coupled in series to
aweak cation-exchange (WCX) offered greater resolution than a single column orWCX-WAX in tandem. Tominimize both chance co-
elution and bias toward one chromatographic fractionation approach, we used our further semi-preparative optimized and reproduc-
ible triple phase IEX-HPLC that comprised our previously optimized columns system preceded with a long weak anion-exchange
(250 3 9.4 mm i.d, 12 mm, 1500-A PolyWAX LP / 250 3 9.4-mm i.d, 12 mm, 1500-A PolyWAX LP / 250 3 9.4 mm i.d, 5 mm,
1500-A PolyCAT A) to fractionate 10-12 mg total proteins in HeLa nuclear extracts into 3753 0.8-ml fractions using elution program
consisting of a 10 min gradient with 100% buffer A to allow protein binding followed by a 50 min gradient with 0 to 50% buffer B fol-
lowed by a10- min gradient with 50 to 100% buffer B, 10 min at 100% buffer B, 10 min with 100 to 0% buffer B, and finally 10- min at
100% buffer A to re-equilibrate the column for the next injection. A flow rate of 4-ml/min was applied in elution gradient program.
Collected fractions were analyzed by LC-MS/MS in duplicates.
Triple-Phase Ion-Exchange Fractionation of HeLa Cytosolic Extracts
To identify macromolecular complexes that populate the HeLa cytoplasmic compartment, we scaled down our optimized semi-
preparative IEX-HPLC fractionation procedure to enhance protein concentration in each collected fraction. Seven to 9 mg total
proteins in HeLa cytoplasmic extract were fractionated on a triple phase IEX-HPLC analytical columns set up (200 3 4.6 mm i.d,
5 mm, 1000-A PolyWAX LP / 200 3 4.6-mm i.d, 5 mm, 1000-A PolyWAX LP / 200 3 4.6 mm i.d, 5 mm, 1000-A PolyCAT A) and
resolved into 3003 0.4-ml fractions using a 2.5 hr gradient elution program (23 min with 100% buffer A; 75 min with 0%–50% buffer
B; 3minwith 50%–100%buffer B; 23minwith 100%buffer B; 3minwith 100 to 0%buffer B; 23minwith 100%buffer A) at flow rate of
0.8 ml/min. Both the 19 fractions representing the column flow through and the 12 fractions representing the re-equilibration step
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were discarded as no proteins were detected in our short quality control LC-MS/MS analysis. All remaining 269 fractions were
analyzed in duplicate by LC-MS/MS.
Biochemical Fractionation Using IEF and Sucrose Gradient Sedimentation
Sample Preparation for Isoelectric Focusing Fractionation
HeLa cells were grown to 70%–80% confluency in 75cm2 flasks and harvested by mechanical scraping. Cells were washed in ice-
cold PBS, pelleted by centrifugation (600xg), and resuspended in lysis buffer [10 mM Tris-HCl (pH 8.0), 10 mM KCl, 1.5 mM MgCl2,
0.5 mM DTT, and 1x Protease Inhibitor Cocktail Set I (Calbiochem)]. Cells were lysed on ice using a Dounce homogenizer and frac-
tionated into cytosolic and nuclear fractions using a protocol adapted from previous publication (Andersen et al., 2002). Briefly, cells
were centrifuged at 1000xg for 5 min (4C). The supernatant was saved as the cytosolic fraction. The pellet was resuspended in
250 mM sucrose/10 mM MgCl2/1x Protease Inhibitor Cocktail, layered over a sucrose cushion of 880 mM sucrose/0.5 mM
MgCl2/1x Protease Inhibitor Cocktail, and centrifuged at 3000xg for 10 min (4
C). The supernatant was discarded and the pellet re-
suspended in lysis buffer with 5% NP-40 by sonicating water bath (15 min). Following sonication, samples were centrifuged at
3,500xg for 10 min to pellet insoluble material, with the supernatant saved as the nuclear fraction.
IEF Fractionation
Cytosolic and nuclear fractions were further fractionated in solution by isoelectric focusing on a MicroRotofor Liquid-Phase IEF cell
(Bio-Rad). Ten fractions per sample were collected across a pH range of either 3-10 or 5-8. Following IEF fractionation, ampholytes
were removed by OrgoSol DetergentOUT detergent removal kit (G-Biosciences).
Trypsin Digestion and MS Analysis of IEF Samples
Samples were denatured and reduced in 50% 2,2,2-trifluoroethanol (TFE) and 15 mM DTT at 55C for 45 min, followed by alkylation
with 55 mM iodoacetamide for 30 min at room temperature in the dark. Following alkylation, samples were diluted to 5% TFE in
50 mM Tris-HCl, pH8.0/2 mM CaCl2 and digested with a 1:50 final concentration of Proteomics Grade trypsin (Sigma) for 5 hr at
37C. Digestion was quenched by addition of 1% formic acid, and the sample volume was reduced to near dry (<20 ml) by speed
vac centrifugation. Samples were resuspended in 5% acetonitrile/0.1% formic acid and bound and washed on HyperSep C18
SpinTips (Thermo). Following elution, the sample volume was reduced by speed vac to remove elution buffer. Samples were resus-
pended in 5% acetonitrile/0.1% formic acid and filtered through Amicon Ultra 10kDa centrifugation filters (Millipore).
Samples were analyzed by LC-MS/MS. Peptides were separated on a Zorbax 300SB-C18 reverse phase column (0.075 3
150mm, 3.5 mm; Agilent) with an elution gradient of 5%–38%acetonitrile over 230min followed by 38%–100%over 15min. Peptides
were analyzed by nanoelectrospray ionization onto an LTQ Orbitrap mass spectrometer (Thermo Scientific). Parent mass scans
(MS1) were collected at high resolution (100,000) with data dependent ion selection activated for ions of greater than +1 charge.
Up to 12 ions per MS1 were selected for CID fragmentation spectrum acquisition (MS2), with ions selected twice within 30 s placed
on a dynamic exclusion list for 45 s.
Sucrose Gradient Fractionation of HeLa
Generation of the sucrose density gradient fractions andMS analysis were described elsewhere (Andersen et al., 2002; Ramani et al.,
2008). Briefly, they were generated using a 7%–47% continuous sucrose gradient and ultra-high-speed centrifugation of the super-
natants from HeLa S3 cell-free extracts. Gradient fractions were analyzed by Mass Spectrometry with LTQ-Orbitrap hybrid mass
spectrometer (ThermoFisher), and tandem mass spectra were searched as described below.
LC-MS/MS Separation and Identification of Chromatographic Peptide Fractions
For LC-MS/MSanalysis ofHPLCprotein fractions, sampleswere overnight 10%-TCAprecipitated andneat-cold acetonewasused to
wash the precipitates. Proteins were then resuspended in 50 ml of trypsin digestion buffer [50 mM Ammonium Bicarbonate, 1 mM
CaCl2, 50 mM Tris; pH7.8], subjected to reduction (10 mM DTT, 30 min, 30
C), alkylation (15 mM IAM, 60 min, 30C in the dark),
and digestion (18 hr, 30C, with gentle agitating) with one mg trypsin sequencing grade (Roche, Mississauga, Canada). The digestion
mixture was dried in the Savant Speed Vacuum, and tryptic peptides were re-solubilised in 20 ml of 5% formic acid prior to analysis by
LC-MS/MS using a linear ion trapmass spectrometer (LTQ; Thermo Fisher Scientific, CA, USA) or LTQOrbitrap Velos (Thermo Fisher)
coupled online to a nanoflow HPLC System (EASY-nLC; Proxeon, Odense, Denmark) via a nanoelectrospray ion source. Reverse-
phase LC-MS/MS using 150-mm i.d 3 40 cm in-house packed fused-silica C18 micro-capillary columns (Zorbax XDB-C18, 3.5 mm,
Agilent Technologies, Canada) at a flow rate of 500 nl/min were used to resolve peptides mixture in each HPLC fraction. To separate
peptides, we used columns with varying between 10-40 cm in length depending on sample complexity in each fractionation experi-
ment. The gradient elution timewas adjusted to the length of the column and varied between 2 and 4 hr. For a 2 hr gradient elution, 5 ml
of tryptic peptides generated for TCS-HPLC fractions were loaded onto a 20-cm column and eluted with a 0 to 35% solvent B (0.1%
formic acid/95% acetonitrile) over 90 min and from 35 to 95% in 15 min. For peptides analyzed on an LTQ ion trap instrument, eluted
peptidesweredirectly sprayed into anLTQ ion trapMS instrument via application of a spray voltageof 3.0 kV toananospray ion source
(Proxeon). TheMSwas operated in a fully automated data-dependent manner using Xcaliber 2.0 software to acquire one full MS scan
(400 - 2,000 m/z) followed by five MS/MS scans selected based on the five most abundant precursor ions and a precursor signal
threshold of 1,000 counts. Ion fragmentation was performed in CID mode through application of normalized collision energy of
35%. Ions subjected to MS/MS were excluded from further sequencing for 30 s. For peptide mixtures analyzed on an LTQ-Orbitrap
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Velos instrument, peptide sampleswere directly autosampled onto a 10 cm in-house packed column (75 mm inner diameter) with 3 mm
reversed phase beads (Zorbx 80XDB-C18, Agilent). Using a 60 min gradient (5%–35% ACN), peptides were directly electro-sprayed
(2.5 kV) into themass spectrometer. Mass spectrometer was operated in data dependentmode switching automatically between one
full scan MS and 10 MS/MS acquisitions. Instrument control was through Tune 2.6.0. and Xcalibur 2.1.0. Full scanMS spectra
(400 – 2,000 m/z) were acquired in the Orbitrap analyzer after accumulation to a target value of 106 in the linear ion trap (resolution
of 60,000 at 400 m/z).Fragmentation was performed in CID mode applying 35% normalized collision energy.
LC-MS/MS Spectra Database Search and Protein Identification
All MS/MS spectra IEF, SGF and IEX experiments acquired during over 9,000 hr of dedicated instrument run time were combined
(resulting in > 18,000,000 mass spectra) and rigorously searched against a target-decoy human database downloaded from
Universal Protein Resources Database (UniProtKB/Swiss-Prot Release 57.11; comprising 20,328 human proteins supplemented
with common contaminants) using the SEQUEST algorithm (V2.7) as previously described (Eng et al., 2008). Static modifications
were permitted to allow for the detection of carboxyamidomethylated (+57amu) cysteine. All peptide matches were required to be
fully tryptic although one missed cleavage was permitted. The probabilistic STATQUEST model (Kislinger et al., 2003) was used
to evaluate and assign confidence scores to all putative matches. Both proteins and peptides were considered positively identified
if detectedwithin a 1% false discovery rate cut off (based on empirical target-decoy database search results). The proteomic patterns
of the HPLC, IEF and SGF fractions were compared using the CONTRAST software tool (Tabb et al., 2002). We then removed from
consideration all proteins that passed our stringent cut off with only a single spectral count across all combined MS runs. Moreover,
to ensure a high quality proteomic data set, we confirmed the expression of our LC-MS detected proteins by cross-comparing with
previously reported HeLa S3 and HEK293 mRNA deep-sequencing data sets (Morin et al., 2008; Sultan et al., 2008). Additionally, we
only kept proteins that were supported by at least two unique peptides in at least one recent comprehensive proteomic study of the
HeLa proteome (Selbach et al., 2008; Wisniewski et al., 2009). This screening procedure resulted in 41,506 unique peptides (sup-
ported by 1.6 million individual mass spectra) matching to 5,584 distinct human proteins. To facilitate cross-mapping between
data sets, we used UniProtKB accession numbers as a common identifier and the UniProt ID mapping tool to interconvert different
gene and protein identifiers.
Polysome Profiling and Quantitative RT-PCR
HeLa cells were maintained in Dulbecco’s Modified Eagle’s Media (DMEM) supplemented with 10% fetal calf serum in a humidified
5% CO2 incubator at 37
C. Cells were transfected with 10 nM ON-TARGETplus SMARTpool siRNA (Thermo Scientific Dharmacon)
by using RNAiMAX (Invitrogen) at about 30% confluency. After 48 hr, 100 mg/ml cycloheximide (Sigma) was added into the culture
medium and cells were incubated for 5 min in the incubator. Then cells were collected by trypsinization and washed with cold PBS
containing 100 mg/ml cycloheximide twice. 1x105 cells were frozen in 80C for RNA extraction. The remaining cells were lysed in
the lysis buffer (20 mM Tris, pH7.4, 100 mM KCl, 10 mMMgCl2, 1% Triton-100, 1 mM DTT, 100 mg/ml cycloheximide, 1x EDTA-free
inhibitor tablet) on ice for 5 min. Extracts were clarified by centrifugation at 13,000 rpm for 10 min at 4 deg. The supernatant was
loaded onto a linear sucrose gradient (15%–45%) prepared in lysis buffer without Triton. After a 4 hr centrifugation at 36,000 rpm
in a Beckman SW40 rotor, the sucrose gradient was fractionated and absorbance at 254 nm was measured (ISCO fractionator).
For qRT-PCR, total RNA was extracted by RNeasy Plus Micro (QIAGEN). QuantiTect reverse transcription kit and QuantiFast
SYBR Green RT-PCR Kit from QIAGEN were used for qRT-PCR. The primer pairs for each gene in qRT-PCR were as follow:
human MKI67IP(rMKI67IP-1: 50-CCTGTTTGGTGAAAGACTCTTG-30; rMKI67IP-2: 50-GCTTTTGTGTTAGTGTCCGATTC-30), Human
GNL3(rGNL3-1: 50-CATTCGGGTTGGAGTAATTGG-30; rGNL3-2: 50-TGTGATCTGTTTGTCCAAGGG-30), Human DDX18(rDDX18-1:
50-GATTGTTCAGTATGACCCTCCG-30; rDDX18-2: 50-CATGCCCTCTCCCATTTAGG-30), Human FTSJ3(rFTSJ3-3: 50-TCTCTGGATA
GTGACCTGGATC-30; rFTSJ3-4: 50-ACTTCAGTAAGTCGCATACGC-30), Human GAPDH(GAPDH-Fr: 50-CTTTGTCAAGCTCATTTC
CTGG-30; GAPDH-Rr: 50-TCTTCCTCTTGTGCTCTTGC-30).
Immunoprecipitation Mass Spectrometry
C-terminal 3X-FLAG tagged expression clones of candidate ribosome biogenesis proteins were constructed via Gateway LR cloning
(Invitrogen) of human ORF clones from the PlasmidID collection into a modified pcDNA3 vector (Invitrogen) followed by sequence
verification. 3x106 HEK293 cells were transfected with 5 mg of DNA of tagged genes and untransfected cells were used as control.
FuGene6 (Roche) reagent in DMEM medium with 10% FBS and 1 U/ml of penicillin and streptomycin (Lonza) was used to transfect
the cells for 24 hr. Cells were harvested after growing in the samemediumwith 10 U/ml of penicillin and streptomycin for an additional
24 hr. Cell lysis, FLAG immunoprecipitation (IP) on M2-agarose (Sigma; A2220), immuno-complex elution and digestions were
performed according to the method of Dunham et al. (2011). Digested peptide mixtures (9 ml) were loaded onto a reverse phase
micro-capillary pre-column (25-mm x 75-mm silica packed with 5-mm Luna C18 stationary phase; Phenomenex) and injected onto
a micro-capillary analytical column (100-mm 3 75-mm). Peptide separation was performed over 105 min with 5%–95% Acetonitrile
(acidified with 0.1% formic acid) via an EASY-nLC system. Eluted peptides were directly sprayed into an Orbitrap Velos mass spec-
trometer (ThermoFisher Scientific) with collision activated dissociation using a nanospray ion source (Proxeon). 10 MS/MS data-
dependent scans were acquired simultaneously with one high resolution (60,000) full scan mass spectrum. An exclusion list was
enabled to exclude a maximum of 500 ions for 30 s. Acquired RAW files were extracted from the mass spectrometry data with
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the extractms program and submitted for database searching using the SEQUEST search engine against a target-decoy UniProtKB/
Swiss-Prot FASTA file. Search parameters were set to allow for one missed cleavage site, one variable modification of +16 for methi-
onine oxidation and one fixed modification of +57 for cysteine carbamidomethylation using precursor ion tolerances of 3 m/z. After




Pearson Correlation Coefficient Score. Proteins belonging to the same multi-protein complex should co-elute across a biochemical
fractionation, giving rise to similar elution profiles for those proteins. The similarity of elution profiles, represented as vectors contain-
ing the observed spectral counts for a protein in each fraction in a single experiment, was initially measured by Pearson correlation
coefficient of the normalized elution profiles.
Each fractionation and mass spectrometry series identifies N proteins across M fractions. The raw data matrix is then an N by M
matrix A where each A(i,j) represents the number of MS/MS spectra observed to match protein i in fraction j. The normalized data
matrix, B, converts numbers of peptides to frequencies, and is calculated as
Bði; jÞ= Aði; jÞP
i
Aði; jÞ
A protein’s normalized elution profile is represented by a row in this matrix, and the Pearson correlation coefficient was measured for
each pair of proteins.
While the Pearson correlation coefficient is a good indicator of a co-complex relationship if both proteins are observed at high counts
in the matrix, proteins observed at very low counts but found in the same fraction are often perfectly correlated but have poor predic-
tive power (Figure S5).
To circumvent this artifact, we synthetically introduced noise into the raw data matrix and measured the extent to which noise
affected the observed correlations and, by extension, the predictive power of correlation as it relates to protein complexmembership.
The observation of each protein in each fraction is modeled as a Poisson process, with lambda parameter assigned as the maximum
likelihood estimate equal to the raw counts of protein i in fraction j (the A(i,j) value). The noise term 1/M was added to the maximum
likelihood estimate for each cell. The value 1/M was chosen on the basis that each protein was represented in the matrix by at least
one peptide count, and the background probability for this should be evenly distributed across theM fractions. Thus the noise-added
matrix C = A + 1/M, a constant. The MS experiment is re-run in silico by drawing randomly from Poisson(C (i, j)) for each cell, then
normalizing as above and calculating the Pearson correlations for each pair of proteins. This process was repeated 1,000 times,
and themeanPearson correlation for each pair was recorded. The noise termhas the effect of giving every cell in thematrix a nonzero,
albeit small, probability of ‘‘discovering’’ a protein count in that cell. The impact of this discovery on the correlation of that protein’s
elution profile with other normalized elution profiles is minimal for proteins observed at high counts and maximal for those observed
with only one count across all fractions.
Weighted Cross-Correlation
In addition to the noise model correlation scores, a weighted cross correlation score was calculated for each pair of proteins in each
experiment. We calculated the similarity of spectra profiles between each pair of proteins using a weighted cross correlation (WCC)
approach (de Gelder et al., 2001), which was implemented in the R package wccsom (http://cran.r-project.org/web/packages/
wccsom/index.html). The similarity value is between 0 and 1.
There are some advantages of this approach over other similarity measures, such as Pearson correlation coefficient. The WCC
approach can take into account the relative shift between spectra profile patterns. In other words, given a protein, we can compare
its spectra profile at a point/fraction with the profiles in that neighborhood of the corresponding point/fraction of another protein.
Moreover, we can weight the different points in the neighborhood. In our calculation, we considered one point/fraction shift between
spectra profile patterns and defined the weights based on a simple triangle function (http://mathworld.wolfram.com/
TriangleFunction.html).
Machine Learning Methods
The noise-model correlations andweighted cross correlations of each pair of proteins observed in each of the seven cytoplasmic and
eleven nuclear MS fractionation experiments were combined into matrices of protein pairs x 14 (cytoplasmic) or x 22 (nuclear) exper-
imental observations. Missing data, where the pair of proteins were not both observed in a given experiment, were interpreted as
zeros.
A gold standard reference set of positive and negative interactions was generated from the CORUM database of curated mamma-
lian protein complexes. Human complexes consisting of 3 or more proteins were identified and filtered for those identified by mass
spectrometry and related methods, removing those identified solely by, e.g., two-hybrid approaches, EMSA, and imaging tech-
niques. Highly overlapping complexes (those with Simpson coefficient > 0.5) were merged, resulting in a reference set of 324
complexes comprised of 2,151 proteins. Each complex was then classified as ‘‘nuclear’’ and/or ‘‘cytoplasmic’’ based on the GO
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Cellular Component annotation of its constituent proteins, resulting in 198 cytoplasmic and 190 nuclear complexes. These
complexes were then randomly split into two groups, one for training pairwise co-complex protein-protein interactions in a machine
learning framework and an independent set for optimizing final protein complex predictions fromputative PPI. For PPI training, a refer-
ence positive interaction was defined as the case when two proteins were annotated to be in the same complex, and a reference
negative interaction was defined where both proteins were in the annotated set but never appeared in the same complex. Although
the CORUM complexes contain a large number of highly overlapping, redundant complex definitions, merging redundant complexes
and reducing the complexes to unique pairwise interactions minimizes this source of bias. To further reduce bias, we omitted the
largest complexes from the CORUM reference set (e.g., spliceosome, ribosome), which would otherwise account for a majority of
reference PPI. Moreover, although our definition of negative interactions almost certainly contains some actual positives due to
incomplete annotations, their effect is necessarily small, as negative interactions greatly outnumber positives. This renders our esti-
mates of accuracy conservative, as some negatives will in fact be mislabeled. Our complete set of reference complexes is listed in
Table S3.
The data were subjected to a variety of machine learning algorithms using the Weka suite of tools and assessed for accuracy and
coverage. Naive Bayes and Logistic Regression classifiers were run using default parameters. Support Vector Machines (SVM) were
applied using the SMO engine with a radial basis function kernel. The Random Forest implementation in Weka was too slow to use in
an exploratory fashion but the Fast Random Forest re-implementation (http://code.google.com/p/fast-random-forest/) gave a signif-
icant performance boost and yielded the best results, as judged by cross-validated recall-precision analysis.
Incorporation of Genomic and Proteomic Evidence
Genomic and proteomic evidence were assembled from the HumanNet functional gene interaction network (Lee et al., 2011).
HumanNet integrates a wide array of alternate data types across both human cell lines and model organism experiments into
a log likelihood score indicating the strength of evidence suggesting that a given pair of genes operates in the same biological
process. We considered only selected lines of evidence from HumanNet, excluding data derived from human experimental and
computational prediction of protein-protein interactions, in order to minimize circularity that might bias predictions of PPIs. In all,
protein-protein linkages from 17 lines of evidence were individually added to the classifier as independent features, with missing
values set to zero. Table S6 lists the data types included in this study.
The nuclear data set thus comprised 41 quantitative features for each protein pair: 11 MS data sets measured by noise-model
correlation, and again by weighted cross-correlation; the 17 features from HumanNet; a Co-Evolution score (Clark et al., 2011; Tillier
and Charlebois, 2009) measuring correlated evolutionary rates; and a Co-Apex score measuring the number of MS experiments in
which both proteins showed maximum (modal) abundance in the same fraction. Likewise, the cytoplasmic data set consisted of 33
features per pair: 14 MS and 19 other.
We used a greedy stepwise feature selection algorithm, implemented in Weka, to rank features and selected only the most infor-
mative ones, with the specific goal of choosing the single best correlationmetric for each particular MS data set. It was observed that,
after the first of the large-scale repeat MS experiments was folded into the classifier, the second repeat added little information and
ranked poorly. To rescue these data, we merged the four largest repeats by addition and recalculated the noise model and weighted
cross correlation scores for these four data sets. Performing feature selection on these data yielded 22 top-performing, non-dupli-
cated features for the cytoplasmic data and 25 features for the nuclear data (Table S2). Predictions were generated for these sets
using the Fast Random Forest classifier in Weka and a combined score was generated for each pair by taking one minus the product
of one minus the posterior probability of the pair interacting, as predicted by the classifier. For pairs that appeared in only one data
set, that data set’s posterior probability was used. Applying the classifier to all pairs which had a correlationmeasure greater than 0.5
in any one MS data set yielded 817,179 protein pairs, of which 48,915 had posterior probability > = 0.5. Notably, incorporation of the
complementary genomic evidence boosted the recall of PPI beyond that from the mass spectrometry evidence alone, across a wide
range of predictive precision, e.g., increasing recall by 20% at a cumulative precision of 0.7. The improvement shown by the final
version of the data is shown in the main text in Figure 2C.
Denoising the Inferred Protein-Protein Interactions
We developed a procedure that exploits the network topology and protein co-localization information in order to further reduce the
amount of noise in the inferred protein-protein interaction network and to filter it prior to discovering protein complexes.
We first delete the connections in the interaction network for which there is little evidence according to the network topology. The
rationale here is that if two proteins belong to the same complex, they should be well connected to each other through many short
paths in the graph. Diffusion methods over random graphs have previously been employed to quantify the amount of connectivity
existing between two nodes in a graph (Coifman et al., 2005; Paccanaro et al., 2006).
Here we use a multiple-step diffusion which calculates the connectivity between proteins i and j as the (i,j) element of the matrix:
el,M  l,M
whereM is the 5,5493 5,549 matrix whose entries are the output of the random forest classifiers, and l is the inverse of the maximal
eigenvalue of M. Edges with diffusion values lower than 5E-05 are then deleted from the original graph. We shall indicate this new
network with D.
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Second, we calibrate the resulting graph using protein co-localization information.
To do this we combine the output of the previous step with the GO-CC (Harris et al., 2004) normalized semantic similarity scores
with the assumption that they are independent. The rationale here is that two proteins located in different cellular locations should not
interact. The final score for each link is thus given by:





where Sim(i,j) is the maximum of the pairwise similarities between the two groups of GO-CC terms to which protein i and protein j are
annotated, andMS is themaximum value among all the semantic similarity scores. In our calculations, for the semantic similarities we
used an improved version of the Resnik semantic similaritymeasure (Resnik, 1999) that we have recently proposed (Yang et al., 2012)
and is able to take into account the ontology beneath the GO terms and to model uncertainty.
Note that, among 5,549 proteins, there are 1,790 proteins that are not annotated in GO-CC. Therefore for these proteins we simply
used D (output of the first step), as this (second) step cannot be applied to unannotated proteins.When considering the GO-CC anno-
tation we discarded those with evidence codes NR, IEA, and ND.
Scores below a threshold of 0.55 were set to zero. The resulting denoised Protein-Protein Interactions graph contains 13,993 inter-
actions (3,006 proteins) at an estimated 21.5% FDR. The effectiveness of the denoising procedure can be seen in a precision-recall
curve for the network after denoising obtained by varying the threshold over the network weights and using as gold standard the
CORUM database of curated mammalian protein complexes described earlier (Figure 2F).
Clustering of the Denoised PPI Network to Discover Protein Complexes
Protein complexes appear as densely connected regions within the de-noised interaction network. Because a protein may belong to
multiple complexes, these densely connected regions may overlap. To elucidate such overlapping sets in our network, we used an
algorithm that we have recently proposed, namedClusterONE (Clustering with Overlapping Neighborhood Expansion) (Nepusz et al.,
2012). ClusterONE finds complexes by growing multiple clusters from seed proteins, independently of each other. The growth of
a putative complex is governed by a greedy rule that tries to maximize the cohesiveness of the complex. The cohesiveness of
a complex C is defined as follows:
win
win +wout +pjCj
whereWin is the total weight of connections within C, Wout is the total weight of interactions connecting the complex with the rest of
the network and jCj is the size of the complex. p is a penalty constant that accounts for the possibility of uncharted connections in the
network as it assumes p extra external connections for the complex for every protein involved. In each step of the growth process, we
add a new adjacent protein to the complex or remove an already added protein in a way that yields the maximal increase in cohe-
siveness. The growth process stops when it is not possible to increase the cohesiveness further. At this stage, the cluster is declared
a protein complex candidate if its density is above a given density threshold d, and the growth process restarts from a different seed.
The first seed is the protein with the largest total weight on its incident connections (i.e., the protein with the most confident set of
interactions), and subsequent seeds are always selected in a similar manner but excluding proteins that have already been added
to some protein complex candidate. Because the growth processes are independent of each other, the calculated complexes
may overlap. More details on ClusterONE can be found in Nepusz et al. (2012). The algorithm has two main parameters: the penalty
p and the density threshold d. The settings for these parameters were chosen to yield the highest MaximumMatching Ratio (Nepusz
et al., 2012) on the cluster-training complex subset (see above). These were p = 2.9 and d = 0.4 and used to derive the final set of
complexes.
To evaluate the overlap of the predicted complexes with the CORUM complexes, we calculated: (1) the number of
CORUM complexes matching at least one predicted complex by a matching score greater than 0.25 (matching score = size of
intersection squared, divided by the product of the two complexes sizes, as defined by (Bader and Hogue, 2003), (2) the Maximum
Matching Ratio, (Nepusz et al., 2012), calculated by matching each predicted complex to at most one reference complex and
vice versa, while maximizing the total matching score between them (with the theoretical maximum of 1.0 considered as a perfect
match), (3) geometric accuracy as defined by (Brohée and van Helden, 2006) (square-root of the product of positive predictive
value and clustering-wise sensitivity). The predicted complexes showed better correspondence with the CORUM catalog
of reference human protein complexes than the results of other popular methods, including MCODE, MCL, CMC and RNSC (see
Table S5). Applying ClusterONE to our denoised network, we obtained a set of 771 complexes. We then further filtered this set using
the same procedure that we had applied to the CORUM set, which combined complexes sharing subunits (Simpson coefficient >0.5
between complexes). This produced our final set of 622 protein complexes.
Enrichment Analysis of Protein Pairs with Shared Annotations
To evaluate interacting and co-complexed protein pairs, we collected the following large-scale sets of protein-protein interactions:
1,991 co-complex interactions related to chromosome segregation (Hutchins et al., 2010); 17,775 ‘‘co-regulator’’ interactions iden-
tified through affinity purification and mass spectrometry-based methods (Malovannaya et al., 2011); and 209,913 interactions from
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a D. melanogaster co-complex interaction network (Guruharsha et al., 2011). In addition, we collected the following sets of gene
annotations: three available sets of 1,023, 3,563, and 114,477 human disease-gene associations (Becker et al., 2004; Hamosh
et al., 2005; UniProt Consortium, 2011), 2,065 gene-mitotic phenotype associations (Hutchins et al., 2010; Neumann et al., 2010),
curated sets of 74,250 mouse, 86,383 yeast, and 27,065 worm gene-phenotype associations assembled in (McGary et al., 2010),
upstream transcription factor regulatory motifs for 265,270 genes (Xie et al., 2005), and a set of 869 essential genes collected
from (Amsterdam et al., 2004; Blake et al., 2011; Harborth et al., 2001; Kittler et al., 2004; Silva et al., 2008).
We tested whether protein interaction partners are enriched for having common functional or phenotypic associations. That is, are
protein pairs which are predicted to interact significantly more likely to share annotations? For each annotation set, we calculated the
total number of protein pairs sharing annotations in the space of all possible pairs formed from the background set of annotated
proteins detectable through our experimental procedures. We compared this ‘‘expected’’ fraction of pairs with shared annotations
with the ‘‘observed’’ fraction of interaction partners with shared annotations. Tomeasure the significance of the observed fraction, we















whereN is the number of possible annotated pairs,m is the number of possible pairs with shared annotation, n is the number of anno-
tated interaction partners, and k is the number of interaction partners with shared annotation. In the case of testing for essentiality
enrichment, we used the complete set of possible proteins pairs. Enrichments were additionally confirmed (data not shown) with
two empirical p-values by calculating shared annotation fractions from 10,000 random trials, in which we (1) drew random protein
partners from the background protein set and (2) shuffled the protein labels on the predicted protein interaction map. Lastly, we
repeated the analysis for protein edges implied in our predicted protein cluster sets.
Tissue/Cell Line Specificity of Protein Complexes
It is important to note that HeLa cells were sampled in our profiling pipeline much more deeply than HEK, for which only nuclear frac-
tionations were performed. Nevertheless, we examined the abundance of the interacting human proteins in HEK293 and HeLa cell
lines on the basis of publicly available next-gen RNA sequencing data for both HeLa versus HEK293, well aware of the fact thatmRNA
expression levels may not necessarily reflect protein abundance. Considering all IEX MS experiments, HeLa proteins are discovered
at slightly higher rates than those expressed at the same level in HEK293 (Figure S2B).We can clearly distinguish the few proteins that
show differential tissue expression e.g., unique to one cell line. Among proteins assigned to complexes, only 82 show HeLa-specific
expression and 11 HEK-specific expression (i.e., difference in Log2 (fpkm) expression > 2), yet these proteins show no preferential
assortment into tissue-specific complexes.
The distribution of potentially tissue-specific proteins in complexesmay reflect possible false positives arising fromour analysis but
is readily explained as a consequence of the false negative rate of protein detection, due to under-sampling by LC-MS. Hence, we
directly examined the reproducibility of our fractionation/mass spectrometry data across biological replicates of the two cell lines,
comparing MS1 intensities versus MS2 spectral counting as alternate methods of quantification. Moreover, it is worth noting that
we find no evidence for stronger sampling biases in either proteome beyondwhat is to be expected formass spectrometry in general.
At the level of predictedPPI (which arederived frommultiple biochemical fractions), wefind that differences in theproteomicmeasure-
ments generated for the twocell lines (again, inwhichHeLawas sampled farmore extensively, particularlywith regards to cytoplasmic
extracts) lie within the variance actually observed between biological replicates of the same cell line (Figures S1 and S2).
The conclusion that the complexes we report are likely ubiquitous is supported by the expression of protein complex subunits
across different tissues. For example, the Mann group surveyed the proteomes of 11 cancer cell lines; proteins in our complexes
are generally found in all 11 lines (Figure S3A). Moreover, across 16 healthy human tissues for which RNA-seq data is available
(EBI accession number E-MTAB-513), we find our complexed proteins to be highly and invariantly expressed (Figure S3B). Across
17,927 confirmed protein-coding genes detected in any of the 16 tissues, the median standard deviation of gene expression is 1.30,
while for the 11,325 genes detected in all 16 tissues (63% of the total) it is 0.90. The standard deviation of genes we assign to protein
complexes is 0.73; among these proteins, 91% are detected in all 16 healthy tissues. Thus the protein complexes described here
exhibit largely invariant expression across the tissues sampled in the RNA-seq study.
Enrichment Analysis of Protein Clusters with Particular Phenotype Associations
We tested whether predicted protein clusters are enriched for particular human, mouse, or worm gene-phenotype associations. The
significance of members of a cluster sharing a particular phenotype was determined by the hypergeometric probability, as above,
where N is the number of annotated proteins in the background protein set, m is the number of proteins annotated with the queried
phenotype, n is the number of annotated proteins in the cluster, and k is the number of proteins in the cluster annotated by the queried
phenotype.
Cross-Validations with Curated Complexes in Public Databases and Independent Studies
We compared our network of complexes to curated complexes in 5 public databases, including CORUM (Ruepp et al., 2010),
REACTOME (Haw et al., 2011), PINdb (Luc and Tempst, 2004), and HPRD (Prasad et al., 2009) databases, and specified complexes
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within the GO cellular component category (Ashburner et al., 2000) to assess the agreement between our complexes and the liter-
ature. Statistically significant overlap between complexes was evaluated using the Fisher’s exact test for hypergeometric distribution
and the Benjamini-Hochberg method (Benjamini and Hochberg, 1995) to correct for multiple testing (estimated false discovery
rate% 0.05), with a minimum of 2 shared subunits. Next, we validated putative new complexes (i.e., not curated in the above public
repositories) through comparison with recently published independent co-affinity purification data (Guruharsha et al., 2011;Malovan-
naya et al., 2011). In particular, we accessed the recent human protein interaction results of Guruharsha et al. (2011). This group per-
formed affinity-tag pull-down experiments for human proteins present in 41 of our complexes. Overall, of the 299 relevant human
bait-prey interactions reported, 143 likewise occur within our complexes, representing a 47.8% validation rate. This agreement is
comparable to the 63.8% validation rate they claim for their own complex predictions, and is probably an underestimate because
they don’t report all the proteins actually detected bymass spectrometry, but rather only human proteins with orthologs in their initial
Drosophila PPI network. The matched clusters are reported in Table S3.
We also compared our complexes with the results of Malovannaya et al. (2011), which verified a total of 127 of our complexes (i.e.,
clusters show a Simpson matching coefficient > 0.5 between studies), including 42 (33%) of our complexes that are not curated in
CORUM. These matched complexes are listed in Table S3. Taken together, these analyses represent a nearly 40% validation rate
and strongly argue for the high fidelity of the mapped complexes.
Conservation of Complexes across Model Organisms
To examine to what extent human protein complexes identified in this study have known counterparts in yeast and fly, we considered
the set of 720 multi-protein complexes in S. cerevisiae identified in a recent study (Babu et al., 2012) and the 556 complexes recently
derived for D. melanogaster (Guruharsha et al., 2011). Both sets of complexes were identified using AP/MS techniques. Briefly,
human complexes were converted into an ortholog representation by mapping, whenever possible, the components of each
complex to their orthologs in yeast and fly, respectively. Using the ortholog representation of individual complexes, we then searched
for the most statistically significant match between this representation and all known complexes from the corresponding organism.
The process was also repeated in the opposite direction, mapping model-organism complexes onto the human collection in order to
identify reciprocally best matches. Statistical significance was established using the Fisher’s exact test for hypergeometric distribu-
tion and the Benjamini-Hochberg method (Benjamini and Hochberg, 1995) to correct for multiple testing (estimated false discovery
rate% 0.05). Orthology relationships for human, yeast and fruit fly were derived from twowell established sources: the InParanoid 7.0
(Ostlund et al., 2010) and Ensembl Compara (Vilella et al., 2009). The latter includes both the current Ensembl release 64 (ftp://ftp.
ensembl.org/pub/release-64/mysql/ensembl_compara_64/) and Ensembl Genomes release 11 (ftp://ftp.ensemblgenomes.org/
pub/pan_ensembl/release-11/mysql/ensembl_compara_pan_homology_11_64/). The Ensembl IDs from Compara were mapped
using BioMart Perl API (http://www.biomart.org/martservice.html). In addition, we extended the human-to-yeast orthology map
by matching human and yeast genes that share a common fly ortholog.
Coevolution
For the calculation of coevolution scores, we used the program MatrixMatchMaker (MMM) (Clark et al., 2011; Tillier and Charlebois,
2009). Orthologous protein sequence clusters were obtained from the OMA Database (Schneider et al., 2007) to obtain 204,689
eukaryotic groups that span 96 species, of which 20,800 contained human orthologs. The groups containing a human protein and
at least 10 orthologous sequences were aligned using MAFFT (Katoh et al., 2005) and distance matrices were obtained by using
protdist from PHYLIP (Felsenstein, 2005) with the PMB distance matrix (Veerassamy et al., 2003) to correct for multiple substitutions.
We ran MMM in an all-by-all manner with a selected tolerance of 0.1 (10%) and chose to use taxon information such that only
sequences from the same species could be matched.
Relative Evolutionary Rate
An average matrix was obtained by averaging the distance matrix entries over all of the OMA groups’ matrices. We used the average
matrix to compute the relative rate of an OMA group’s evolution, as the ratio of its rate (average distance to the human ortholog) over
the average matrix’s rate for the same subset of species pairs. Values greater than 1 are proteins that are evolving faster than
average, whereas values less than one indicate more slowly evolving proteins.
Evolutionary Age
The distribution of species present in the OMA orthologous groups determined the ancestral node in the phylogenetic tree of all
eukaryotic species. The evolutionary distance from the human sequence to this last common ancestral node was then calculated
and, in the case of complexes, averaged over the proteins in the complex. This gives an approximate evolutionary origin of the human
orthologs.
Interaction Database and PPI Orthology
All OMA proteins were assigned ROGiDs based on their amino acid sequence. These IDs were then used to identify the known phys-
ical (or inferred by the author) protein-protein interactions from the iRefIndex database (Razick et al., 2008), which combines protein
interaction data from multiple public databases: BIND, BioGRID, CORUM, DIP, HPRD, IntAct, MINT, MPact, MPPI and OPHID.
Human protein interaction data were also downloaded from most of these public databases and some other online available
resources independently. These databases / resources included BioGRID (Stark et al., 2011), DIP (Salwinski et al., 2004), MINT
(Ceol et al., 2010), HPRD (Prasad et al., 2009), INTACT (Aranda et al., 2010), NCBI Gene (http://www.ncbi.nlm.nih.gov/gene/),
CORUM (Ruepp et al., 2010) and the Human interactome database (Rual et al., 2005). Orthology of the PPIs was then determined
using the species distribution of the OMA groups.
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Approximation of Subunit Stoichiometries
The relative stoichiometries of interacting proteins were approximated from their associatedmass spectral MS/MS counts as follows:
For each pair of interacting proteins, we considered all biochemical fractions in which both proteins were observed, and calculated
relative stoichiometries for interacting protein pairs observed together in at least 10 fractions. Their relative stoichiometry was esti-
mated as the median (across the fractions) of the ratios of their MS/MS spectral counts divided by their expected ratios of spectral






where c1,j and c2,j are the spectral counts of protein 1 and protein 2 in fraction j (out of n), and e1 and e2 are the numbers of potential
tryptic peptides for proteins 1 and 2, respectively, calculated using the same parameters as in the initial identification of proteins from
the rawmass spectrometry data (e.g., considering up to one missing tryptic cleavage and employing the same spectral lookup data-
base). Stoichiometries estimated by this approach between ribosomal subunits and between core proteasomal subunits were
consistent with the expected 1:1 ratios, as shown in Figure 7.
Evaluating Potential Bias
We evaluated our final complexes for possible biases toward hydrophobic or low abundant proteins, underrepresented organelles,
and complex size–considerations that address some of the technical limitations of our approach. By design, insoluble membrane-
associated (hydrophobic) protein complexeswere largelymissed in this study. Consistent with other proteomics studies, our data are
biased toward highly expressed genes (Figure S2B). Our protein complexes are preferentially enriched for water-soluble nuclear and
cytosolic proteins (Benjamini-corrected p % 1052 and p % 1012, respectively), which nevertheless cover a wide spectrum of bio-
logical functions (as judged by enrichment for diverse functional annotation terms).
We also compared both the isoelectric point (pI) and subunit memberships of our predicted protein complexes versus those re-
ported in the CORUM database. To this end, we first minimized the inflated number of redundant protein complexes in CORUM
by merging complexes with similar annotated subunit compositions but reported by different authors. We then integrated protein
complexes with Simpson coefficients > 0.5 to deduce a consolidated non-redundant set of 734 curated protein complexes ranging
from 2 to 142 (spliceosome) annotated protein subunits per complex. As shown in Figure S4B, we do not observe significant bias
toward negatively (pI % 7) or positively (pI R 7) charged protein complexes in our data set as compared to CORUM.
Our clustering strategy, ClusterONE, underweights small clusters of size 2 or 3 in an effort to control the false positive rate, resulting
in a peak of clusters at size = 4 subunits as evident in Figure 3A in themain text. Despite this apparent bias, ClusterONE outperformed
the competing clustering algorithms we tested against the independent benchmark set of reference complexes, as detailed above
and summarized in Table S5. In practice, we find that most competing algorithms yield an exceptionally large number of small clus-
ters, for which it is difficult to establish meaningful measures of accuracy. Nevertheless, although our informatic approach yields
complexes with a biased size distribution, overall our complexes show demonstrably good performance against the reference
sets noted in the text.
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Figure S1. Assessment of LC-MS/MS Protein Detection Bias, Related to Figure 1 and Table S1
(A) Approximately 5% of proteins are unique to HEK cells (most likely to technical variations or sampling).
(B) Approximately 95% of the proteins identified in this study are supported by mRNA cognate transcript/or proteomic data produced with high resolution mass
spectrometer (Nagaraj et al., 2011; Morin et al., 2008; Sultan et al., 2008).
(C) Proteins identified in this study covered 64% of the proteins present in the CORUM reference database.
(D) Deep fractionation allows to enrich and identify low abundance nuclear proteins by LC-MS/MS. Proteins abundances were estimated from recent study of
HeLa Proteome by Mann group (Nagaraj et al., 2011).
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Figure S2. Comparison of HeLa and HEK Protein Profiles, Related to Figures 1 and 4 and Tables S1, S2, and S3
(A) Few proteins detected preferentially in HeLa or HEK293 cells have proportionally higher relative mRNA transcript levels in one of the two cell lines (Morin et al.,
2008; Sultan et al., 2008); most show consistent transcript levels in both cell lines. Proteins detected in both cell lines are represented as black dots, and those
detected only in HeLa or HEK cells are shown in blue or red, respectively.
(B) Gene products expressed in HeLa (blue) and HEK293 (red) cells (Morin et al., 2008; Sultan et al., 2008) were rank-ordered by mRNA-seq abundance level
(log2(fpkm)) and binned (bin size = 250). For each bin, the fraction of gene products detected across all IEX fractionation experiments is plotted against the mean
(+/ s.d.) expression of genes in the bin. Higher detection rate of HeLa proteins is consistent with deeper sampling of this cell line in our experiments.
(C) Positive correlation (r = 0.82) between HeLa (blue) and HEK (red) proteins assigned in our 622 complexes (2,634 proteins). For each protein in our set of 622
complexes, we retrieved its maximum spectral count across our 1,163 fraction and divided it by its length (i.e., number of amino acids). We then plotted the HEK
versus HeLa after logarithmic transformation of the normalized spectral counts. Observed differences in protein detection, particular in HeLa, is mostly due to the
protein detected in HeLa cytoplasmic extract.
(D) Box-and-whiskers quartile plots showing the high consistency (profile correlation > 0.8) of the co-fractionation data using different measures of protein
abundance (MS2 spectral counts versus MS1 peptide intensities). Data reproducibility was calculated using the Spearman rank correlation coefficients of
replicate profiles. Horizontal solid lines mark the minimum, first quartile, median, third quartile and maximum spearman correlation values; black dashed lines
mark mean Spearman correlations. High-scoring interacting protein pairs show reproducible HeLa and HEK293 co-elution profiles measured on a linear ion-trap
(i and ii, MS2 spectral counts for HeLa and HEK293, respectively) or a high precision Orbitrap instrument (iv, MS2 spectral counts; iii, MS1 peptide intensities
based on MaxQuant).
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Figure S3. Tissue Expression of Proteins in Complexes, Related to Figure 6
(A) Histogram of number of cancer cell lines in which proteins assigned to our complexes were observed. Data from Mann group proteomic survey of 11 cancer
cell lines (Geiger et al., 2012).
(B) Expression levels of RefSeq protein-coding genes across 16 healthy human tissues measured using the Illumina BodyMap 2.0 RNA-seq data (EBI accession
E-MTAB-513). Here, mean expression (log2(fpkm)) across all tissues in which a gene product is observed is plotted against the standard deviation of expression:
black, all genes; red, subunits assigned to protein complexes in this study. High mean and low variability of expression among protein complex components
implies ubiquitous expression.
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Figure S4. Physical and Biological Properties of our Predicted Human Protein Complexes, Related to Figure 4 and Table S3
(A) Size distribution of mapped protein complexes. The frequency distribution of the number of proteins per complex approximates an inverse power law.
(B) Evaluating bias in complexes. Theoretical pI for each individual protein was calculated using the open source ‘‘Compute pI/Mw’’ tool from the ExPASy (http://
web.expasy.org/compute_pi/). To estimate the pI of the protein complex, theoretical pI for individual proteins in complex were averaged and rounded to integer
values. Blue; complexes in CORUM reference. Black; complexes derived in this study.
(C) Distribution of annotated disease-associated proteins that are present in our compendium of 622 protein complexes.
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Figure S5. Pearson Correlation between Elution Profiles Breaks Down at High Correlations, Related to Figure 2B
Data from the cytoplasmic fraction of the sucrose gradient MS experiment were analyzed by ranking pairs according to the Pearson correlation coefficient of the
normalized elution profiles (x axis), binning, and calculating for each bin the log likelihood of containing reference set co-complex protein pairs (y axis). Correlation
coefficient is predictive of LLS score but breaks down as correlation approaches unity. This drop-off is caused by low-count proteins showing perfect corre-
lations, and was compensated through the use of a Poisson weighted correlation test.
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Appendix B
Tempo and Mode of Genome Evolution in a
50,000 Generation Experiment1,2
1Tenaillon, O [et al., including Wu, GC]. Tempo and Mode of Genome Evolution in a
50,000 Generation Experiment. Nature, 536(7615):165170, August 2016.
2In the following work, I performed fitness experiments, and analyzed genomes, including
synonymous and non-synonymous mutations, and intergenic mutations. In addition, I wrote
data analysis tools for parsing the breseq output that aided in the analysis. I also edited
and reviewed the manuscript prior to publication and approved the final version.
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Tempo and mode of genome evolution in 
a 50,000-generation experiment
Olivier tenaillon1*, Jeffrey E. Barrick2,3*, Noah Ribeck3,4, Daniel E. Deatherage2, Jeffrey L. Blanchard5, aurko Dasgupta2†, 
gabriel c. Wu2, sébastien Wielgoss6,7, stéphane cruveiller8, claudine Médigue8, Dominique schneider7,9 & Richard E. Lenski3,4*
Comparative genomic studies have identified the molecular basis of 
adaptations including lactase permanence in humans1, domestication 
of plants2 and animals3, and pathogenicity in bacteria4. Nevertheless, 
it is difficult to determine more generally what fraction of new muta-
tions in an evolving lineage are beneficial. Answering this question 
is important for modelling sequence changes used in phylogenetic 
methods5 and would inform debate about adaptive and non-adaptive 
modes of genome evolution6,7.
The combination of experimental evolution and genome sequencing 
provides a way forward that has been used with viruses, bacteria, yeast 
and flies8–13. In a study of bacteria, the diversity of mutations involved 
in adaptation to high-temperature stress was studied by sequencing 
>100 lineages after a 2,000-generation experiment10. In another study, 
sequencing a series of clones from one population over 40,000 genera-
tions showed the trajectory of genome evolution9. However, a short-term 
experiment reveals only the early steps of adaptation, and it is difficult 
to distinguish adaptive ‘driver’ and non-adaptive ‘passenger’ mutations 
when only one population is examined. Beneficial mutations can also 
be identified by lineage tracking14 and genetic reconstruction15 experi-
ments, but these approaches become impractical after an initial selective 
sweep or when mutations become too numerous over time, respectively.
To overcome these limitations, we analysed complete genomes of 
264 clones from 12 populations across 50,000 generations of the long-
term evolution experiment (LTEE) with E. coli16,17. These populations 
have evolved in a defined medium with scarce resources since 1988. 
Mean fitness measured in competition with their ancestor increased by 
~70% in that time17. The LTEE is a model system for studying many 
fundamental evolutionary questions9,15–23.
Genome-wide mutations and hypermutability
We sequenced the genomes of two clones from each population after 
500, 1,000, 1,500, 2,000, 5,000, 10,000, 15,000, 20,000, 30,000, 40,000 
and 50,000 generations using the Illumina platform (Supplementary 
Data 1). We called mutations, including structural variants, using 
the breseq pipeline24,25. In total, we found 14,572 point mutations; 
500 insertions of insertion sequence (IS) elements; 726 deletions 
and 1,132 insertions each ≤ 50 base pairs (bp) (small indels); and 
267 deletions and 45 duplications each >50 bp (large indels). After 
50,000 generations, average genome length declined by 63 kb (~1.4%) 
relative to the ancestor (Extended Data Fig. 1). Mutations were not 
distributed uniformly across the populations. Instead, six popula-
tions (Ara−1, Ara−2, Ara−3, Ara−4, Ara+3 and Ara+6) had 96.5% 
of the point mutations, having evolved hypermutable phenotypes 
caused by mutations that affect DNA repair or removal of oxidized 
nucleotides18,20. Figure 1a shows the trajectories for the total mutations 
in all 12 populations; Fig. 1b is rescaled for better resolution of those 
that did not become point-mutation mutators. Hypermutability tended 
to decline over time as the load of deleterious mutations favoured 
antimutator alleles20. All four populations that were hypermutable at 
10,000 generations accumulated synonymous substitutions (a proxy 
for the underlying point-mutation rate) between generations 40,000 
and 50,000 at much lower rates than from 10,000 to 20,000 generations 
(Extended Data Fig. 2).
Increased numbers of IS elements can also cause hypermutability26, 
with higher rates not only of transpositions but also deletions and dupli-
cations through homologous recombination. In population Ara+1, 
31.8% of all mutations up to 50,000 generations were IS150 insertions, 
compared with 12.3% for the other populations that never evolved ele-
vated point-mutation rates. This mode of hypermutability arose early in 
Ara+1; IS150 insertions are overrepresented in each Ara+1 clone from 
5,000 generations onwards when compared individually to all other 
non-mutator clones from the same generation (Fisher’s exact test with 
Bonferroni correction, P < 0.05). Two clones from other populations 
were also IS150 hypermutators by this test: 38.7% of the mutations in 
Adaptation by natural selection depends on the rates, effects and interactions of many mutations, making it difficult 
to determine what proportion of mutations in an evolving lineage are beneficial. Here we analysed 264 complete 
genomes from 12 Escherichia coli populations to characterize their dynamics over 50,000 generations. The populations 
that retained the ancestral mutation rate support a model in which most fixed mutations are beneficial, the fraction of 
beneficial mutations declines as fitness rises, and neutral mutations accumulate at a constant rate. We also compared 
these populations to mutation-accumulation lines evolved under a bottlenecking regime that minimizes selection. 
Nonsynonymous mutations, intergenic mutations, insertions and deletions are overrepresented in the long-term 
populations, further supporting the inference that most mutations that reached high frequency were favoured by 
selection. These results illuminate the shifting balance of forces that govern genome evolution in populations adapting 
to a new environment.
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a 30,000-generation clone from Ara−5 and 31.7% of the mutations 
in a 40,000-generation clone from Ara−3 were IS150 insertions. The 
aberrant Ara−5 clone shares only one mutation with other sequenced 
Ara−5 clones, indicating early divergence; it does not share point muta-
tions with any other population, excluding cross-contamination. The 
emergence of these various mutator types shows that evolution can 
alter the production of genetic diversity20,27, which in turn changes the 
tempo and mode of genome evolution.
Population phylogenies
Figure 2a shows phylogenetic trees constructed using point mutations 
for each population; Fig. 2b shows the trees with branches rescaled 
after mutators evolved. Some populations—including Ara−2, which 
became hypermutable early, and Ara−6, which never did—harbour 
lineages that coexisted for tens of thousands of generations. Some 
others—including Ara−4, which became hypermutable, and Ara+2, 
which did not—are more linear in structure, without deep branches 
among the sequenced clones. Deep branches were probably supported 
by the diversity-promoting effects of negative-frequency-dependent 
interactions, as shown in the Ara−2 population22,23. Sequencing 
whole-population samples would provide more detailed information 
on within-population diversity11,12.
Dynamics of genome evolution
The accumulation of point mutations increased greatly in hypermu-
table populations9,19,20, potentially overwhelming the genomic signa-
ture of adaptation. Although mutator lineages may experience higher 
rates of fitness improvement17,27, the effect is usually small owing to 
clonal interference between competing beneficial mutations28,29 and 
the increased load of deleterious mutations20,30. Therefore, beneficial 
mutations become harder to detect in a sea of unselected mutations in 
mutator lineages. To understand better the dynamic coupling between 
adaptation and genome evolution, we first analysed the populations 
that retained the ancestral mutation rate up to 50,000 generations and 
the others before they became point-mutation or IS150 mutators.
It was previously found17 that the mean-fitness trajectory of the LTEE 
is well described by a power-law relation, in which log fitness increases 
linearly with log time. Moreover, the power law accurately predicts 
fitness to 50,000 generations using data from only the first 5,000 gen-
erations. It was shown that a population-dynamical model that incor-
porates two phenomena known to be important in the LTEE—clonal 
interference29,31 and diminishing-returns epistasis15,29—generates a 
power-law relation. This model in turn predicts that the number of 
beneficial mutations should increase with the square root of time17. 
However, not all mutations that accumulate are beneficial; neutral and 
nearly neutral mutations can spread by recurring mutation, random 
drift, and hitchhiking32–34. Selective sweeps will purge some neutral 
mutations but cause others to increase; overall, the expected number 
of neutral mutations should increase linearly with time35.
To test these predictions, we fit three models to the trajectory for the 
total number of mutations in the non-mutator and premutator lineages:
=m at
= √m b t
= + √m at b t
where m is the number of mutations, t is time (generations), and a 
and b govern the genome-wide rates of accumulation of neutral and 
beneficial mutations, respectively (Fig. 3). (Extended Data Fig. 3 shows 
the models fit to each population separately.) Using the Akaike infor-
mation criterion (AIC), the two-parameter model fits the data much 
better than those with only the linear (ΔAIC = −77.7) or square-root 
(ΔAIC = −99.7) terms. Because the one-parameter models are nested 
within the two-parameter model, we can also assess the significance of 
adding the second parameter; P values are 7.5 × 10−5 and 5.2 × 10−7 
relative to the linear and square-root models, respectively. The trajec-
tory for genome evolution thus shows signatures of both adaptive and 
non-adaptive changes. However, the model that predicts the square-
root trajectory of beneficial substitutions makes various assumptions 
(for example, about the form of epistasis), and both the predicted and 
observed trajectories have statistical uncertainties. (Extended Data Fig. 4 
shows the uncertainty in estimating a and b from the observed trajec-
tory.) Therefore, we examined additional evidence to shed light on the 
proportion and identity of beneficial mutations.
Evidence for beneficial mutations
We sought to understand what proportion of the genomic changes in 
the non-mutator populations was adaptive, and how that proportion 
changed over time. One line of evidence derives from the expecta-
tion that synonymous substitutions—point mutations in protein-cod-
ing genes that do not affect the amino-acid sequence—are neutral 
and should therefore accumulate at a rate equal to the underlying 
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Figure 1 | Total number of mutations over time in the 12 LTEE 
populations. a, Total mutations in each population. b, Total mutations 
rescaled to reveal the trajectories for the six populations that did not 
become hypermutable for point mutations, and for the other six before 
they evolved hypermutability. Each symbol shows a sequenced genome; 
some points are hidden behind others. Each line passes through the 

























Figure 2 | Phylogenetic trees for LTEE populations. a, Phylogenies for 
22 genomes from each population, based on point mutations. b, The 
same trees, except branches are rescaled as follows: branches for lineages 
with mismatch-repair defects are orange and shortened by a factor of 
25; branches for mutT mutators are red and shortened by a factor of 50. 
Strain REL606 (on the left) is the ancestor. No early mutations are shared 
between any populations, confirming their independent evolution. Most 
populations have multiple basal lineages that reflect early diversification 
and extinction; some have deeply divergent lineages with sustained 
persistence, most notably Ara−2.
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mutation rate20,35. This expectation is not strictly true owing to selec-
tion on codon usage, RNA folding, and other effects, but it is gener-
ally thought that such selection is extremely weak, affects only a small 
fraction of sites at risk for synonymous mutations, or both36,37. We 
calculate whether nonsynonymous and intergenic point mutations are 
found in excess relative to synonymous mutations, given the number 
of sites at risk for each class. Figure 4a shows the number of synony-
mous mutations in non-mutator and premutator populations, scaled 
so the mean at 50,000 generations is unity. As expected, synonymous 
mutations accumulated at an approximately constant rate (Extended 
Data Fig. 5). Figure 4b shows the number of nonsynonymous mutations 
relative to the neutral expectation based on synonymous mutations. 
Nonsynonymous mutations accumulated ~17.1 times faster than 
synonymous ones during the first 500 generations and ~3.4 times 
faster over 50,000 generations. Nonsynonymous mutations continued 
to accumulate at over twice the rate of synonymous mutations in the 
later generations (Extended Data Fig. 6), implying that most nonsyn-
onymous mutations that reached high frequency were beneficial even 
after so long in a constant environment. The same approach applied to 
intergenic point mutations (Fig. 4c) also reveals a large excess relative 
to synonymous mutations, although the number of events is smaller 
and the uncertainty greater. This result implicates adaptive changes in 
noncoding regions that presumably affect the binding sites for regu-
latory proteins38–40.
Synonymous mutations provide an internal benchmark for non-
synonymous and intergenic point mutations. However, synonymous 
mutations are not directly informative for understanding how selec-
tion affects the accumulation of indels that comprise almost half the 
mutations in non-mutator clones at 50,000 generations (Extended Data 
Fig. 7). To estimate the proportion of beneficial changes for other 
types of mutation, we compare the LTEE and a mutation accumulation 
experiment (MAE) in which 15 lines were propagated via repeated 
single-cell bottlenecks41. Such bottlenecks eliminate the variation 
needed for natural selection, so that all types of mutations accumulate 
at the rates at which they happen, regardless of fitness effects, except for 
lethal or highly deleterious mutations that preclude cells from making 
colonies used to propagate lines29. MAE lines thus provide an external 
baseline for distinguishing beneficial and non-beneficial mutations. In 
fact, because more unselected mutations are deleterious than benefi-
cial, MAE lines are expected to lose fitness over time, which they did 
(Extended Data Fig. 8).
To quantify the relative rates for all types of mutations in the absence 
of selection, we sequenced clones from the MAE lines after 550 daily 
bottlenecks (Supplementary Data 1). Consistent with the random 
accumulation of mutations, the number of nonsynonymous (including 
nonsense) mutations was similar to the expectation based on synon-
ymous mutations (117 observed, 105.02 expected); the resulting ratio 
of 1.11 is well within the 95% confidence interval (0.70–1.50) obtained 
by a randomization test. Also, there was no among-line variation in 
total mutations (χ2 = 5.46, degrees of freedom (df) = 14, P = 0.978). 
We can therefore reasonably use the MAE lines to estimate relative 
rates of different types of mutations, with synonymous ones providing 
a benchmark largely free of selection in both experiments. For example, 
LTEE population Ara−1 had 21 nonsynonymous mutations at 
20,000 generations and the expected number of synonymous muta-
tions based on the average non-mutator population was 1.08 (Extended 
Data Fig. 5); the 15 MAE lines in total had 117 nonsynonymous and 
39 synonymous mutations; thus, the ratio of observed mutations 
to the neutral expectation is (21/1.08)/(117/39) = 6.5. These ratios 
show that all major classes of mutations—including various indels—are 
substantially overrepresented in the LTEE relative to the MAE 
(Extended Data Fig. 9), implying that many mutations in each class 
were adaptive during the LTEE.
Parallel evolution at many gene loci
Parallel evolution occurs when similar changes arise independently 
in multiple lineages, and it is often used to discover putative targets 
of selection4,8,10–13,21. Genetic parallelism can be studied at the level 
of DNA sequence, affected genes, or integrated functions. Parallelism 
at the nucleotide level tends to be rare because different mutations 
in a gene often produce similar benefits4,10–12,21, although there are 
exceptions8. Parallelism at a functional level requires detailed under-
standing that may be unavailable, and it is difficult to interpret when 
there are many mutations. We therefore examined parallelism at the 
gene level.


















Figure 3 | Alternative models fit to the trajectory of genome evolution. 
Each symbol shows total mutations in a clone from five populations 
that never became mutators and seven before point mutation or IS150 
hypermutability evolved. Colours are the same as in Fig. 1; open triangles 
indicate grand means. Dashed grey line shows the best fit to the linear 
model, m = at. Solid grey curve shows the fit to the square-root model, 
m = b √t. Black curve is fit to the composite model, m = at + b √t, where 









































































































































Figure 4 | Trajectories for synonymous, nonsynonymous and intergenic 
point mutations. a, Synonymous mutations, scaled so that the mean 
of five non-mutator populations (excluding point mutation and IS150 
hypermutators) is unity at 50,000 generations. b, Nonsynonymous 
mutations, scaled using the same rate as synonymous mutations after 
adjusting for sites at risk for both classes. c, Intergenic point mutations, 
scaled using the same rate as synonymous mutations after adjusting for 
sites at risk. Each symbol shows the mean for sequenced genomes from 
a non-mutator or premutator lineage. Colours are as in Fig. 1. Note the 
discontinuous scale; populations with zero mutations are plotted below. 
Black lines connect grand means; shading shows standard errors calculated 
from replicate populations.
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We focused on lineages that retained the ancestral point-mutation 
rate (including clones from populations that later became hypermu-
table) because, as shown earlier, most mutations are drivers in those 
cases; we expect hypermutability to make the analysis less informative 
because many more mutations are passengers. We first calculated the 
expected number of nonsynonymous mutations for each single-copy 
protein-coding gene based on its length as a fraction of all such genes 
and the total number of nonsynonymous mutations in the relevant 
lineages (Supplementary Data 2). We computed G scores for good-
ness of fit between observed and expected values; the total score is 
2,593.7. We compared that total with simulated data sets in which 
positions of mutations in the coding genome were randomized, and the 
observed total significantly exceeded the simulations (mean simulated 
G = 1,933.7, Z = 25.5, P < 10−143). Fifty-seven genes had two or more 
mutations; these genes had 50.1% of the nonsynonymous mutations 
but constituted only 2.1% of the coding genome. (Only one gene 
had multiple synonymous changes.) Table 1 shows the 15 genes that 
contribute the most to the total G score. Several encode proteins with 
core metabolic or regulatory functions, including three involved in 
peptidoglycan synthesis.
We ran the same analysis for lineages that evolved hypermutability 
(Supplementary Data 3), and the randomization test indicates signif-
icant parallelism (G statistic = 5,098.4, mean simulated G = 4,581.1, 
Z = 5.745, P < 10−8). As expected, however, the signal-to-noise ratio 
reflected in the significance level is much weaker than for the non- 
mutator lineages. Most genes with the highest scores in mutator 
lineages differ from those in non-mutators, in part because those genes 
often had beneficial mutations before hypermutability evolved.
Table 2 lists the 16 genes with the most deletions, duplications, 
insertions and intergenic point mutations in non-mutator lineages 
Table 1 | Protein-coding genes with the highest G scores
Gene Length Observed Expected G Annotation
pykF 1,413 19 0.16 181 Pyruvate kinase
iclR 825 13 0.10 128 Transcriptional repressor, glyoxylate bypass
spot 2,109 14 0.25 113 Stringent response
nadR 1,233 12 0.14 106 Bifunctional transcriptional repressor and NMN adenylyltransferase
hslU 1,332 11 0.15 94 Molecular chaperone and ATPase component of protease
yijC (also known as fabR) 705 7 0.08 62 Transcriptional repressor, fatty acid and phosphatidic acid pathway
topA 2,598 8 0.30 52 DNA topoisomerase I subunit
malt 2,706 8 0.31 52 Transcriptional activator, maltotriose-ATP-binding
mrdA 1,902 7 0.22 48 Transpeptidase in peptidoglycan synthesis
mreB 1,044 6 0.12 47 Longitudinal peptidoglycan synthesis
infB 2,673 7 0.31 44 Translation initiation factor IF-2
arcA 717 5 0.08 41 Response regulator in two-component system, anoxic redox control
argR 471 4 0.05 34 Repressor of arginine regulon
rplF 534 4 0.06 33 50S ribosomal subunit protein
mreC 1,104 4 0.13 28 Longitudinal peptidoglycan synthesis
Genes are ranked by G scores computed using observed independent nonsynonymous mutations relative to expected number given gene length (bp). Data are from populations with the ancestral 
point-mutation rate throughout and other populations before they evolved hypermutability.
Table 2 | Genes with the most mutations of other types
Genes Mutations Number IS MAE Annotation
rbsD Mostly large deletions 41 Yes No d-Ribose utilization; most deletions affect entire rbs operon
nupC Various intergenic 19 Yes Yes Nucleoside transporter
iap Mostly large indels 19 Yes No Alkaline-phosphatase isozyme conversion; most indels affect tens of adjacent 
genes including rpoS, which encodes stationary-phase σ factor
mokB Various indels 17 Yes Yes Enables hokB toxin expression
yhgI/gntt Intergenic point mutations 16 No No Gluconate transport
mokC Various indels 15 Yes Yes Enables hokC toxin expression
ybcU (also known 
as borD)
Large indels 14 Yes No Indels affect this and adjacent remnants of DLP12 prophage
ECB_02013 Various indels 14 No Yes Indels affect this and adjacent remnants of P2-like prophage
ECB_02816 (also  
known as kpsD)
Various indels 14 Yes No Polysialic-acid transport protein precursor
acs/nrfA Various intergenic 14 No No Acetyl-CoA synthase; nitrite reductase
hokE Large indels 12 Yes No Toxin in plasmid-derived toxin–antitoxin system; most indels affect several  
adjacent genes involved in iron acquisition
ybeB/phpB Various intergenic 11 Yes No Unknown functions, but adjacent to genes involved in cell-wall synthesis
ydiJ/ydiK Various intergenic 11 No No Predicted FAD-linked oxidoreductase; putative inner membrane protein
ldrC Various indels 10 Yes Yes Small toxic polypeptide
menC IS insertions 10 Yes Yes Menaquinone biosynthesis
fimA Mostly IS insertions 10 Yes No Component of fimbrial complex
Genes are ranked by total mutations excluding nonsynonymous and synonymous point mutations. When two genes are separated by a solidus, the affected sequence includes the intergenic region 
between them. IS column indicates whether the majority of mutations involve IS elements. MAE column indicates whether the same or nearly identical mutations occurred in one or more MAE lines. 
Data are from populations with the ancestral point-mutation rate throughout and others before they evolved hypermutability.
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(Supplementary Data 2). For mutations that impact multiple genes, 
we show the most frequently affected gene (or adjacent pair when 
most events are intergenic). In 12 cases, the majority of the mutations 
were mediated by IS elements; these include insertions as well as 
deletions and duplications that appear to involve homologous recom-
bination. In six cases (five with IS insertions), the same or nearly 
identical mutations occurred in one or more MAE lines, suggesting 
mutational hotspots. These changes may indicate high-frequency 
events, but recall that IS insertions and large indels are enriched in 
the LTEE relative to the MAE (Extended Data Fig. 9), implying that 
many are also beneficial. Indeed, the IS-mediated rbsD deletions 
occur at a high rate and are beneficial in the LTEE environment42, 
and some IS-mediated mutations appear to be beneficial in other 
studies as well43,44.
The parallelisms involving nonsynonymous substitutions and other 
mutations in the LTEE, coupled with their high rates of accumulation 
relative to the MAE, indicate that many observed mutations were 
drivers of adaptation. For indels, however, the specific target genes are 
difficult to identify owing to the multiplicity of genes affected and the 
potentially confounding effect of mutational hotspots.
Discussion
Adaptation by natural selection sits at the heart of phenotypic evolu-
tion. However, the random processes of spontaneous mutation and 
genetic drift often overwhelm and obscure genomic signatures of 
adaptation. We overcame this difficulty by analysing genomes from 
12 bacterial populations that evolved for 50,000 generations under 
identical culture conditions. Even so, six populations evolved hyper-
mutable phenotypes that increased point-mutation rates ~100-fold, 
and another evolved hypermutability caused by a transposable element. 
By focusing on populations that retained the ancestral mutation 
rate, we identified several key features of the tempo and mode of 
their genome evolution. First, a population-genetic model with two 
terms—one for beneficial drivers, the other for neutral hitchhikers— 
fits the dynamics much better than models without both terms. 
Second, the great majority of mutations observed during the early 
generations were beneficial drivers. Third, the proportion of observed 
mutations that were beneficial declined over time but remained sub-
stantial even after 50,000 generations. The second and third findings 
follow from the population-genetic model. Both are also strongly sup-
ported by the excess of nonsynonymous to synonymous substitutions 
in the LTEE and by the excess of several classes of mutations, including 
indels, in comparison to mutation-accumulation lines. Fourth, there 
was strong gene-level parallel evolution across the replicate LTEE 
populations.
Our analyses also show a contrast between the contributions 
of beneficial mutations to molecular evolution and to the fitness 
trajectory in a stable environment. In particular, beneficial mutations 
continued to constitute a large fraction of genetic changes throughout 
the 50,000 generations of the LTEE, whereas the resulting fitness 
gains were only a few per cent in the last 10,000 generations17. 
Beneficial mutations with very small selection coefficients are none-
theless visible to natural selection17. Hence, adaptation can remain 
a major driver of molecular evolution long after an environmental 
shift. Our experimental results thus support a selectionist view of 
molecular evolution, complementing indirect evidence based on 
comparative genomics in bacteria, Drosophila and humans45–47. 
Of course, the LTEE may differ from many natural populations in 
important respects including its low mutation rate, the absence of sex 
or horizontal gene transfer, and a stable environment. As we showed, 
high mutation rates tend to obscure the role of selection in molecu-
lar evolution. The effects of horizontal gene transfer48 and variable 
environments49,50 on the dynamic coupling of genomic and adaptive 
evolution should also be examined further. Long-term experiments 
with microorganisms provide opportunities for rigorous analyses of 
these issues.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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Long-term evolution experiment. The LTEE has 12 populations founded from 
two almost identical strains of Escherichia coli. Six populations, designated 
Ara−1 to Ara−6, started from REL606, a descendant of the B strain of Luria and 
Delbrück51–53. The other six, Ara+1 to Ara+6, derive from REL607, which differs 
from REL606 by point mutations in araA and recD. The mutation in araA was 
selected before starting the LTEE; it confers the ability to grow on l-arabinose, 
which provides a marker in competition assays used to measure fitness16,17. The 
recD mutation arose inadvertently before starting the LTEE. The LTEE began in 
1988, and the populations have been propagated (with occasional interruptions) 
at 37 °C by daily 100-fold dilutions in 10 ml Davis minimal medium with 25 μg/ml 
glucose (http://lenski.mmg.msu.edu/ecoli/dm25liquid.html). The regrowth allows 
~6.67 generations per day; the population size fluctuates between ~3 × 106 and 
~3 × 108 cells except in population Ara−3, which has had a population size 
several times larger since ~33,000 generations, when cells gained the ability to 
consume the citrate that is also present in the medium19,54. Whole-population 
samples are taken every 75th transfer (500 generations) and stored with glycerol 
as a cryoprotectant at −80 °C, where they are available for later analysis. Here 
we analysed the genomes of two clones sampled from each population at 500, 
1,000, 1,500, 2,000, 5,000, 10,000, 15,000, 20,000, 30,000, 40,000 and 50,000 gen-
erations (Supplementary Data 1). We deliberately included clones from the deeply 
diverged lineages in population Ara−2 from 20,000 generations onwards and both 
the majority Cit+ lineage and the minority Cit− lineage in population Ara−3 at 
generation 40,000. This sampling scheme does not affect inferences about the rates 
and patterns of genome evolution because both populations were hypermutable 
at these time points and thus excluded from the main analyses. These clones were 
included to illustrate diversity within populations, although we also found previ-
ously unknown cases of divergent lineages. No statistical methods were used to 
predetermine sample size. The experiments were not randomized. The investiga-
tors were not blinded during experiments and outcome assessment.
Mutation-accumulation experiment. The 15 MAE lines analysed here started 
from strain REL1207, which is an Ara+ mutant of a clone sampled from LTEE 
population Ara−1 at 2,000 generations. REL1207 differs from REL606 by a total 
of eight mutations, including one in araA that confers the Ara+ marker phenotype. 
Each line was propagated through 550 single-cell bottlenecks by picking a colony at 
random from a Davis minimal agar plate with glucose at 200 μg/ml and streaking 
the cells onto a fresh plate. Given ~25 cell doublings to produce a typical colony41, 
the 550 cycles represent ~13,750 generations. The bottlenecks imposed by this 
procedure eliminate the genetic variation that fuels adaptation by natural selection; 
as a consequence, mutations accumulate at rates that depend on their underlying 
mutation rate but not their fitness effects, except for highly deleterious mutations 
that preclude sufficient growth to form a colony29. Because more mutations are 
deleterious than are beneficial, fitness declined under this regime (Extended Data 
Fig. 8). The 15 sequenced clonal isolates, each from a different MAE line, are 
JEB807–JEB821 (Supplementary Data 1). None of the lineages became hypermu-
table based on their mutational signatures and the absence of significant hetero-
geneity in the total mutations accumulated (see main text). However, the mean 
per-generation rate at which synonymous mutations arose was ~3.5-fold higher 
in the MAE lines than in the five LTEE populations that remained non-mutators 
for all 50,000 generations (Supplementary Data 4; ts = 3.0755, P = 0.0065). This 
difference may reflect the different conditions in liquid and agar media, including 
the glucose concentration and local cell density, which might affect the reactive 
oxygen species that cells experience. The comparisons between the LTEE and 
MAE (Extended Data Fig. 9) would change if the underlying rates of the various 
types of mutation responded disproportionately to the different conditions in the 
MAE. That possibility seems implausible for the different classes of point mutation 
(Extended Data Fig. 9a, b), and the differences would have to be substantially 
larger than the different rates of synonymous mutations to produce the excess 
IS150 insertions (Extended Data Fig. 9c) and large indels (Extended Data Fig. 9f) 
observed in the LTEE relative to the MAE.
Genome sequencing. Frozen samples from the LTEE and MAE were revived via 
overnight growth at 37 °C in either LB or Davis minimal medium supplemented 
with 1,000 μg/ml glucose. Genomic DNA was isolated from each culture using the 
Qiagen Genomic-tip 100/G kit or equivalent. The DNA samples were sequenced 
at Genoscope or Integragen SA (Évry, France), the Michigan State University 
Research Technology Support Facility (East Lansing, USA), or the University of 
Texas at Austin Genome Sequencing and Analysis Facility (Austin, USA). Illumina 
Genome Analyzer and HiSeq instruments were used to generate single-end or 
paired-end reads ranging in length from 35 to 150 bases according to standard 
procedures, with median coverage of 80-fold and 95-fold for the 264 LTEE and 15 
MAE clones, respectively (Supplementary Data 1). Of the 264 LTEE genomes in 
this study, 40 were previously analysed in other studies9,19,20,55–57. Supplementary 
Data 4 shows the number of every type of mutation inferred after performing 
the analyses described below on each of the LTEE and MAE genomes used in 
this study.
Mutation calling. We used breseq (versions 0.26.0 to 0.27.0) to predict both 
single-nucleotide and structural differences24,25 based on how the Illumina reads 
for each sample mapped to the genome sequence of E. coli B REL606 (GenBank 
accession NC_012967.1)52. We counted and classified mutations using an updated 
version of the REL606 reference genome with improved feature annotations. The 
updated genome file (in both GenBank and GFF3 formats) and lists of predicted 
mutations in each evolved genome (in the Genome Diff format described in an 
appendix to the breseq manual) are freely available online (http://github.com/ 
barricklab/LTEE-Ecoli).
Most types of single-step mutations, including large deletions and transposition 
events leading to copies of IS elements at new positions in the genome, are directly 
predicted by breseq when they occur in non-repetitive genomic regions. The initial 
lists of predicted mutations were curated and refined as previously described24. 
Briefly, complex mutations involving multiple steps (such as a new IS insertion 
followed by a flanking deletion) and structural mutations that overlap repetitive 
regions of the genome were manually resolved from unassigned new junction and 
missing coverage evidence in the breseq output. Large duplications and amplifica-
tions were detected by examining the coverage depth of mapped reads across the 
reference genome and comparing this information with the positions of repeat 
sequences and unassigned junctions. Owing to limitations of short-read DNA 
sequencing data, we could not fully predict point mutations and indels of one to a 
few base pairs within repeat regions (for example, IS elements) or gene conversions, 
in which intragenomic recombination between nearly identical copies of a large 
repeat region (for example, the seven copies of the rRNA operon) converts a minor 
variation in one copy to match exactly the sequence of another copy. Instead, all 
such genetic changes in repetitive regions of the genome were uniformly ignored 
in downstream analyses, as described later.
To validate the final lists of mutations predicted in each clone, we applied 
these changes to the ancestral REL606 sequence and used breseq to compare the 
Illumina reads against this simulated evolved genome to verify there were no 
further, unexplained discrepancies. This step of applying mutations to the reference 
genome was also used to estimate the final genome size of each evolved clone, with 
the assumption that new IS insertions were of the most common size for that IS 
element in the reference genome.
For 6 of the 264 LTEE samples, there was evidence of non-clonality in the 
sequence data. Some samples appeared to be mixtures of two very closely related 
clones that shared nearly all mutations but had one to several mutations specific 
to each type, together adding to a frequency of 100% (for example, sets of muta-
tions at frequencies of 35% and 65%). This situation might result from inadvert-
ently sampling two adjacent colonies on an agar plate when picking clones from 
an LTEE population. In other cases, only one or two mutations were found at 
an intermediate frequency. This type of heterogeneity might arise from strong 
selection favouring new mutations during colony outgrowth, subculturing and 
revival of samples before DNA extraction, as these conditions differ from the 
LTEE. In each case, we reconstructed the major genotype in the sample, as noted 
in Supplementary Data 1.
We also ignored putative genome variation associated with a cryptic 186-like 
prophage element (REL606 genome coordinates 880528–904682). In ten of the 
LTEE populations, we observed clones with increased read-coverage depth of 
this region and reads spanning a new sequence junction consistent with either 
tandem head-to-tail amplifications of this region or the production of circular 
DNA molecules joined at these exact nucleotides. The changes in the apparent 
copy number of this region often deviated from the integer values expected for 
a stable duplication or amplification. The prophage-related changes in coverage 
appeared most often in genomes isolated from 2,000 generations or earlier in the 
LTEE. There is no evidence of infective phage production in the LTEE, but it is 
possible that replication of DNA encoding a defective phage occurs stochastically 
at some low level in the ancestral strain REL606 or that production of this DNA is 
induced by stress when culturing samples for DNA isolation.
Phylogenetic consistency. Owing to the long duration of the LTEE and the evolution 
of mutators in several lineages, some mutations may be hidden or initially grouped 
with other mutations into a single change when comparing a late-generation 
evolved genome with the ancestral genome. For example, a point mutation might 
occur early in the experiment and then the region containing that mutation is 
later deleted. Similarly, the deletion of one base early and the subsequent deletion 
of an adjacent base would be called as a single two-base deletion in later samples. 
To obtain more accurate counts in light of these issues, we used each population’s 
inferred phylogeny to split or add mutations, as appropriate, so that the mutation 
list for each clone reflects the most parsimonious set of mutational steps between 
that clone and its ancestor. Specifically, we chose histories with the fewest total 
mutations, the fewest mutations on early branches (in case of ties), and the fewest 
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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total nucleotide changes summed over all mutations. Because this procedure is con-
servative in adding mutations to achieve phylogenetic consistency, it might under-
estimate the number of mutations on branches leading to an evolved genome when 
intermediate states are not resolved by the relationships of the sequenced clones.
Final mutation lists. We performed two final filtering steps to enable the sets of 
mutations to be uniformly compared across all genomes. In doing so, we classi-
fied as ‘small mutations’ all single-nucleotide substitutions, insertions and dele-
tions of 20 or fewer bp, substitutions replacing 20 or fewer bp in the reference 
genome with 20 or fewer other bp, and all simple sequence repeat (SSR) mutations 
regardless of their size. SSR mutations add or remove one or more copies of a 
tandem-repeat unit consisting of one or a few bp. We defined SSR mutations as 
containing at least two copies of the repeat unit and having a total length of at least 
five bp when including all copies of the tandem repeat in the reference genome. 
For example, the genetic changes GGGGG→GGGG, TATATA→TATATATA 
and TACGTTACGT→TACGT would all be classified as SSR mutations, but 
GGGG→GGGGG, TATA→TATATA and TACGT→TACGTTACGT would 
not. All other genomic changes were considered ‘large mutations’ for purposes of 
filtering.
The ability to call small mutations located in repetitive regions of the genome 
is dependent on read length, so we removed all such mutations in regions where 
it would be a problem to uniformly detect them from the mutation lists before 
further analyses. To do this, we enumerated all regions of ≥ 20 bp that had an exact 
match elsewhere in the genome of the ancestral strain REL606 using MUMmer 
v.3.23 (ref. 58). We then merged regions from this list that were separated by five 
or fewer bp. All resulting regions that were now ≥ 35 bp were included in a list of 
masked genomic intervals. We also added to this list a hypervariable SSR consisting 
of seven copies of a tetranucleotide sequence that could not be reliably called in 
data sets with short reads (coordinates 2103889–2103919). Any small mutations 
contained in these masked regions were excluded from all downstream analyses.
Finally, we flagged all nucleotide substitutions or small indels occurring within 
20 bp of the end of an IS element. The sequences directly adjacent to IS elements 
appear to experience an unusually high mutation rate, possibly due to frequent 
transposase cleavage and DNA repair. Mutations at these IS-adjacent sites probably 
have no effect on cellular phenotypes and fitness. We excluded them from the final 
lists of mutations used in all further analyses because they could bias the inferred 
mutational spectra and rates.
Phylogenetic analyses. To produce the phylogenetic trees shown in Fig. 2, we used 
the point mutations associated with each clone. A minimum-evolution tree was 
built using the Jukes–Cantor one-parameter model59. We used this model for two 
reasons. First, the mutator lineages had very different mutational spectra from the 
non-mutators9,20,55,57. Second, many mutations seen in non-mutator lineages were 
under positive selection, and so it is appropriate to give the mutations equal weight 
and not, for instance, reduce the importance of transitions relative to transversions. 
The trees were plotted with the R package APE60. The composite tree has the star-
like structure expected for independent evolution of the populations. Therefore, 
trees were made separately for each population and then combined in Fig. 2, which 
allowed multiple basal branches to be placed with the appropriate populations.
Parallel evolution in non-mutator lineages. For genomes that did not come from 
point-mutation hypermutator lineages (Supplementary Data 1), we examined the 
extent of parallelism at the gene level in two ways. The first approach was based 
only on nonsynonymous mutations, because it is straightforward to quantify the 
overall extent of parallelism, determine the statistical significance of the paral-
lelism, and rank genes based on their contributions to the significance. For each 
protein-coding gene i, we know its length, Li, and the number of independent non-
synonymous mutations observed in that gene across all clones from non-mutator 
and premutator lineages, Ni. We summed the lengths and relevant mutations 
over all single-copy protein-coding genes in the ancestral genome to obtain Ltot 
(3,920,306) and Ntot (457, including two mutations that each affected overlapping 
reading frames), respectively. We computed the expected number of mutations in 
each gene, Ei, as follows:
= ( / )E N L Li itot tot
We then computed a Gi score for each gene for which Ni > 0 as follows:
= ( / )G N N E2 logi i i ie
We set Gi = 0 for those genes for which Ni = 0. This analysis ignores variability 
among genes in the proportion of sites at risk for nonsynonymous mutations. 
However, such differences are small and should hardly affect the analysis. The total 
G statistic equals the sum of the scores over all genes. To compute the expected 
G statistic under the null hypothesis of a random distribution of mutations, we 
generated 1,000 simulated data sets in which Ntot mutations were randomly 
placed throughout the coding genome. We computed the total G statistic for each 
simulated data set, and we calculated its mean and standard deviation across the 
1,000 simulations. To assess the significance of the observed G statistic, we com-
puted the Z score as the difference between the observed and mean simulated values, 
divided by the standard deviation of the simulated values. Supplementary Data 2 
lists each gene and the information used to calculate its G score. Table 1 shows the 
15 genes with the highest G scores.
Supplementary Data 2 also shows other categories of mutation in or near each 
protein-coding gene including synonymous mutations, intergenic point muta-
tions (between any particular gene and one of its immediately adjacent genes), 
IS insertions, small indels (≤50 bp), large deletions (>50 bp) and long duplications 
(>50 bp). Table 2 shows the 16 genes that had the most total deletions, duplications, 
insertions and intergenic point mutations (that is, all mutations except synonymous 
and nonsynonymous mutations in the coding gene itself).
Parallel evolution in mutator lineages. We examined parallel changes in lineages 
that evolved point-mutation hypermutability by analysing nonsynonymous 
substitutions as above. To identify mutations that occurred after a lineage became 
hypermutable (Supplementary Data 3), we subtracted the mutations that occurred 
on non-mutator branches from the total mutations. This approach may result in a 
few mutations that arose before hypermutability being included in the counts for 
mutator lineages, but given the large increases in the point-mutation rate in the 
mutators (Fig. 1) it provides a reasonable approximation.
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Extended Data Figure 1 | Changes in genome size during the LTEE. 
Box-and-whiskers plot showing the distribution of average genome 
length (Mb) for each of the 12 LTEE populations based on the two clones 
sequenced at each time point shown from 500 to 50,000 generations. 
The red line shows the length of the ancestral genome. The boxes are the 
interquartile range (IQR), which spans the second and third quartiles of 
the data (25th to 75th percentiles); the thick black lines are medians; the 
whiskers extend to the outermost values that are within 1.5 times the IQR; 
and the points show all outlier values beyond the whiskers.
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 2 | Accumulation of synonymous mutations in 
populations that evolved point-mutation hypermutability. Each symbol 
shows a sequenced genome from a hypermutable lineage. Colours are the 
same as those in Fig. 1. The accumulation of synonymous substitutions 
serves as a proxy for the underlying point-mutation rate. All four of 
the populations that became hypermutable before 10,000 generations 
accumulated synonymous mutations at higher rates between 10,000 
and 20,000 generations than between 40,000 and 50,000 generations, 
indicating the evolution of reduced mutability.
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 3 | Alternative models fit to trajectory of genome 
evolution for each LTEE population. a, Ara−1. b, Ara+1. c, Ara−2.  
d, Ara+2. e, Ara−3. f, Ara+3. g, Ara−4. h, Ara+4. i, Ara−5. j, Ara+5.  
k, Ara−6. l, Ara+6. Each symbol shows the total mutations in a sequenced 
genome; in many cases, the symbols for the two genomes from the same 
population and generation are not distinguishable because they have 
the same, or almost the same, number of mutations. For the populations 
that evolved hypermutability, data are shown only for time points before 
mutators arose. In each panel, the dashed grey line shows the best fit to 
the linear model; the solid grey curve shows the best fit to the square-root 
model; and the solid black curve shows the best fit to the composite model 
with both linear and square-root terms.
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 4 | Uncertainty in parameter estimation for the 
model describing the rates of accumulation for neutral and beneficial 
mutations. Contours show relative likelihoods for simultaneously 
estimating the linear and square-root coefficients from the observed 
numbers of mutations that accumulated over time in non-mutator and 
premutator lineages (Fig. 3). The black central point shows the maximum 
likelihood estimates, and the three black contours show solutions 2, 6 and 
10 log units away. The points on the horizontal and vertical axes show 
values for the best one-parameter models.
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 5 | Accumulation of synonymous substitutions 
in non-mutator lineages. Each filled symbol shows the mean number 
of synonymous mutations in the (usually two) non-mutator genomes 
from an LTEE population that were sequenced at that time point; non-
integer values can occur if the two genomes have different numbers. 
Small horizontal offsets were added so that overlapping points are visible. 
Colours are the same as in Fig. 1. Open triangles show the grand means of 
the replicate populations. The grey line extends from the intercept to the 
final grand mean. The slope of that line was used to scale the relative rates 
of synonymous, nonsynonymous and intergenic point mutations in Fig. 4.
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 6 | Temporal trend in accumulation of 
nonsynonymous mutations relative to the neutral expectation in non-
mutator lineages. Interval-specific accumulation of nonsynonymous 
mutations calculated from changes in the total number of nonsynonymous 
mutations between successive samples. As with the cumulative data 
in Fig. 4b, values are scaled by the average rate of accumulation for 
synonymous mutations over 50,000 generations, after adjusting for the 
numbers of genomic sites at risk for nonsynonymous and synonymous 
mutations. Each point shows the average rate calculated for a non-mutator 
or premutator population; small horizontal offsets were added so that 
overlapping points are visible. Note the discontinuous scale; populations 
with no additional mutations over an interval are plotted below. Colours 
are the same as in Fig. 1. Black lines connect grand means; the grey 
shading shows standard errors calculated from the replicate populations.
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 7 | Mutational spectrum for non-mutator 
lineages in the LTEE. Shaded bars show the distribution of different 
types of genetic change for all independent mutations found in the set 
of non-mutator clones that were sequenced at each generation. The total 
number of mutations in this set at each time point (N) is shown above each 
column. Base substitutions are divided into synonymous, nonsynonymous, 
intergenic, and other categories; the nonsynonymous category includes 
nonsense mutations, and the ‘other’ category includes rare point mutations 
in noncoding RNA genes and pseudogenes.
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 8 | Changes in fitness of MAE lines after 550 
single-cell bottlenecks and ~13,750 generations. Each point shows 
the mean fitness based on nine competition assays between the MAE 
ancestor (REL1207) or one of the 15 MAE lineages (JEB807–JEB821) and 
the Ara− variant of the MAE ancestor (REL1206). One-day competition 
assays were performed using the standard procedures and same conditions 
as for the LTEE16,17. Error bars show 95% confidence intervals. *P < 0.05, 
**P < 0.01, based on two-tailed t-tests of the null hypothesis that relative 
fitness equals 1. Ten of the fifteen MAE lines experienced significant 
fitness declines, while none had significant gains.
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Extended Data Figure 9 | Trajectories for mutations by class in the 
LTEE in comparison with neutral expectations based on the MAE.  
a–f, Accumulation of nonsynonymous mutations (a), intergenic point 
mutations (b), IS150 insertions (c), all other IS-element insertions (d), 
small indels (e) and large indels (f). Colours are the same as in  
Fig. 1. All values are expressed relative to the rate at which synonymous 
mutations accumulated in non-mutator LTEE lineages over 50,000 
generations (Fig. 4a), and then scaled by the ratio of the number of 
the indicated class of mutation relative to the number of synonymous 
mutations in the MAE lines. In all panels, each symbol shows a non-
mutator or premutator population. Note the discontinuous scale, in which 
populations with no mutations of the indicated type are plotted below. 
Black lines connect grand means over the replicate LTEE populations; the 
grey shading shows the corresponding standard errors.
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[1] Eltaf Alamyar, Véronique Giudicelli, Shuo Li, Patrice Duroux, and
Marie Paule Lefranc. IMGT/Highv-quest: The IMGT web portal for
immunoglobulin (IG) or antibody and T cell receptor (TR) analysis from
NGS high throughput and deep sequencing. Immunome Research, 8(1),
2012.
[2] Ian J Amanna, Nichole E Carlson, and Mark K Slifka. Duration of hu-
moral immunity to common viral and vaccine antigens. The New England
journal of medicine, 357(19):1903–15, November 2007.
[3] Ian J Amanna and Mark K Slifka. Contributions of humoral and cellular
immunity to vaccine-induced protection in humans. Virology, 411(2):206–
15, March 2011.
[4] Ramy Arnaout, William Lee, Patrick Cahill, Tracey Honan, Todd Spar-
row, Michael Weiand, Chad Nusbaum, Klaus Rajewsky, and Sergei B
Koralov. High-resolution description of antibody heavy-chain repertoires
in humans. PloS one, 6(8):e22365, January 2011.
[5] Jennifer Benichou, Rotem Ben-Hamo, Yoram Louzoun, and Sol Efroni.
Rep-Seq: uncovering the immunological repertoire through next-
generation sequencing. Immunology, 135(3):183–91, March 2012.
120
[6] R Benner, W Hijmans, and J J Haaijman. The bone marrow: the major
source of serum immunoglobulins, but still a neglected site of antibody
formation. Clinical and experimental immunology, 46(1):1–8, October
1981.
[7] Nadia L Bernasconi, Elisabetta Traggiai, and Antonio Lanzavecchia.
Maintenance of serological memory by polyclonal activation of human
memory B cells. Science (New York, N.Y.), 298(5601):2199–202, Decem-
ber 2002.
[8] Erin Bromage, Rebecca Stephens, and Lama Hassoun. The third dimen-
sion of ELISPOTs: quantifying antibody secretion from individual plasma
cells. Journal of immunological methods, 346(1-2):75–9, July 2009.
[9] D R Burton, C F Barbas, M A Persson, S Koenig, R M Chanock, and
R A Lerner. A large array of human monoclonal antibodies to type 1
human immunodeficiency virus from combinatorial libraries of asymp-
tomatic seropositive individuals. Proceedings of the National Academy
of Sciences of the United States of America, 88(22):10134–7, November
1991.
[10] G Cambridge, M J Leandro, M Teodorescu, J Manson, A Rahman, D A
Isenberg, and J C Edwards. B cell depletion therapy in systemic lupus
erythematosus: effect on autoantibody and antimicrobial antibody pro-
files. Arthritis and rheumatism, 54(11):3612–22, November 2006.
121
[11] Geraldine Cambridge, Maria J Leandro, Jonathan C W Edwards,
Michael R Ehrenstein, Martin Salden, Mark Bodman-Smith, and An-
thony D B Webster. Serologic changes following B lymphocyte depletion
therapy for rheumatoid arthritis. Arthritis and rheumatism, 48(8):2146–
54, August 2003.
[12] Zhiliang Chen, Andrew M Collins, Yan Wang, and Bruno A Gaëta.
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